# Witt_2021_Interventions for self-harm in children and adolescents.

Cochrane
Library

Cochrane Database of Systematic Reviews

Interventions for self-harm in children and adolescents (Review)

Witt KG, Hetrick SE, Rajaram G, Hazell P, Taylor Salisbury TL, Townsend E, Hawton K

Witt KG, Hetrick SE, Rajaram G, Hazell P, Taylor Salisbury TL, Townsend E, Hawton K. 
Interventions for self-harm in children and adolescents. 
Cochrane Database of Systematic Reviews 2021, Issue 3. Art. No.: CD013667. 
DOI: 10.1002/14651858.CD013667.pub2.

www.cochranelibrary.com

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
RISK OF BIAS................................................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1: Individual CBT-based psychotherapy versus TAU or other comparator, Outcome 1: Repetition of SH
by post-intervention.............................................................................................................................................................................
Analysis  1.2.  Comparison  1:  Individual  CBT-based  psychotherapy  versus  TAU  or  other  comparator,  Outcome  2:  Treatment
adherence: Proportion completing treatment....................................................................................................................................
Analysis  1.3.  Comparison  1:  Individual  CBT-based  psychotherapy  versus  TAU  or  other  comparator,  Outcome  3:  Treatment
adherence: Number of treatment sessions attended.........................................................................................................................
Analysis  1.4.  Comparison  1:  Individual  CBT-based  psychotherapy  versus  TAU  or  other  comparator,  Outcome  4:  Depression
scores at post-intervention..................................................................................................................................................................
Analysis 1.5. Comparison 1: Individual CBT-based psychotherapy versus TAU or other comparator, Outcome 5: Suicidal ideation
scores at post-intervention..................................................................................................................................................................
Analysis 2.1. Comparison 2: DBT-A versus TAU or another comparator, Outcome 1: Repetition of SH at post-intervention..........
Analysis  2.2.  Comparison  2:  DBT-A  versus  TAU  or  another  comparator,  Outcome  2:  Frequency  of  SH  repetition  at  post-
intervention...........................................................................................................................................................................................
Analysis 2.3. Comparison 2: DBT-A versus TAU or another comparator, Outcome 3: Treatment adherence: Number of individual
therapy sessions attended...................................................................................................................................................................
Analysis 2.4. Comparison 2: DBT-A versus TAU or another comparator, Outcome 4: Treatment adherence: Number of group
therapy sessions attended...................................................................................................................................................................
Analysis 2.5. Comparison 2: DBT-A versus TAU or another comparator, Outcome 5: Treatment adherence: Number of family
therapy sessions attended...................................................................................................................................................................
Analysis 2.6. Comparison 2: DBT-A versus TAU or another comparator, Outcome 6: Treatment adherence: Number of telephone
therapy sessions....................................................................................................................................................................................
Analysis 2.7. Comparison 2: DBT-A versus TAU or another comparator, Outcome 7: Depression scores at post-intervention........
Analysis 2.8. Comparison 2: DBT-A versus TAU or another comparator, Outcome 8: Hopelessness scores at post-intervention.....
Analysis  2.9.  Comparison  2:  DBT-A  versus  TAU  or  another  comparator,  Outcome  9:  General  functioning  scores  at  post-
intervention...........................................................................................................................................................................................
Analysis  2.10.  Comparison  2:  DBT-A  versus  TAU  or  another  comparator,  Outcome  10:  Suicidal  ideation  scores  at  post-
intervention...........................................................................................................................................................................................
Analysis 2.11. Comparison 2: DBT-A versus TAU or another comparator, Outcome 11: Suicidal ideation scores by 12-months......
Analysis 3.1. Comparison 3: MBT-A versus TAU or another comparator, Outcome 1: Repetition of SH by post-intervention.........
Analysis 3.2. Comparison 3: MBT-A versus TAU or another comparator, Outcome 2: Repetition of SH at post-intervention (Risk-
Taking and Self-Harm Inventory).........................................................................................................................................................
Analysis 3.3. Comparison 3: MBT-A versus TAU or another comparator, Outcome 3: Depression scores at post-intervention.......
Analysis 4.1. Comparison 4: Group-based psychotherapy, Outcome 1: Repetition of SH by six months.........................................
Analysis 4.2. Comparison 4: Group-based psychotherapy, Outcome 2: Repetition of SH by 12 months.........................................
Analysis 4.3. Comparison 4: Group-based psychotherapy, Outcome 3: Depression scores at six months......................................
Analysis 4.4. Comparison 4: Group-based psychotherapy, Outcome 4: Depression scores at 12 months.......................................
Analysis 4.5. Comparison 4: Group-based psychotherapy, Outcome 5: General functioning scores at six months........................

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
4
8
11
11
17
18
21
28
31
32
33
48
76
78
79

79

80

80

80

83
84

84

85

85

86

86
86
87

87

88
88
89

89
90
90
90
91
91

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.6. Comparison 4: Group-based psychotherapy, Outcome 6: General functioning scores at 12 months.........................
Analysis 4.7. Comparison 4: Group-based psychotherapy, Outcome 7: Suicidal ideation scores at six months.............................
Analysis 4.8. Comparison 4: Group-based psychotherapy, Outcome 8: Suicidal ideation scores at 12 months..............................
Analysis 5.1. Comparison 5: Family therapy, Outcome 1: Repetition of SH at post-intervention.....................................................
Analysis 5.2. Comparison 5: Family therapy, Outcome 2: Treatment adherence by six months......................................................
ADDITIONAL TABLES....................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
WHAT'S NEW.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

91
91
92
93
93
93
94
97
97
98
98
98
98
98

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Interventions for self-harm in children and adolescents

Katrina G Witt1,2, Sarah E Hetrick3,4, Gowri Rajaram1,2, Philip Hazell5, Tatiana L Taylor Salisbury6, Ellen Townsend7, Keith Hawton8

1Orygen, Parkville, Melbourne, Australia. 2Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia.
3Department of Psychological Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
4Children and Young People Satellite, Cochrane Common Mental Disorders, The University of Auckland, Auckland, New Zealand.
5Speciality of Psychiatry, University of Sydney School of Medicine, Sydney, Australia. 6Health Service and Population Research
Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. 7Self-Harm Research Group,
School of Psychology, University of Nottingham, Nottingham, UK. 8Centre for Suicide Research, Department of Psychiatry, University of
Oxford, Oxford, UK

Contact: Katrina G Witt, katrina.witt@orygen.org.au.

Editorial group: Cochrane Common Mental Disorders Group.
Publication status and date: New, published in Issue 3, 2021.

Citation: Witt KG, Hetrick SE, Rajaram G, Hazell P, Taylor Salisbury TL, Townsend E, Hawton K. Interventions for self-harm in children and
adolescents. Cochrane Database of Systematic Reviews 2021, Issue 3. Art. No.: CD013667. DOI: 10.1002/14651858.CD013667.pub2.

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Self-harm (SH; intentional self-poisoning or self-injury regardless of degree of suicidal intent or other types of motivation) is a growing
problem  in  most  countries,  often  repeated,  and  associated  with  suicide.  Evidence  assessing  the  effectiveness  of  interventions  in  the
treatment of SH in children and adolescents is lacking, especially when compared with the evidence for psychosocial interventions in
adults. This review therefore updates a previous Cochrane Review (last published in 2015) on the role of interventions for SH in children
and adolescents.

Objectives

To assess the effects of psychosocial interventions or pharmacological agents or natural products for SH compared to comparison types
of care (e.g. treatment-as-usual, routine psychiatric care, enhanced usual care, active comparator, placebo, alternative pharmacological
treatment, or a combination of these) for children and adolescents (up to 18 years of age) who engage in SH.

Search methods

We searched the Cochrane Common Mental Disorders Specialized Register, the Cochrane Library (Central Register of Controlled Trials
[CENTRAL] and Cochrane Database of Systematic Reviews [CDSR]), together with MEDLINE, Ovid Embase, and PsycINFO (to 4 July 2020).

Selection criteria

We included all randomised controlled trials (RCTs) comparing specific psychosocial interventions or pharmacological agents or natural
products  with  treatment-as-usual  (TAU),  routine  psychiatric  care,  enhanced  usual  care  (EUC),  active  comparator,  placebo,  alternative
pharmacological treatment, or a combination of these, in children and adolescents with a recent (within six months of trial entry) episode
of  SH  resulting  in  presentation  to  hospital  or  clinical  services.  The  primary  outcome  was  the  occurrence  of  a  repeated  episode  of  SH
over a maximum follow-up period of two years. Secondary outcomes included treatment adherence, depression, hopelessness, general
functioning, social functioning, suicidal ideation, and suicide.

Data collection and analysis

We independently selected trials, extracted data, and appraised trial quality. For binary outcomes, we calculated odds ratios (ORs) and their
95% confidence internals (CIs). For continuous outcomes, we calculated the mean difference (MD) or standardised mean difference (SMD)

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

and 95% CIs. The overall quality of evidence for the primary outcome (i.e. repetition of SH at post-intervention) was appraised for each
intervention using the GRADE approach.

Main results

We included data from 17 trials with a total of 2280 participants. Participants in these trials were predominately female (87.6%) with a
mean age of 14.7 years (standard deviation (SD) 1.5 years). The trials included in this review investigated the effectiveness of various forms
of psychosocial interventions. None of the included trials evaluated the effectiveness of pharmacological agents in this clinical population.
There was a lower rate of SH repetition for DBT-A (30%) as compared to TAU, EUC, or alternative psychotherapy (43%) on repetition of SH
at post-intervention in four trials (OR 0.46, 95% CI 0.26 to 0.82; N = 270; k = 4; high-certainty evidence). There may be no evidence of a
difference for individual cognitive behavioural therapy (CBT)-based psychotherapy and TAU for repetition of SH at post-intervention (OR
0.93, 95% CI 0.12 to 7.24; N = 51; k = 2; low-certainty evidence). We are uncertain whether mentalisation based therapy for adolescents
(MBT-A) reduces repetition of SH at post-intervention as compared to TAU (OR 0.70, 95% CI 0.06 to 8.46; N = 85; k = 2; very low-certainty
evidence). Heterogeneity for this outcome was substantial ( I2 = 68%). There is probably no evidence of a difference between family therapy
and either TAU or EUC on repetition of SH at post-intervention (OR 1.00, 95% CI 0.49 to 2.07; N = 191; k = 2; moderate-certainty evidence).
However, there was no evidence of a difference for compliance enhancement approaches on repetition of SH by the six-month follow-up
assessment, for group-based psychotherapy at the six- or 12-month follow-up assessments, for a remote contact intervention (emergency
cards) at the 12-month assessment, or for therapeutic assessment at the 12- or 24-month follow-up assessments.

Authors' conclusions

Given the moderate or very low quality of the available evidence, and the small number of trials identified, there is only uncertain evidence
regarding a number of psychosocial interventions in children and adolescents who engage in SH. Further evaluation of DBT-A is warranted.
Given the evidence for its benefit in adults who engage in SH, individual CBT-based psychotherapy should also be further developed and
evaluated in children and adolescents.

P L A I N   L A N G U A G E   S U M M A R Y

Interventions for children and adolescents who self-harm

We have reviewed the international literature regarding psychosocial interventions, pharmacological (drug), and natural product (dietary
supplementation) treatment trials in the field. A total of 17 trials meeting our inclusion criteria were identified. There is little evidence of
beneficial effects for individual cognitive behavioural therapy (CBT)-based psychotherapy, mentalisation-based therapy for adolescents
(MBT-A), group-based psychotherapy, enhanced assessment approaches, compliance enhancement approaches, family interventions, or
remote contact interventions. There is some evidence of effectiveness for dialectical behaviour therapy (DBT-A) for adolescents. However,
few trials have been conducted and those that have are generally small, meaning that possible beneficial effects of some of these therapies
cannot be ruled out.

Why is this review important?

Self-harm (SH), which includes intentional self-poisoning/overdose and self-injury, is a major problem in many countries and is strongly
linked with suicide. It is therefore important that effective treatments for SH patients are developed. There has been an increase in the use
of interventions for SH in children and adolescents. It is therefore important to assess the evidence for their effectiveness.

Who will be interested in this review?

Hospital administrators (e.g. service providers), health policy officers and third party payers (e.g. health insurers), clinicians working with
patients who engage in SH, patients themselves, and their relatives.

What questions does this review aim to answer?

This review is an update of a previous Cochrane Review from 2015 which found little evidence of beneficial effects of interventions for SH
in children and adolescents. This updated review aims to further evaluate the evidence for effectiveness of interventions for children and
adolescents with SH with a broader range of outcomes.

Which studies were included in the review?

To be included in the review, studies had to be randomised controlled trials of either psychosocial or drug treatments for children and
adolescents up to 18 years of age who had recently engaged in SH.

What does the evidence from the review tell us?

There have been surprisingly few investigations of treatments for SH in children and adolescents, despite the size of this problem in many
countries. We found positive effects of DBT-A on repetition of SH. There is currently no clear evidence for the effectiveness of individual
CBT-based psychotherapy, MBT-A, group-based psychotherapy, enhanced assessment approaches, compliance enhancement approaches,
family interventions, or remote contact interventions in preventing repetition of SH.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

What should happen next?

Cochrane Database of Systematic Reviews

We recommend further trials of DBT-A. Given the evidence for its benefit for adults who engage in SH, individual CBT-based psychotherapy
should also be further developed and evaluated in children and adolescents. Given the extent of SH in children and adolescents, greater
attention should be paid to the development and evaluation of specific therapies for this population.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
I
n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
s
e
l
f
-
h
a
r
m

i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

4

S U M M A R Y   O F   F I N D I N G S

Summary of findings 1.   Comparison 1: Individual CBT-based psychotherapy compared to TAU or other comparator for self-harm in children and
adolescents

Comparison 1: Individual CBT-based psychotherapy compared to TAU or other comparator for self-harm in children and adolescents

Patient or population: self-harm in children and adolescents  (up to 18 years or age)
Intervention: Individual CBT-based psychotherapy
Comparison: TAU or other comparator

Outcomes

Anticipated absolute effects* (95% CI)

Risk with TAU or
other compara-
tor

Risk with Comparison
1: Individual CBT-based
psychotherapy

Repetition of
SH by post-in-
tervention

Study population

160 per 1,000

150 per 1,000
(22 to 580)

Relative effect
(95% CI)

№ of partici-
pants
(studies)

Certainty of
the evidence
(GRADE)

Comments

OR 0.93
(0.12 to 7.24)

51
(2 RCTs)

⊕⊕⊝⊝
LOW 1 2

Our confidence in the effect estimate of in-
dividual CBT-based psychotherapy on rep-
etition of SH at post-intervention is limited.
The true effect may be substantially different
from the estimate of the effect.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 We downgraded this domain by one level as we rated any of the sources of risk of bias (as described in Assessment of risk of bias in included studies) at high risk for one of
the studies included in the pooled estimate.
2 We downgraded this domain by one level where the 95% CI for the pooled effect included the null value.

Summary of findings 2.   Comparison 2: DBT-A compared to TAU or another comparator for self-harm in children and adolescents

Comparison 2: DBT-A compared to TAU or another comparator for self-harm in children and adolescents

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
I
n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
s
e
l
f
-
h
a
r
m

i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

Patient or population: self-harm in children and adolescents  (up to 18 years or age)
Intervention: DBT-A
Comparison: TAU or another comparator

Outcomes

Anticipated absolute effects* (95% CI)

Risk with TAU or
another compara-
tor

Risk with Comparison
2: DBT-A

Relative effect
(95% CI)

№ of partici-
pants
(studies)

Certainty of
the evidence
(GRADE)

Comments

Repetition of
SH at post-in-
tervention

Study population

432 per 1,000

259 per 1,000
(165 to 384)

OR 0.46
(0.26 to 0.82)

270
(4 RCTs)

⊕⊕⊕⊕
HIGH

We are very confident that the true effect lies
close to that of the estimate of the effect esti-
mate of DBT-A on repetition of SH at post-in-
tervention.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

Summary of findings 3.   Comparison 3: MBT-A compared to TAU or another comparator for self-harm in children and adolescents

Comparison 3: MBT-A compared to TAU or another comparator for self-harm in children and adolescents

Patient or population: self-harm in children and adolescents  (up to 18 years or age)
Intervention: MBT-A
Comparison: TAU or another comparator

Outcomes

Anticipated absolute effects* (95% CI)

Risk with TAU or an-
other comparator

Risk with Comparison
3: MBT-A

Relative effect
(95% CI)

№ of partici-
pants
(studies)

Certainty of
the evidence
(GRADE)

Comments

5

Study population

OR 0.70
(0.06 to 8.46)

85
(2 RCTs)

⊕⊝⊝⊝
VERY LOW 1,2,3

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Repetition of
SH at post-in-
tervention

805 per 1,000

743 per 1,000
(198 to 972)

The evidence is very uncertain about
the effect of MBT-A on repetition of self-
harm by post-intervention.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 We downgraded this domain by one level as we rated any of the sources of risk of bias (as described in Assessment of risk of bias in included studies) at high risk for one of
the studies included in the pooled estimate.
2 We downgraded this domain by one level as one of the studies included in the pooled estimate used a proxy measure (i.e. cut-scores on the Risk Taking and Self-Harm Inventory)
to ascertain repetition of SH. It is unclear how scores on this measure may relate to actual SH behaviour.
3 We downgraded this domain by one level where the 95% CI for the pooled effect included the null value.

Summary of findings 4.   Comparison 7: Family therapy compared to placebo for self-harm in children and adolescents

Comparison 7: Family therapy compared to placebo for self-harm in children and adolescents

Patient or population: self-harm in children and adolescents  (up to 18 years or age)
Intervention: Family therapy
Comparison: placebo

Outcomes

Anticipated absolute effects* (95% CI)

Risk with
placebo

Risk with Compari-
son 7: Family thera-
py

Repetition of
SH at post-in-
tervention

Study population

216 per 1,000

216 per 1,000
(119 to 364)

Relative effect
(95% CI)

№ of partici-
pants
(studies)

Certainty of
the evidence
(GRADE)

Comments

OR 1.00
(0.49 to 2.07)

191
(2 RCTs)

⊕⊕⊕⊝
MODERATE 1

We are moderately confident in the effect estimate
of family therapy on repetition of SH at post-inter-
vention. The true effect is likely to be close to the
estimate of the effect, but there is a possibility that
it is substantially different.

I
n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
s
e
l
f
-
h
a
r
m

i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

6

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 We downgraded this domain by one level where the 95% CI for the pooled effect included the null value.

I
n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
s
e
l
f
-
h
a
r
m

i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
1
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

Self-harm (SH), which includes all intentional acts of self-poisoning
(such  as  intentional  drug  overdoses)  or  self-injury  (such  as  self-
cutting),  regardless  of  degree  of  suicidal  intent  or  other  types  of
motivation (Hawton 2003), has been a growing problem in children
and  adolescents  up  to  18  years  of  age  (Hawton  2012b).  Rates  of
SH in children and adolescents have been increasing over recent
decades  across  a  number  of  comparable  countries,  according  to
the  number  of  presentations  to  general  hospitals  and  primary
care  (Cairns  2019;  Griffin  2018;  Morgan  2017).  This  increase  may
be  attributable  to  a  number  of  factors,  including: younger  age  of
onset  of  SH  behaviours  (Gardner  2019;  Griffin  2018;  Jung  2018;
Perera 2018), changes in the potential lethality of methods of SH
used  by  children  and  adolescents  (Griffin  2018),  increased  risk
of  SH  repetition  in  children  and  adolescents,  relative  to  young
adults (i.e. 20 to 24-year-olds; Bennardi 2016), changes in clinical
documentation and improved administrative coding of cases of SH
in children and adolescents, resulting in a higher detection rate of
young people who engage in SH (McGill 2018).

In  contrast  to  suicide  rates,  rates  of  hospital-presenting  SH  are
higher in young females than males in most countries. The female
to  male  ratio  peaks  at  approximately  five  to  six  times  in  12  to
14-year-olds,  before  decreasing  with  age  (Diggins  2017;  Griffin
2018; McMahon 2014). While reasons for the differential prevalence
of  SH  behaviours  in  young  females  compared  to  young  males
are  complex,  an  earlier  age  of  onset  of  psychiatric  disorders  in
young females may represent an important factor (Rhodes 2014).
However,  only  about  1:28  young  males,  and  1:18  young  females
who  SH  ever  present  to  hospital  (Geulayov  2018).  Therefore,  it  is
apparent  that  SH  in  children  and  adolescents  in  the  community
(i.e. without hospital presentation) is very common, although less
is known about the treatment needs of these youth (Hawton 2012b;
Madge 2008; McMahon 2014).

For  those  who  present  to  hospital,  the  most  common  method  of
SH  is  self-poisoning.  Overdoses  of  analgesics  and  psychotropics,
especially  paracetamol  or  acetaminophen,  are  common  in  some
countries, particularly high-income countries (Cairns 2019; Hawton
2012c; Sheen 2002). Self-cutting is the next most frequent method
used by those who present to hospital. However, in the community,
self-cutting and other forms of self-injury are far more frequent than
self-poisoning (Geulayov 2018; Madge 2008; Müller 2016).

SH is associated with increased risk of future suicide. While suicide
is  relatively  uncommon  in  younger  children,  rates  have  been
increasing across a number of countries in recent years, particularly
among young females (Bould 2019; Lahti 2011; Roh 2018; Stefanac
2019; Skinner 2012; Sullivan 2015). For example, recent data from
the  UK  showed  that  children  and  adolescents  who  presented  to
hospital on at least one occasion following an episode of SH were 30
times more likely to die by suicide within a year (Hawton 2020a). A
history of SH, particularly with frequent repetition, is the strongest
risk factor for suicide across a range of psychiatric disorders (Zahl
2004).

SH  and  suicide  in  children  and  adolescents  are  the  result  of
a  complex  interplay  between  genetic,  biological,  psychiatric,
psychosocial,  social,  cultural,  and  other  factors  (Hawton  2012b).
Psychiatric disorders, particularly mood disorders, are associated

Cochrane Database of Systematic Reviews

with the largest population attributable risk for SH in children and
adolescents. While personality disorders should not be diagnosed
in  younger  children,  emergent  traits  consistent  with  those  in
adult borderline personality disorder have also been found to be
associated  with  a  significant  population  attributable  risk  for  SH
in  this  population  (Witt  2019a),  particularly  those  who  engage  in
frequent  repetition  of  SH  (Crowell  2012).  Alcohol  and  illicit  drug
misuse may also play an important role.

Both  psychological  and  biological  factors  appear  to  further
increase  vulnerability  to  SH.  Psychological  factors  may  include
poor  emotion  regulation  abilities,  or  poor  emotional  intelligence
may also contribute to the risk of SH in this population (Brausch
2019; Mikolajczak 2009). Psychological influences on children and
adolescents  who  engage  in  SH  include  feelings  of  entrapment,
lack  of  belonging,  and  perceiving  oneself  as  a  burden  (O'Connor
2012). Other contributors include perfectionism, low self-esteem,
social  isolation,  impulsivity,  hopelessness,  and  poor  parent-child
attachment (Hawton 2012b).

Relationship  problems  are  common  in  children  and  adolescents
who  engage  in  SH,  especially  problems  with  family  members
(Fortune  2016).  Relationship  problems  with  partners  are  more
common  in  older  adolescents  (i.e.  15  to  18-year-olds)  than  in
younger children (i.e. 10 to 14-year-olds; Hawton 2012c). A history
of emotional, physical, or sexual abuse has been associated with a
significant population attributable risk of SH (Liu 2018; Madge 2011;
Witt  2019a).  Bullying  and  victimisation  (Heerde  2019),  including
cyber-bullying (Heerde 2019; John 2018), can also increase the risk
of  SH.  Exposure  to  suicidal  behaviour  in  others,  either  through
personal  contact,  or  through  portrayals  in  traditional  (e.g.  films
or television dramas) or new media (including social media), may
also  be  an  important  factor  as  SH  in  children  and  adolescents
often  has  a  'contagious'  quality  (Hawton  2020b;  McMahon  2013).
Biological  factors  include  disturbances  in  the  serotonergic  and
stress response systems (Van Heeringen 2014).

Description of the intervention

Treatment  for  SH  in  children  and  adolescents  may  involve
psychosocial  interventions,  pharmacological  interventions,  or  a
combination of the two approaches.

Psychosocial interventions

Psychological approaches used to treat children and adolescents
who engage in SH typically involve brief individual- or group-based
psychological therapy. Treatment may vary in initial management,
location  of  treatment,  continuity,  intensity,  and  frequency  of
contact  with  therapists.  There  is  also  considerable  variation
among  countries  in  the  availability  of  services  to  provide  such
interventions.  Consequently,  there  is  no  standard  psychosocial
treatment  of  SH  in  children  and  adolescents.  However,  in  high-
income  countries,  treatment  generally  consists  of  a  combination
of  assessment,  support,  involvement  of  parents,  family,  and
caregivers, and individual psychological therapies.

Pharmacological interventions

Given  the  prevalence  of  psychiatric  disorders  in  children  and
adolescents  who  engage  in  SH  (Hawton  2013),  pharmacological
treatments  may  include  antidepressants,  antipsychotics,  and
lithium).
mood  stabilisers 
the  context  of  anxiety  and  general
SH  also  arises 

(including  anticonvulsants  and 
in 

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

8

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

distress  and  thus  anxiolytics  (including  both  benzodiazepines
and  non-benzodiazepine  anxiolytics)  may  be  trialled.  Other
pharmacological agents may also be trialled. However, treatment
with  pharmacological  agents  is  generally  less  common  than
treatment  with  psychosocial  interventions  in  this  population,
partly  due  to  concerns  about  the  risk  of  exacerbating  SH  (Miller
2014).

Combined psychosocial and pharmacological interventions

Treatment  may  also  involve  a  combination  of  both  psychosocial
and  pharmacological  approaches,  such  as  cognitive  behavioural
therapy combined with fluoxetine (Gilbert 2020).

How the intervention might work

Psychosocial interventions

Mood  disorders,  in  particular,  have  been  identified  as  key
modifiable risk factors for children and adolescents who engage in
SH (Witt 2019a). Psychosocial interventions may address some of
the underlying psychological risk factors associated with SH. The
mechanisms of action of these interventions might help children
and  adolescents  improve  their  coping  skills  and  tackle  specific
problems,  manage  psychiatric  disorders,  improve  self-esteem,
increase a sense of social connectedness, and reduce impulsivity
and  harmful  reactions  to  distressing  situations.  What  follows,  is
a  description  of  the  psychosocial  interventions  that  are  typically
available for children and adolescents who engage in SH.

Cognitive behavioural therapy-based psychotherapy

Cognitive  behavioural  therapy  (CBT)-based  psychotherapy  helps
people  to  identify  and  critically  evaluate  the  ways  in  which
they interpret and evaluate disturbing emotional experiences and
events, and aims to help them change the ways in which they deal
with  problems  (Westbrook  2008).  This  is  achieved  in  three  steps:
first, people are helped to change the ways in which they interpret
and evaluate distressing emotions; second, they learn strategies to
help them change the way in which they think about the meanings
and  consequences  of  these  emotions;  finally,  with  the  benefit  of
modified interpretation of emotions and events, they are helped to
change their behaviour and develop positive functional behaviour
(Jones 2012).

Problem-solving therapy (PST) is an integral part of CBT, although
it  can  be  delivered  as  a  therapy  in  and  of  itself.  PST  assumes
that ineffective and maladaptive coping behaviours that drive SH
might be overcome by helping the person to learn skills to actively,
constructively, and effectively solve the problems he or she faces in
their daily lives (Nezu 2010). PST typically involves identification of
the problem, generation of a range of solutions, implementation of
chosen solutions based on appraisal, and the evaluation of these
solutions (D'Zurilla 2010). Treatment goals include helping people
to  develop  a  positive  problem-solving  orientation,  use  rational
problem-solving strategies, reduce the tendency to avoid problem-
solving, and reduce the use of impulsive problem-solving strategies
(Washburn 2012).

Dialectical behaviour therapy

In  contrast  to  CBT  and  PST,  which  focus  on  changing  behaviour
and cognitive patterns, the focus of dialectical behavioural therapy
(DBT) is to provide people with the skills to develop an awareness
and  acceptance  of  thoughts  and  emotions,  including  painful  or

Cochrane Database of Systematic Reviews

distressing  internal  experiences,  without  judgement  or  attempts
to  alter,  suppress,  avoid,  or  otherwise  change  these  experiences
(Lynch 2006). The primary treatment goals of DBT are three-fold:
to  reduce  SH,  reduce  behaviours  that  interfere  with  the  success
of  treatment,  such  as  treatment  non-adherence,  and  reduce  any
other factors that may adversely affect the person's quality of life
(e.g. frequency or duration of psychiatric hospitalisations) (Linehan
1993).

Miller 2007 adapted dialectical behaviour therapy for adolescents
(DBT-A)  from  Linehan’s  initial  conceptualisation  of  DBT,  which
was  developed  for  adults  diagnosed  with  borderline  personality
disorder.  DBT-A  typically  includes  a  combination  of  weekly
individual and family therapy sessions, and telephone support as
needed.  As  the  aim  of  DBT-A  is  to  help  children  and  adolescents
adjust to maladaptive personality characteristics, the treatment is
intensive and relatively prolonged, although usually less so than in
adults (James 2008; Miller 2007).

Mentalisation-based therapy

Mentalisation refers to the ability to understand the behaviour of
both one's self and others in terms of motivational and emotional
states (Allen 2008). Maladaptive and impulsive coping behaviours,
including  SH,  are  presumed  to  arise  from  a  disrupted  ability
to  engage  in  these  processes.  In  mentalisation-based  therapy
(MBT),  the  goal  is  to  help  people  understand  their  emotions  and
behaviours, and develop strategies to regulate them to minimise
the  risk  that  they  will  engage  in  SH  during  times  of  distress
(Rossouw 2018).

Mentalisation-based therapy for adolescents (MBT-A) is a relatively
prolonged  (one  year)  treatment  which  typically  includes  weekly
individual sessions, and monthly family sessions (Fonagy 2019).

Group-based psychotherapy

integrates  techniques 

Group-based psychotherapy treatment of children and adolescents
who  have  self-harmed 
from  several
therapies,  including  CBT,  DBT-A,  MBT-A,  and  specific  group
techniques.  Group-based  psychotherapy  may  be  more  effective
for children and adolescents than individual psychotherapy, as it
provides them with a chance to work on skills related to developing
interpersonal relationships and problem-solving, which have been
identified  as  important  modifiable  proximal  risk  factors  for  SH
behaviours in this age group (Kaess 2020b).

Enhanced assessment approaches

Enhanced therapeutic assessment approaches combine standard
psychosocial  history  and  risk  assessment  techniques  with  brief
cognitive analytic therapy and PST. Children and adolescents learn
to  identify  sources  of  psychological  pain  and  their  connection
to  problem  behaviours,  such  as  SH,  and  identify  ways  to  break
this  cycle  (Ougrin  2012).  The  aim  is  to  enhance  adherence  with
subsequent treatment, and the potential benefit from it.

Compliance enhancement approaches

Of  particular  concern  regarding  after-care  of  children  and
adolescents  who  present  to  hospital  following  an  episode  of  SH,
is the fact that adherence to recommended treatment tends to be
relatively poor; between 25% and 50% of children and adolescents
will  not  attend  any  follow-up  outpatient  treatment  sessions
(Granboulan  2001;  Taylor  1984).  Efforts  to  maintain  contact  with

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

children  and  adolescents,  such  as  following  up  with  them  in  the
community,  as  well  as  efforts  to  address  factors  likely  to  impede
attendance  at  treatment  sessions,  may  be  effective  in  improving
treatment  engagement  and  adherence  in  this  population  (Yuan
2019).

Family interventions

Family  interventions  typically  involve  conjoint  therapy  sessions
with  the  child  or  adolescent  and  family  members.  It  includes
negotiation  of  goals,  exploration  of  the  episode  of  SH,
communication  between  family  members,  problem-solving,  and
discussion of developmental issues and their impact on the family.
The  basis  of  this  therapy  is  that  SH  in  children  and  adolescents
may relate to family dysfunction, and therefore, efforts to improve
family  cohesion,  attachment,  adaptability,  support,  and  parental
warmth could help families function better and hence, reduce the
risk of SH (Fortune 2016).

Remote contact interventions

Remote contact interventions, which may include letters, brief text
messages delivered by telephone, telephone calls, and postcards,
are  low  resource  and  non-intrusive  interventions  that  seek  to
maintain long-term contact with children and adolescents. These
interventions  provide  a  sense  of  ongoing  concern,  and  may
mitigate  the  sense  of  social  isolation  reported  by  many  children
and adolescents who engage in SH. They may also help to improve
their knowledge about triggers and warning signs for SH, provide
them with information on alternative coping behaviours to SH, and
where they can access help (Milner 2016).

These  interventions  may  also  be  combined  with  emergency  card
interventions, which encourage children and adolescents to seek
help  when  they  feel  distressed,  and  offer  on-demand  emergency
contact  with  psychiatric  services  or  inpatient  care.  The  aim  is  to
reduce the risk of SH by facilitating rapid access to care.

Pharmacological interventions

Antidepressants

In  relation  to  the  prevention  of  SH  and  suicidal  behaviour,  the
primary  mechanism  would  be  the  effect  of  antidepressants  on
depression.  However,  there  might  also  be  other  relevant  specific
effects, such as with drugs acting on the serotonin system, it having
been  suggested  that  serotonin  levels  are  relevant  to  impulsivity,
which  is  a  feature  sometimes  associated  with  suicidal  behaviour
(Van Heeringen 2014).

classification 

currently  accepted 

While  different  classifications  of  antidepressants  have  been
suggested,  a 
is  non-
selective monomamine inhibitors (e.g. amitriptyline, imipramine,
dosulepin), selective serotonin reuptake inhibitors, subgrouped as
non-selective monomaine oxidase inhibitors (e.g., phenelzine) and
monoamine  oxidase  A  inhibitors  (e.g.,  moclobemide),  and  other
antidepressants  (e.g.,  venlafaxine,  mirtazapine,  trazadone)  (WHO
2014b).

An  earlier  approach  was  to  group  antidepressants  as  tricyclics,
newer generation antidepressants (NGAs) (while recognising that
many specific drugs in this category were introduced many years
ago),  and  other  antidepressants.  This  approach  was  used  in  the
previous  version  of  this  review  (Hawton  2015).  For  pragmatic

Cochrane Database of Systematic Reviews

reasons, we have therefore continued to use this categorisation in
this update.

Antidepressants are often prescribed in the same dose range used
to treat major depression. However, owing to the increased risk of
overdose in this population, including the likelihood that children
and adolescents who engage in self-poisoning may use their own
medication (Gjelsvik 2014), antidepressants associated with lower
case  fatality  indices  (e.g.  SSRIs)  are  generally  preferred  (Hawton
2010), especially in people thought to be at risk of suicide.

In children and adolescents, there have been significant concerns
that  certain  classes  of  antidepressants,  particularly  SSRIs,  may
increase  suicidal  ideation  (Healy  2003).  As  a  result,  regulatory
agencies in the UK (Medicines and Healthcare products Regulatory
Agency;  MHRA  2003),  the  US  (US  Food  and  Drug  Administration;
FDA  2004),  and  Europe  (the  European  Medicines  Agency;  EMA
2005) have cautioned practitioners on the use of SSRIs in children
and  adolescents.  More  recently,  review  evidence  suggests  that
risks may be elevated regardless of antidepressant class (Hetrick
2012). However, warnings from regulatory agencies may have had
unintended consequences (Gibbons 2007; Lu 2014), although the
evidence is mixed (Plöderl 2019; Whitely 2020).

Antipsychotics

In people with a history of repeat SH, treatment with antipsychotics
may  be  used  to  reduce  heightened  levels  of  arousal  often
experienced by them, especially in relation to stressful life events.
By reducing this arousal, the urge to engage in SH may be reduced.
Low  potency  second  generation  antipsychotics  may  reduce  SH
in  children  and  adolescents  diagnosed  with  major  depression
(Good  2006),  and  schizophrenia  (Ma  2018).  Lower  doses  may  be
prescribed  to  obtain  this  effect  than  is  generally  used  in  the
treatment of psychotic disorders.

Anxiolytics, including both benzodiazepines and non-
benzodiazepine anxiolytics

Given that this population experiences a high prevalence of anxiety
disorders  (Hawton  2013),  anxiolytics,  including  benzodiazepines
and  non-benzodiazepine  anxiolytics,    may  be  used  to  reduce
suicidal  behaviour  through  their  specific  effects  on  anxiety
(Tyrer  2012).  However,  because  of  their  GABAminergic  effects,
benzodiazepines  may 
increase  aggression  and  disinhibition
(Albrecht  2014).  In  children  and  adolescents,  current  evidence
from  case  series  is  that  benzodiazepines  are  associated  with
an  increased  risk  of  suicidal  ideation  and  SH  (Kandemir  2008).
Therefore,  it  is  usually  recommended  that  benzodiazepines  are
used very cautiously, if at all, in children and adolescents at risk of
SH.

Mood stabilisers (including antiepileptics)

Mood  stabilisers  may  have  a  role  for  children  and  adolescents
diagnosed with bipolar disorder or unipolar depression, especially
to prevent the recurrence of episodes of mood disorder (Cipriani
2013b). Therefore, these drugs may reduce the risk of SH. However,
to date, this effect has only been found for lithium in adults (Cipriani
2013a). Lithium may reduce the risk of SH via a serotonin-mediated
reduction in impulsivity and aggression. It is also possible that the
long-term clinical monitoring, which all persons prescribed lithium
treatment  must  undergo,  might  contribute  to  a  reduction  in  SH
(Cipriani 2013a).

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Other pharmacological agents

Other  pharmacological  agents,  particularly  the  N-Methyl-D-
aspartate  receptor  antagonist,  ketamine,  may  also  be  trialed.
Ketamine  has  been  shown  to  have  an  antisuicidal  effect,
independent  of  its  antidepressant  effects  (Sanacora  2017).  As
a  result,  the  FDA  has  recently  granted  approval  for  the  use
of  both  ketamine  and  esketamine  as  adjunctive  treatments  to
antidepressant therapy (FDA 2019). Ketamine has been associated
with reduced suicidal ideation severity in the short term in adults
with  treatment-resistant  mood  disorders  (Wilkinson  2018;  Witt
2020a). However, few trials have investigated the effect of ketamine
over  longer  time  periods.  The  effectiveness  of  ketamine  on  SH,
and potential adverse effects of ketamine administration, such as
dissociation, emergence psychosis, and rebound suicidal ideation,
or behaviour, or both, remain under-studied (Witt 2020a).

2016), and German Professional Associations and Societies (Plener
2016), amongst others (Courtney 2019).

In 2021, the guidance contained in the 2011 NICE guidelines for the
longer-term management of SH will be due for updating. Therefore,
we  are  updating  our  review  (Hawton  2015),  in  order  to  provide
contemporary evidence to guide clinical policy and practice.

O B J E C T I V E S

for  self-harm 

To  assess  the  effects  of  psychosocial  or  pharmacological
interventions 
(SH)  compared  to  comparison
types  of  care  (e.g.  treatment-as-usual,  routine  psychiatric  care,
enhanced  usual  care,  active  comparator,  placebo,  alternative
pharmacological treatment, or a combination of these) for children
and adolescents (up to 18 years of age) who engage in SH.

Natural products

M E T H O D S

In  adults,  there  is  some  interest  in  the  use  of  natural  products,
for example dietary supplementation of omega-3 fatty acids (fish
oils; Tanskanen 2001). Omega-3 fatty acids have been implicated
in  the  neural  network,  which  is  shown  to  correlate  with  the
lethality of recent SH (Mann 2013). Blood plasma polyunsaturated
fatty  acid  levels  have  also  been  implicated  in  the  serotonin-
mediated  link  between  low  cholesterol  and  SH,  suggesting  that
low  omega-3  fatty  acid  levels  may  have  a  negative  impact  on
serotonin  function  (Sublette  2006).  For  those  in  whom  SH  is
impulsive,  omega-3  supplementation  may  stimulate  serotonin
activity, thereby reducing the likelihood of engaging in SH (Brunner
2002).

Criteria for considering studies for this review

Types of studies

We  considered  all  randomised  controlled  trials  (RCTs)  of  specific
psychosocial  or  pharmacological  treatments  versus  treatment-
as-usual,  routine  psychiatric  care,  enhanced  usual  care,  active
comparator, placebo, alternative pharmacological treatment, or a
combination of these, in the treatment of children and adolescents
with a recent (within six months of trial entry) presentation for SH.
All RCTs (including cluster-RCTs and cross-over trials) were eligible
for inclusion regardless of publication type or language; however,
we excluded quasi-randomised trials.

Combined psychosocial and pharmacological interventions

Types of participants

A  growing  number  of  trials  have  investigated  the  effectiveness
of  combined  psychosocial  and  pharmacological  interventions,
particularly  in  children  and  adolescents  diagnosed  with  major
depression.  Given 
for
psychosocial therapy alone may take up to four weeks or longer,
combined  approaches  may  provide  a  faster  treatment  response,
and may have a superior effect to psychosocial intervention alone
(Cox  2014).  However,  the  effect  of  combined  approaches  on  SH
remains unclear (Cox 2014).

that  achieving 

treatment 

response 

Why it is important to do this review

SH  in  children  and  adolescents  is  a  major  social  and  healthcare
problem. It represents significant morbidity, is often repeated, and
is linked with suicide. Many countries now have suicide prevention
strategies, all of which include a focus on improved management of
children and adolescents who engage in SH (WHO 2014a). SH is also
associated with substantial healthcare costs (Kinchin 2017; Sinclair
2011).

In  the  UK,  the  National  Collaborating  Centre  for  Mental  Health
(NCCMH)  produced  the  first  guideline  on  the  treatment  of  SH
behaviours  in  2004  (NCCMH  2004).  This  guideline  focused  on
the  short-term  physical  and  psychological  management  of  SH.
They  updated  this  guidance  in  2011,  using  interim  data  from  a
previous version of this review as the evidence-base, and focused
on the longer-term psychological management of SH (NICE 2011).
Subsequently, similar guidelines have been published by the Royal
College  of  Psychiatrists  (Royal  College  of  Psychiatrists  2014),  the
Royal Australian and New Zealand College of Psychiatrists (Carter

While exact eligibility criteria often differ both within and between
regions  and  countries  (Witt  2020b),  we  included  participants  of
both sexes and all ethnicities, who were up to 18 years of age, with a
recent (i.e. within six months of trial entry) presentation to hospital
or clinical services for SH.

We  defined  SH  as  all  intentional  acts  of  self-poisoning  (such  as
intentional  drug  overdoses)  or  self-injury  (such  as  self-cutting),
regardless of degree of suicidal intent or other types of motivation
(Hawton 2003). This definition includes acts intended to result in
death  ('attempted  suicide'),  those  without  suicidal  intent  (e.g.  to
communicate distress, to temporarily reduce unpleasant feelings;
sometimes termed 'non-suicidal self-injury'), and those with mixed
motivation.  We  did  not  distinguish  between  attempted  suicide
and non-suicidal self-injury in this review, because there is a high
level of co-occurrence between them, particularly in children and
adolescents  (Andover  2012).  Attempted  suicide  and  non-suicidal
self-injury cannot be distinguished in any reliable way, including on
levels of suicidal intent (Klonsky 2011). Lastly, the motivations for
SH are complex and can change, even within a single episode (De
Beurs 2018).

We  excluded  trials  in  which  participants  were  hospitalised  for
suicidal ideation only (i.e. without evidence of SH).

Types of interventions

Psychosocial interventions

These included:

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

1. Individual CBT-based psychotherapy;
2. Dialectical behavioural therapy;
3. Mentalisation therapy;
4. Group-based psychotherapy;
5. Enhanced assessment approaches;
6. Compliance enhancement approaches;
7. Family interventions;
8. Remote contact interventions.

Comparators

Treatment-as-usual  (TAU)  is  likely  to  vary  widely  both  between
settings and between trials conducted over different time periods
(Witt  2018).  Following  previous  work,  we  defined  TAU  as  routine
clinical  service  provision  that  children  and  adolescents  would
receive  had  they  not  been  included  in  the  trial  (i.e.  routine  care
or  'standard  disposition';  Hunt  2013).  Other  comparators  could
include no specific treatment or enhanced usual care, which refers
to TAU that has in some way been supplemented, such as providing
psychoeducation, assertive outreach, or more regular contact with
case managers, and standard assessment approaches.

Pharmacological interventions

These included:

inhibitor 

reuptake 

(SSRIs,  e.g. 

1. Tricyclic antidepressants (TADs, e.g. amitriptyline);
2. Newer  generation  antidepressants  (NGAs),  such  as  selective
fluoxetine),
serotonin 
serotonin  and  noradrenaline  reuptake 
(SNRIs,
e.g.  venlafaxine),  norepinephrine  reuptake  inhibitors  (NRIs,
e.g. reboxetine), norepinephrine-dopamine reuptake inhibitors
tetracyclic  antidepressants
(NDRIs,  e.g.  bupropion), 
serotonergic
(e.g.  maprotiline),  noradrenergic 
antidepressants 
serotonin
antagonist  or  reuptake  inhibitors  (SARIs,  e.g.  trazodone),  or
reversible inhibitors of monoamine oxidase type A (RIMAs, e.g.
moclobemide);

e.g.  mirtazapine), 

inhibitors 

(NaSSAs, 

specific 

3. Other antidepressants, such as irreversible monoamine oxidase

inhibitors (MAOIs, e.g. phenelzine);

4. Antipsychotics (e.g. quetiapine);
5. Anxiolytics,  including  both  benzodiazepines  (e.g.  diazepam),

and non-benzodiazepine anxiolytics (e.g. buspirone);

6. Mood  stabilisers, 

including  antiepileptics 

(e.g.  sodium

valporate) and lithium;

7. Other pharmacological agents (e.g. ketamine);
8. Natural  products 
supplementation).

(e.g.  omega-3  essential 

Comparators

In  pharmacological  trials,  where  a  comparison  with  the  specific
effects of a drug is being made, the comparator is typically placebo,
which consists of any pharmacologically inactive treatment, such
as  sugar  pills  or  injections  with  saline.  We  also  included  trials
in  which  another  pharmacological  intervention  (such  as  another
standard pharmacological agent, reduced dose of the intervention
agent, or active comparator) was used.

Cochrane Database of Systematic Reviews

Types of outcome measures

For all outcomes, we were primarily interested in quantifying the
effect  of  treatment  assignment  to  the  intervention  at  baseline,
regardless  of  whether  the  intervention  was  received  as  intended
(i.e. the intention-to-treat effect).

Primary outcomes

The primary outcome measure in this review was the occurrence
of  repeated  SH  over  a  maximum  follow-up  period  of  two  years.
Repetition  of  SH  was  identified  through  self-report,  collateral
report,  clinical  records,  or  research  monitoring  systems.  As  we
wished  to  incorporate  the  maximum  data  from  each  trial,  we
included  both  self-reported  and  hospital  records  of  SH,  where
available.  Preference  was  given  to  clinical  records  over  self-
report  where  a  study  reported  both  measures.  We  also  reported
proportions  of  participants  repeating  SH,  frequency  of  repeat
episodes, and time to SH repetition (where available).

Secondary outcomes

Given  increasing  interest  in  the  measurement  of  outcomes  of
importance to those who engage in SH (Owens 2020), we analysed
data for the following secondary outcomes (where available) over
a maximum follow-up period of two years.

Treatment adherence

This  was  assessed  using  a  range  of  measures  of  adherence,
including:  pill  counts,  changes  in  blood  measures,  and  the
proportion  of  participants  that  both  started  and  completed
treatment.

Depression

This  was  assessed  as  either  continuous  data,  by  scores  on
psychometric  measures  of  depression  symptoms,  for  example,
total  scores  on  the  Beck  Depression  Inventory  (BDI;  Beck  1961),
or scores on the depression subscale of the Hospital Anxiety and
Depression Scale (HADS; Zigmond 1983), or as dichotomous data
as  the  proportion  of  children  and  adolescents  who  met  defined
diagnostic criteria for depression.

Hopelessness

This  was  assessed  as  either  continuous  data,  by  scores  on
psychometric  measures  of  hopelessness,  for  example,  total
scores  on  the  Beck  Hopelessness  Scale  (BHS;  Beck  1974),  or  as
dichotomous  data  as  the  proportion  of  children  and  adolescents
reporting hopelessness.

This  was  assessed  as  either  continuous  data,  by  scores  on
psychometric measures of general functioning, for example, total
scores on the Global Assessment of Functioning (GAF; APA 2000), or
as dichotomous data as the proportion of children and adolescents
reporting improved general functioning.

Social functioning

This  was  assessed  as  either  continuous  data,  by  scores  on
psychometric  measures  of  social  functioning,  for  example,  total
scores on the Social Adjustment Scale (SAS; Weissman 1999), or as
dichotomous  data  as  the  proportion  of  children  and  adolescents
reporting improved social functioning.

fatty  acid

General functioning

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Suicidal ideation

This  was  assessed  as  either  continuous  data,  by  scores  on
psychometric  measures  of  suicidal  ideation,  for  example,  total
scores on the Beck Scale for Suicidal Ideation (BSSI; Beck 1988), or
as dichotomous data as the proportion of children and adolescents
reaching a defined cut-off for ideation.

Suicide

This included register-recorded deaths, or reports from collateral
informants, such as family members or neighbours.

Other

interventions  for  SH  in  children  and  adolescents  (Asarnow  2019;
Berk  2016;  Brent  2019;  Busby  2020;  Calear  2016;  Cox  2017;
Davasaambuu  2019;  Devenish  2016;  Flaherty  2018;  Glenn  2019;
Hawton  2015;  Iyengar  2018;  Joe  2018;  Kothgassner  2020;  Labelle
2015; Morken 2020; Robinson 2018; Yuan 2019).

Correspondence

We consulted the corresponding authors of trials, and other experts
in  the  field  to  find  out  if  they  were  aware  of  any  ongoing  or
unpublished  RCTs  on  the  treatment  of  children  and  adolescents
who  engage  in  SH  that  were  not  identified  by  the  electronic
searches.

We  remain  open  to  including  additional  secondary  outcomes,
based on current outcome prioritisation work being undertaken by
the author team.

Data collection and analysis

Selection of studies

Search methods for identification of studies

Electronic searches

Review  authors  KW,  KH,  and  one  of  either  SH,  GR,  TTS,  ET,  or
PH, independently assessed the titles of reports identified by the
electronic search for eligibility. We distinguished between:

An 
information  specialist  searched  the  following  databases
(to  4  July  2020),  using  relevant  subject  headings  (controlled
vocabularies)  and  search  syntax  as  appropriate 
for  each
resource: Cochrane Common Mental Disorders Specialised Register
(Appendix  1),  Cochrane  Library  (Cochrane  Central  Register  of
Controlled  Trials;  CENTRAL),  Cochrane  Database  of  Systematic
Reviews (CDSR), MEDLINE Ovid, Embase Ovid, and PsycINFO Ovid
(Appendix 2).

A date restriction was applied as the search was to update an earlier
version  of  this  review  (Hawton  2015).  However,  we  did  not  apply
any  further  restrictions  on  language  or  publication  status  to  the
searches.

We searched for retraction statements and errata once the included
studies were selected.

We  also  searched  the  World  Health  Organization  International
Clinical Trials Registry Platform, and the US National Institutes of
Health Ongoing Trials Register ClinicalTrials.gov to identify ongoing
trials.

The  search  was  based  on  population  only,  participants  who  self-
harm (all ages). Records were screened to identify trials which were
relevant to this review and two others (Witt 2021; Witt 2020c).

Searching other resources

Conference abstracts

In addition to conference abstracts retrieved via the main electronic
search, we also screened the proceedings of recent (last five years)
conferences organised by the largest scientific committees in the
field:

1. International  Association  for  Suicide  Prevention  (both  global

congresses and regional conferences), and;

2. Joint International Academy of Suicide Research and American
Foundation  for  Suicide  Prevention  International  Summits  on
Suicide Research.

Reference lists

We  also  checked  the  reference  lists  of  all  relevant  RCTs,  and
the  reference  lists  of  major  reviews  that  included  a  focus  on

1. eligible  or  potentially  eligible  trials  for  retrieval,  in  which
any  psychosocial  or  psychopharmacological  treatment  was
compared  with  a  comparator 
treatment-as-usual,
routine  psychiatric  care,  enhanced  usual  care,  active
comparator, placebo, alternative pharmacological treatment, or
a combination of these);
ineligible  general  treatment  trials,  not  for  retrieval  (i.e.  where
there was no control treatment).

(e.g. 

2.

All  trials  identified  as  potentially  eligible  for  inclusion  then
underwent  a  second  screening.  Pairs  of  review  authors,  working
independently from one another, screened the full text of eligible
or  potentially  eligible  trials  to  identify  whether  the  trial  met  our
inclusion criteria. We resolved disagreements in consultation with
the senior review author (KH). Where disagreements could not be
resolved  from  the  information  reported  in  the  trial,  or  where  it
was  unclear  whether  the  trial  satisfied  our  inclusion  criteria,  we
contacted corresponding trial authors for additional clarification.

We identified and excluded duplicate records, and collated multiple
reports of the same trial, so that each trial, rather than each report,
represented  the  unit  of  interest  in  the  review.  We  recorded  the
selection  process  in  sufficient  detail  to  complete  a  PRISMA  flow
diagram,  and  completed  a  'Characteristics  of  excluded  studies'
table (Liberati 2009).

Data extraction and management

Review  author  KW  and  one  of  either  SH  or  GR  independently
extracted  data  from  the  included  trials,  using  a  standardised
extraction form. Where there were any disagreements, they were
resolved in consensus discussions with KH.

Data extracted from each eligible trial included:

1. Participant  information:  number  randomised,  number  lost  to
follow-up  or  withdrawn,  number  analysed,  mean  or  median
age,  sex  composition,  diagnoses,  diagnostic  criteria,  inclusion
criteria, and exclusion criteria.

2. Methods: trial design, total duration of the trial, details of any
'run in' period (if applicable), number of trial centres and their
location, setting, and date.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

3. Intervention(s):  details  of  the  intervention,  including  dose,
duration,  route  of  administration,  whether  concomitant
treatments were permitted and details of these treatments, and
any excluded treatments.

4. Comparators(s):  details  on  the  comparator,  including  dose,
duration,  route  of  administration,  whether  concomitant
treatments were permitted and details of these treatments, and
any excluded treatments.

5. Outcomes:  raw  data  for  each  eligible  outcome  (see  Types  of
outcome  measures),  details  of  other  outcomes  specified  and
reported, and time points at which outcomes were reported.
6. Notes:  source  of  trial  funding,  and  any  notable  conflicts  of

interest of trial authors.

We  extracted  both  dichotomous  and  continuous  outcomes  data
from  eligible  trials.  As  the  use  of  non-validated  psychometric
scales is associated with bias, we extracted continuous data only
if the psychometric scale used to measure the outcome of interest
had been previously published in a peer-reviewed journal, and was
not  subjected  to  item,  scoring,  or  other  modification  by  the  trial
authors (Marshall 2000).

We planned the following main comparisons:

1. Individual  CBT-based  psychotherapy  (e.g.  CBT,  PST)  versus

treatment as usual (TAU) or other comparator;

2. Dialectical  behaviour  therapy  (DBT)  versus  TAU  or  other

comparator;

3. Mentalisation-based therapy versus TAU or other comparator;
4. Group-based psychotherapy versus TAU or other comparator;
5. Enhanced  assessment  approaches  versus  TAU  or  other

comparator;

6. Compliance  enhancement  approaches  versus  TAU  or  other

comparator;

7. Family interventions versus TAU or other comparator;
8. Remote contact interventions versus TAU or other comparator;
9. Tricyclic  antidepressants  versus  placebo  or  other  comparator

drug or dose;

10.Newer  generation  antidepressants  versus  placebo  or  other

comparator drug or dose;

11.Any other antidepressants versus placebo or other comparator

drug or dose;

12.Antipsychotics  versus  placebo  or  other  comparator  drug  or

dose;

13.Anxiolytics, 

including  both  benzodiazepines  and  non-
benzodiazepine anxiolytics, versus placebo or other comparator
drug or dose;

14.Mood  stabilisers,  including  antiepileptics  and  lithium,  versus

placebo or other comparator drug or dose;

15.Other  pharmacological  agents  versus  placebo  or  other

comparator drug or dose;

16.Natural  products  versus  placebo  or  other  comparator  drug  or

dose.

Assessment of risk of bias in included studies

Highly  biased  studies  are  more  likely  to  overestimate  treatment
effectiveness  (Moher  1998).  Review  author  KW  and  one  of  either
SH or GR independently evaluated the risk of bias for the primary
outcome  (i.e.,  repetition  of  SH  at  post-intervention)  by  using

Cochrane Database of Systematic Reviews

version 2 of the Cochrane Risk of Bias tool, RoB 2 (Sterne 2019). This
tool encourages consideration of the following domains:

1. Bias in the randomisation process.
2. Deviations  from  the  intended  intervention  (assignment  to

intervention).

3. Missing outcome data.
4. Bias in the measurement of the outcome.
5. Bias in the selection of the reported result.

For cluster-RCTs, we also evaluated the following:

1. Bias arising from the timing of identification and recruitment of

participants.

Signalling  questions  in  the  RoB  2  tool  provided  the  basis  for  the
tool’s domain-level judgements about the risk of bias. Two review
authors independently judged each source of potential bias as low
risk, high risk, or some concerns. An overall 'Risk of bias' judgement
was then made for each study by combining ratings across these
domains.  Specifically,  if  any  of  the  above  domains  were  rated  at
high risk, the overall 'Risk of bias' judgement was rated as high risk.
We reported this overall judgement, which could be low risk, high
risk, or some concerns, in the text of the review, and in the 'Risk of
bias' tables.

Where inadequate details were provided in the original report, we
contacted corresponding trial authors to provide clarification. We
resolved disagreements through discussions with KH.

We  entered  and  organised  our  RoB  2  assessments  on  an  Excel
spreadsheet  (Microsoft  Excel  RoB2  Macro),  and  made  them
available as electronic supplements.

Measures of treatment effect

Dichotomous outcomes

We  summarised  dichotomous  outcomes,  such  as  the  number
of  participants  engaging  in  a  repeat  SH  episode,  or  number  of
deaths  by  suicide,  using  the  summary  odds  ratio  (OR)  and  the
accompanying  95%  confidence  interval  (CI),  as  the  OR  is  the
most appropriate effect size statistic for summarising associations
between two dichotomous groups (Fleiss 1994).

Continuous outcomes

For  outcomes  measured  on  a  continuous  scale,  we  used  mean
differences  (MD)  and  accompanying  95%  CI  where  the  same
outcome  measure  was  used.  Where  different  outcome  measures
were used, we used the standardised mean difference (SMD) and its
accompanying 95% CI.

We aggregated trials in a meta-analysis only where treatments were
sufficiently similar. For trials that could not be included in a meta-
analysis, we provided narrative descriptions of the results.

Hierarchy of outcomes

Where  a  trial  measured  the  same  outcome  (for  example,
depression)  in  two  or  more  ways,  we  planned  to  use  the  most
common  measure  across  trials  in  any  meta-analysis.  We  also
planned to report scores from other measures in a supplementary
table.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Timing of outcome assessment

The  primary  end  point  for  this  review  was  post-intervention
(i.e. at the conclusion of the treatment period). We also reported
outcomes for the following secondary end points (where data were
available):

1. Between  zero  and  six  months  after  the  conclusion  of  the

treatment period.

2. Between six and 12 months after the conclusion of the treatment

period.

3. Between 12 and 24 months after the conclusion of the treatment

period.

Where  there  was  more  than  one  outcome  assessment  within  a
time  period,  we  used  data  from  the  last  assessment  in  the  time
period, unless different outcomes were assessed at different points.
For treatment adherence, we also planned to use within-treatment
period results.

Unit of analysis issues

Zelen design trials

Trials in this area are increasingly using Zelen’s method, in which
consent is obtained subsequent to randomisation and treatment
allocation  (Witt  2020b).  This  design  may  lead  to  bias  if,  for
example,  participants  allocated  to  one  particular  arm  of  the
trial disproportionally refuse to provide consent for participation
or,  alternatively,  if  participants  only  provide  consent  if  they  are
allowed to cross over to the other treatment arm (Torgerson 2004).

Although no trial included in this review used Zelen's design, should
we  identify  a  trial  using  Zelen's  method  in  future  updates  of  this
review,  we  plan  to  extract  data  for  all  randomised  participants
as  this  is  consistent  with  Zelen's  original  intention  (Zelen  1979),
and  preserves  randomisation.  This  will  typically  be  possible  for
our  primary  outcome,  repetition  of  SH,  as  this  will  generally
be  ascertained  from  clinical,  hospital,  and/or  medical  records.
However,  for  certain  self-reported  outcome  measures,  data  may
only  be  reported  on  the  basis  of  those  who  consented  to
participation. We therefore also plan to conduct sensitivity analyses
to investigate what impact, if any, the inclusion of these trials may
have on the pooled estimate of treatment effectiveness.

Cluster-randomised trials

Cluster randomisation, for example by clinician or general practice,
can  lead  to  overestimation  of  the  significance  of  a  treatment
effect,  resulting  in  an  inflation  of  the  nominal  type  I  error  rate,
unless appropriate adjustment is made for the effects of clustering
(Donner 2002; Kerry 1998).

One trial included in this review used cluster randomisation (Ougrin
2011). We had planned to follow the guidance outlined in Higgins
2019a.  Specifically,  where  possible,  we  planned  to  analyse  data
using measures that statistically accounted for the cluster design.
Where this is was not possible, we planned to analyse data using
the effective sample size. However, the trial authors were unable
to provide values for either the inter-cluster correlation coefficient
or the design effect, and further, there was no similar cluster RCT
of  this  intervention  approach  from  which  these  values  could  be
approximated. We were therefore unable to statistically account for
the effects of clustering for this trial.

Cochrane Database of Systematic Reviews

In  future  updates  of  this  review,  should  we  be  able  to  obtain
information on either the inter-cluster correlation coefficient or the
design effect, we will follow the guidance outlined in Higgins 2019a.

Cross-over trials

is  the  carry-over
A  primary  concern  with  cross-over  trials 
effect, 
intervention  treatment
in  which  the  effect  of  the 
(e.g.  pharmacological,  physiological,  or  psychological)  influences
the  participant’s  response  to  the  subsequent  control  condition
(Elbourne 2002). As a consequence, on entry to the second phase
of the trial, participants may differ systematically from their initial
state,  despite  a  wash-out  phase.  In  turn,  this  may  result  in  a
concomitant underestimation of the effectiveness of the treatment
intervention (Curtin 2002a; Curtin 2002b). No trial included in this
review used cross-over methodology. However, should we identify
any cross-over trials in future updates of this review, we will only
extract data from the first phase of the trial, prior to cross-over, to
protect against the carry-over effect.

Studies with multiple treatment arms

No  trial  included  multiple  treatment  arms.  Should  any  trial
include  multiple  treatment  groups  where  the  intervention  arms
are  sufficiently  similar,  for  example,  where  comparison  is  made
between  two  interventions  of  the  same  type,  we  will  combine
dichotomous data. For outcomes reported on a continuous scale,
we will combine data using the formula in Higgins 2011.

Where the interventions are not sufficiently similar, we will split the
comparator arm data following the advice in Higgins 2011.

Studies with adjusted effect sizes

Where trials reported both unadjusted and adjusted effect sizes, we
included only observed, unadjusted effect sizes.

Dealing with missing data

We  did  not  impute  missing  data,  as  we  considered  that  the
bias  that  would  be  introduced  by  doing  this  would  outweigh
any  benefit  of  increased  statistical  power  that  may  have  been
gained by including imputed data. However, where authors omitted
standard  deviations  (SD)  for  continuous  measures,  we  contacted
corresponding authors to request missing data. Where missing data
could not be provided, we calculated missing SDs using other data
from the trial, such as CIs, based on methods outlined in Higgins
2019b.

Assessment of heterogeneity

Between-study heterogeneity can be assessed using either the Chi2
or I2 statistics. However, in this review, we used only the I2 statistic
to quantify inconsistency, as this is considered to be more reliable
(Deeks 2019). The I2 statistic indicates the percentage of between-
study variation due to chance, and can take any value from 0% to
100% (Deeks 2019).

We  used  the  following  values  to  denote  relative  importance  of
heterogeneity, as per Deeks 2019:

1. unimportant: 0% to 40%;
2. moderate: 30% to 60%;
3. substantial: 50% to 90%;
4. considerable: 75% to 100%.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

We also took the magnitude and direction of effects and strength of
evidence for heterogeneity into account (e.g. the CI for I2).

Where substantial levels of heterogeneity were found, we explored
reasons  for  this  heterogeneity  (see  Subgroup  analysis  and
investigation of heterogeneity for details).

Assessment of reporting biases

Reporting bias occurs when the decision to publish a particular trial
is influenced by the direction and significance of the results (Egger
1997). Research suggests, for example, that trials with statistically
significant findings are more likely to be submitted for publication,
and subsequently, be accepted for publication, leading to possible
overestimation of the true treatment effect (Hopewell 2009).

To  assess  whether  trials  included  in  any  meta-analysis  were
affected by reporting bias, we planned to enter data into a funnel
plot  when  a  meta-analysis  included  results  of  at  least  10  trials.
Should  evidence  of  any  small  study  effects  be  identified,  we
planned  to  explore  reasons  for  funnel  plot  asymmetry,  including
the presence of possible publication bias (Egger 1997).

Data synthesis

Sensitivity analysis

We  planned  to  undertake  the  following  sensitivity  analyses,
where appropriate, to test whether key methodological factors or
decisions may have influenced the main result:

1. Where a trial made use of Zelen's method of randomisation (see

Unit of analysis issues);

2. Where  a  trial  contributed  to  substantial  between-study
heterogeneity  (see  Subgroup  analysis  and  investigation  of
heterogeneity).

No  included  trial  made  use  of  Zelen's  method  of  randomisation.
We  were  therefore  unable  to  undertake  sensitivity  analyses  to
investigate what impact, if any, Zelen's design had on the pooled
estimate of treatment effectiveness.

However, several meta-analyses were associated with substantial
levels  of  between-study  heterogeneity.  We  therefore  reported
results of these sensitivity analyses in the text, alongside discussion
of the likely causes of these differences.

Summary of findings and assessment of the certainty of the
evidence

For the purposes of this review, we calculated the pooled OR and
accompanying 95% CI using the random-effects model, as this is the
most appropriate model for incorporating heterogeneity between
studies  (Deeks  2019).  We  used  the  Mantel-Haenszel  method  for
dichotomous data, and the inverse variance method for continuous
data.  We  conducted  all  analyses  in  Review  Manager  5.4  (Review
Manager 2020).

For  each  comparison,  we  constructed  a  'Summary  of  findings'
table  for  our  primary  outcome  measure,  repetition  of  SH  at
post-intervention,  following  the  recommendations  outlined  in
Schünemann  2019.  These  tables  provide  information  concerning
the  overall  quality  of  the  evidence  from  all  included  trials  that
measured the outcome. We assessed the quality of evidence across
the following domains:

Subgroup analysis and investigation of heterogeneity

Subgroup analyses

We planned to undertake the following subgroup analyses where
there were sufficient data to do so:

1. sex (males versus females);
2. repeater status (first SH episode versus repeat SH episode).

Given the increasing use of enhanced usual care rather than TAU
in  trials  in  the  field  (Witt  2020b),  we  also  planned  to  undertake
subgroup  analyses  to  determine  whether  comparator  choice
influenced the pattern of results observed.

Formal tests for subgroup differences were undertaken in Review
Manager 5.4 (Review Manager 2020). However, it is only possible to
undertake these subgroup analyses if randomisation was stratified
by  these  factors,  otherwise,  there  is  the  risk  that  doing  so  could
lead  to  confounding.  Randomisation  was  stratified  by  sex  in  one
trial  (Cottrell  2018).  We  therefore  requested  data  for  the  primary
outcome of interest, repetition of SH, disaggregated by sex from the
authors for this trial. No included trial stratified randomisation by
repeater status or comparator choice.

Investigation of heterogeneity

Several  meta-analyses  were  associated  with  substantial  levels  of
heterogeneity (i.e. I2 ≥ 75%). For these analyses, KW and KH firstly
independently triple-checked data to ensure these were correctly
entered.  Next,  we  investigated  the  source  of  this  heterogeneity
using a formal statistical approach as outlined in Viechtbauer 2020.

1.
'Risk of bias' assessment.
2. Indirectness of evidence.
3. Unexplained heterogeneity or inconsistency of results.
4. Imprecision of effect estimates.
5. Potential publication bias.

For  each  of  these  domains,  we  downgraded  the  evidence  from
high certainty by one level (for serious) or by two levels (for very
serious). For risk of bias, we downgraded this domain by one level
when  we  rated  any  of  the  sources  of  risk  of  bias  (as  described
in  Assessment  of  risk  of  bias  in  included  studies)  at  high  risk  for
any  of  the  studies  included  in  the  pooled  estimate,  or  by  two
levels when we rated multiple studies at high risk for any of these
sources. For indirectness of evidence, we considered the extent to
which  trials  included  in  any  meta-analysis  used  proxy  measures
to ascertain repetition of SH; we downgraded this domain by one
level if one study used proxy measures, and by two levels if multiple
studies  used  proxy  measures.  For  unexplained  heterogeneity  or
inconsistency of results, we downgraded this domain by one level
where the I2 value indicated substantial levels of heterogeneity, or
by  two  levels  where  the  I2  value  indicated  considerable  levels  of
heterogeneity. For imprecision, we downgraded this domain by one
level where the 95% CI for the pooled effect included the null value.
Finally,  for  the  potential  publication  bias  domain,  we  considered
any  evidence  of  funnel  plot  asymmetry  (if  available),  as  well  as
other evidence such as suspected selective availability of data, and
downgraded  by  one  or  more  levels  where  publication  bias  was
suspected.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

We  then  used  these  domains  to  rate  the  overall  certainty  of
evidence for the primary outcome according to the following:

recommendations for practice and research suggest priorities for
future research, and outline the remaining uncertainties in the area.

1. High  certainty:  further  research  is  very  unlikely  to  change  our

R E S U L T S

confidence in the estimate of effect;

2. Moderate  certainty:  further  research  is  likely  to  have  an
important  impact  on  our  confidence  in  the  estimate  of  effect,
and may change the estimate;

3. Low  certainty:  further  research  is  very  likely  to  have  an
important  impact  on  our  confidence  in  the  estimate  of  effect,
and may change the estimate;

4. Very low certainty: we are very uncertain about the estimate.

We constructed 'Summary of findings' tables using GRADEpro GDT
software (GRADEpro GDT 2015).

Reaching conclusions

We based our conclusions only on findings from the quantitative
or  narrative  synthesis  of  the  studies  included  in  this  review.  Our

Description of studies

Results of the search

For this update, a total of 7186 records were found using the search
strategy  as  outlined  in  Appendix  1  and  Appendix  2.  Five  further
records were identified following correspondence and discussion
with researchers in the field. After deduplication, the initial number
was  reduced  to  4678.  Of  these,  4454  were  excluded  following
title/abstract  screening,  whilst  a  further  157  were  excluded  after
reviewing  the  full  texts  (Figure  1).  There  were  23  new  studies
(representing  nine  independent  trials)  of  interventions  for  SH  in
children and adolescents identified by this update.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   Study Flow Diagram

Cochrane Database of Systematic Reviews

Included studies

In  the  previous  version  of  this  review  (Hawton  2015),  11  trials  of
interventions  for  SH  in  children  and  adolescents  were  included.
The present update located six new trials of interventions for SH
in children and adolescents. The present review therefore includes
17  non-overlapping  trials  (Asarnow  2017;  Cooney  2010;  Cotgrove
1995;  Cottrell  2018;  Donaldson  2005;  Green  2011;  Griffiths  2019;
Harrington 1998; Hazell 2009; McCauley 2018; Mehlum 2014; Ougrin
2011; Rossouw 2012; Santamarina-Pérez 2020; Sinyor 2020; Spirito
2002; Wood 2001a).

All  trials  have  been  published.  Unpublished  data  were  obtained
from the study authors for 13 of these trials (Asarnow 2017; Cooney
2010; Cotgrove 1995; Donaldson 2005; Green 2011; Griffiths 2019;

McCauley  2018;  Ougrin  2011;  Rossouw  2012;  Santamarina-Pérez
2020; Sinyor 2020; Spirito 2002; Wood 2001a).

Design

Most  trials  (94.1%)  were  randomised  at  the  individual  level
employing  either  simple  randomisation  (Cooney  2010;  Cotgrove
1995;  Donaldson  2005;  Harrington  1998;  Santamarina-Pérez
2020;  Sinyor  2020;  Spirito  2002;  Wood  2001a),  or  a  restricted
randomisation  scheme,  such  as  a  blocking  (Griffiths  2019;  Hazell
2009; Mehlum 2014) or minimisation (Green 2011; McCauley 2018;
Rossouw 2012) procedure. Two trials used stratification (Asarnow
2017;  Cottrell  2018).  In  one  trial,  cluster  randomisation  was  used
(Ougrin 2011).

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Setting

Of  the  17  independent  RCTs  included  in  this  review,  eight  were
from  the  UK  (Cotgrove  1995;  Cottrell  2018;  Green  2011;  Griffiths
2019; Harrington 1998; Ougrin 2011; Rossouw 2012; Wood 2001a),
four were from the USA (Asarnow 2017; Donaldson 2005; McCauley
2018;  Spirito  2002),  and  one  was  from  each  of  Australia  (Hazell
2009), Canada (Sinyor 2020), New Zealand (Cooney 2010), Norway
(Mehlum 2014), and Spain (Santamarina-Pérez 2020).

In  the  majority  of  trials,  participants  were  recruited  following  a
clinical presentation for SH. In one trial (Asarnow 2017), a minority
(<  5%)  of  participants  were  recruited  from  schools;  however,  all
participants  in  this  trial  had  a  history  of  multiple  episodes  of  SH
resulting  in  presentation  to  clinical  services  within  three  months
preceding trial entry.

For  most  trials,  treatment  was  delivered  in  an  outpatient  setting
or  the  participants'  home  environment.  In  the  remaining  two
trials,  one  of  compliance  enhancement  (Spirito  2002)  and  one  of
enhanced therapeutic assessment (Ougrin 2011), the intervention
was  delivered  whilst  the  adolescent  was  receiving  treatment  in
hospital and/or the emergency department.

Participants and participant characteristics

The  included  trials  comprised  a  total  of  2280  participants.  All
had  engaged  in  at  least  one  episode  of  SH  prior  to  trial  entry.  A
history of SH prior to the index episode (i.e. a history of multiple
episodes of SH) was a requirement for participation in nine trials
(Asarnow  2017;  Cooney  2010;  Cottrell  2018;  Green  2011;  Hazell
2009;  McCauley  2018;  Mehlum  2014;  Santamarina-Pérez  2020;
Wood  2001a).  In  two  further  trials,  around  half  the  sample  had
a  history  of  multiple  episodes  of  SH  (Donaldson  2005;  Ougrin
2011). For the remaining six trials, information on the proportion
of  participants  with  a  history  of  multiple  episodes  of  SH  prior  to
the index episode was not reported (Cotgrove 1995; Griffiths 2019;
Harrington 1998; Rossouw 2012; Sinyor 2020; Spirito 2002).

Information on the methods of SH for the index episode was not
reported in the majority of trials. In one trial, only those who had
engaged in self-poisoning were eligible to participate (Harrington
1998),  whilst  in  three  further  trials,  the  majority  of  participants
had  engaged  in  self-poisoning  (Cotgrove  1995;  Donaldson  2005;
Spirito 2002). Full details on the methods used at the index episode
is  provided  in  Table  1.  Whilst  the  predominance  of  participants
engaging in self-poisoning in the majority of these trials reflects the
typical pattern observed in those who present to hospital, SH in the
community more often involves self-cutting and other forms of self-
injury (Geulayov 2018; Müller 2016).

Whilst  all  trials  included  both  male  and  female  participants,  the
majority of participants was female (87.6%), reflecting the typical
pattern  for  SH  (Hawton  2008).  Of  the  15  trials  that  reported
information on age, the weighted mean age of participants at trial
entry  was  14.7  years  (SD  1.5  years).  In  the  15  trials  that  reported
information on psychiatric diagnoses (Asarnow 2017; Cooney 2010;
Donaldson  2005;  Green  2011;  Griffiths  2019;  Harrington  1998;
Hazell 2009; McCauley 2018; Mehlum 2014; Ougrin 2011; Rossouw
2012;  Santamarina-Pérez  2020;  Sinyor  2020;  Spirito  2002;  Wood
2001a),  participants  were  most  commonly  diagnosed  with  major
depression  (64.3%),  followed  by  any  anxiety  disorder  (54.4%),
any  mood  disorder  (49.2%),  substance  use  disorder  (33.9%),  and
bipolar  disorder  (25.4%).  Around  half  (49.1%)  were  diagnosed

Cochrane Database of Systematic Reviews

with  borderline  personality  disorder.  Only  two  studies  reported
information on the proportion of participants without psychiatric
diagnoses  at  trial  entry  (Ougrin  2011;  Spirito  2002);  in  these  two
trials, just over one-third (34.5%) were not diagnosed with a major
psychiatric disorder.

Information  on  comorbid  diagnoses  was  reported  in  two  trials
(Cooney  2010;  Donaldson  2005).  Around  two-thirds  (67.6%)  were
diagnosed  with  comorbid  psychiatric  diagnoses;  however,  the
nature  of  these  co-morbidities  was  not  clearly  reported  in  either
trial.

Interventions

The trials included in this review investigated the effectiveness of
various forms of psychosocial interventions:

1. Individual  CBT-based  psychotherapy  (e.g.  CBT,  PST)  versus
treatment-as-usual (TAU) or other comparator (Donaldson 2005;
Sinyor 2020).

2. Dialectical  behaviour  therapy  (DBT)  versus  TAU  or  other
comparator  (Cooney  2010;  McCauley  2018;  Mehlum  2014;
Santamarina-Pérez 2020).

3. Mentalisation-based  therapy  versus  TAU  or  other  comparator

(Griffiths 2019; Rossouw 2012).

4. Group-based  psychotherapy  versus  TAU  or  other  comparator

(Green 2011; Hazell 2009; Wood 2001a).

5. Enhanced  assessment  approaches  versus  TAU  or  other

comparator (Ougrin 2011).

6. Compliance  enhancement  approaches  versus  TAU  or  other

comparator (Spirito 2002).

7. Family interventions versus TAU or other comparator (Asarnow

2017; Cottrell 2018; Harrington 1998).

8. Remote contact interventions versus TAU or other comparator

(Cotgrove 1995).

There were no eligible trials of pharmacological interventions for
SH in children and adolescents.

Comparators

Of  the  17  RCTs  included  in  this  review,  the  majority  (64.7%)
compared  the  intervention  to  TAU  (Cooney  2010;  Cotgrove  1995;
Cottrell  2018;  Green  2011;  Griffiths  2019;  Harrington  1998;  Hazell
2009; Ougrin 2011; Rossouw 2012; Spirito 2002; Wood 2001a). The
remaining  trials  compared  the  effectiveness  of  the  intervention
to  enhanced  usual  care  (EUC;  Asarnow  2017;  Mehlum  2014;
Santamarina-Pérez 2020), or to alternative forms of psychotherapy
(Donaldson 2005; McCauley 2018; Sinyor 2020).

Outcomes

Primary outcome

All  trials  reported  data  on  the  primary  outcome  of  this  review,
repetition of SH. In the majority of these trials this was based on
self-reported information (Asarnow 2017; Cooney 2010; Donaldson
2005;  Harrington  1998;  Hazell  2009;  McCauley  2018;  Mehlum
2014;  Rossouw  2012;  Sinyor  2020;  Spirito  2002;  Wood  2001a),
self-reported  information  supplemented  with  information  from
a  collateral  informant  such  as  a  parent  (Green  2011),  or  self-
reported  information  supplemented  by  clinical  records  (Griffiths
2019;  Santamarina-Pérez  2020).  For  the  remaining  three  trials,
information  on  repetition  of  SH  was  obtained  from  clinical  or

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

hospital  records  supplemented  with  information  from  general
practitioners,  social  workers,  and  psychologists,  where  relevant
(Cotgrove 1995), or on re-presentation to hospital (Cottrell 2018) or
emergency departments (Ougrin 2011).

Secondary outcomes

Treatment adherence

Treatment  adherence  was  assessed  as  the  proportion  of
full  course  of  treatment
participants  that  completed  the 
(Donaldson  2005;  Harrington  1998;  Ougrin  2011;  Rossouw  2012;
Hazell 2009; Sinyor 2020), or the total number of treatment sessions
attended (Cooney 2010; Mehlum 2014; Spirito 2002).

Depression

Depression  was  assessed  using 
the  Mood  and  Feelings
Questionnaire (MFQ; Angold 1995) in the majority of trials (Green
2011;  Hazell  2009;  Mehlum  2014;  Rossouw  2012;  Wood  2001a),
followed  by  the  Montgomery-Åsberg  Depression  Rating  Scale
(MADRS;  Montgomery  1979)  (Mehlum  2014;  Sinyor  2020),  the  BDI
(Santamarina-Pérez 2020; Sinyor 2020), the Children's Depression
Rating  Scale-Revised  (CDRS-R;  Poznanski  1985)  (Cottrell  2018),
the  Center  for  Epidemiologic  Studies  Depression  Scale  (CES-D;
Radloff 1991) (Donaldson 2005), and the depression subscale of the
Revised Child Anxiety and Depression Scale (RCADS; Chorpita 2000)
(Griffiths 2019).

Suicidal ideation

Suicidal 
ideation  was  assessed  using  the  Suicidal  Ideation
Questionnaire-Junior  (SIQ-JR;  Reynolds  1985;  Reynolds  1988)
in  the  majority  of  trials  (Donaldson  2005;  Green  2011;  Hazell
2009;  McCauley  2018;  Mehlum  2014;  Santamarina-Pérez  2020;
Wood  2001a),  followed  by  the  BSSI  (Cooney  2010;  Cottrell  2018;
Harrington 1998; Sinyor 2020).

Suicide

Suicide  was  assessed  using  medical  or  health  service  records
(Cottrell  2018;  Green  2011;  Hazell  2009),  or  via  interviews  with
collateral informants, like parents (Donaldson 2005). In the majority
of trials, however, it was unclear how suicide was assessed (Cooney
2010; Harrington 1998; McCauley 2018; Mehlum 2014; Ougrin 2011;
Rossouw 2012; Spirito 2002; Wood 2001a).

Excluded studies

A  total  of  157  studies  were  excluded  from  this  update.  The  most
common reason for exclusion was that not all trial participants had
engaged in SH within six month of trial entry (90 studies). Reasons
for exclusion for the remaining studies are reported in Figure 1.

Details  on  the  reasons  for  exclusion  for  the  28  trials  related  to
interventions in children and adolescents identified by this update
are reported in the Characteristics of excluded studies section.

Hopelessness

Ongoing studies

Hopelessness  was  assessed  using  the  Beck  Hopelessness  Scale
(BHS)  in  two  trials  (Harrington  1998;  Mehlum  2014),  followed  by
the  Hopelessness  Scale  for  Children  (HSC;  Kazdin  1983)  (Cottrell
2018), and by the future optimism subscale score on the Reasons
for  Living  Inventory-Adolescent  (RFL-A;  Osman  1998),  which  was
reverse coded in the present review to indicate a perceived lack of
optimism about the future (Cooney 2010).

General functioning

General  functioning  was  assessed  using  the  Children's  Global
Assessment Scale (C-GAS; Shaffer 1985) in three trials (Hazell 2009;
Ougrin  2011;  Santamarina-Pérez  2020),  and  by  the  Health  of  the
Nation  Outcome  Scales  for  Children  and  Adolescents  (HoNOSCA;
Gowers 1999) in one trial (Green 2011).

Social functioning

No included trial reported data on social functioning.

Of  the  five  ongoing  trials  identified  in  the  previous  version  of
this  review  (Hawton  2015),  three  were  included  in  this  update
(Asarnow 2017; Cottrell 2018; McCauley 2018). Two were excluded:
one was subsequently published as a case report, and one recruited
participants from non-clinical settings.

Thirteen  ongoing  studies  were  identified  in  this  update  (see
Characteristics of ongoing studies section for further information).

Studies awaiting classification

There  were  no  potentially  eligible  studies  which  have  not  been
included in this review.

Risk of bias in included studies

Risk of bias was evaluated for the primary outcome repetition of SH
at post-intervention. The results of the 'Risk of bias' assessments
can be seen in Figure 2. Full 'Risk of bias' assessments, including
the  evidence  we  used  to  justify  our  ratings,  are  available  here:
doi.org/10.6084/m9.figshare.14152364.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 2.   Results of 'Risk of bias' assessments for each study

Bias arising from randomisation process

All  trials  used  random  allocation  to  assign  participants  to  the
intervention and comparator arms. We therefore rated the majority
(76.5%)  as  having  a  low  risk  of  bias  for  this  domain.  Most  trials
(94.1%)  randomised  at  the  individual  level.  In  one  trial,  cluster
randomisation  was  used  (Ougrin  2011).  Three  trials  were  rated
as  having  some  concerns  for  this  domain.  For  two  older  trials
(Cotgrove 1995; Donaldson 2005), insufficient detail on allocation
concealment  was  reported.  For  the  third,  baseline  differences
between  the  intervention  and  comparator  arms  suggested  there
may  have  been  a  problem  with  the  randomisation  process.
Specifically, over half (55.0%) of those allocated to the intervention
arm were diagnosed with probable borderline personality disorder,
compared  to  15.0%  of  those  allocated  to  the  comparator  arm
(Griffiths 2019). One trial was rated as having high risk of bias for
this  domain  as  those  allocated  to  the  intervention  arm  had  very
significantly  higher  hopelessness  scores  at  baseline  compared  to
those in the comparator arm (Spirito 2002), suggesting there may
have been a problem with the randomisation process. Additionally,
no information on allocation concealment was reported in this trial.

it  is  unclear  how  these  cases  were  assessed  in  subsequent
analyses.  Additionally,  the  trial  authors  claimed  the  intervention
was effective in preventing repeat SH even though comparison of
repetition rates did not show a difference between arms, suggesting
that selective reporting may have been apparent.

Bias due to missing outcome data

The  majority  of  trials  (88.2%)  were  at  low  risk  of  bias  for  this
domain  as  fewer  than  5%  of  the  data  were  missing  at  the  post-
intervention  assessment,  or  the  proportion  of  missing  data  was
balanced  between  the  intervention  and  control  arms  at  post-
intervention. However, there were some concerns with respect to
this domain for two trials. For one of these, there was evidence of
a slightly larger proportion of missing data for the comparator arm
as  compared  to  the  intervention  arm  (Hazell  2009),  whilst  in  the
second, the proportion of missing data in the intervention arm was
over  double  that  of  the  proportion  missing  from  the  comparator
arm  (Spirito  2002).  Neither  of  these  trials  undertook  sensitivity
analyses to investigate the impact that missing data may have had
on the estimate of treatment effectiveness.

Bias due to deviations from intended interventions

Bias in measurement of the outcome

Whilst participants and clinical personnel were, typically, not blind
to  allocation  owing  to  likely  differences  in  treatment  intensity
between  the  intervention  and  control  arms,  most  trials  (82.3%)
were  nonetheless  rated  as  at  low  risk  of  bias  for  this  domain
as  no  deviations  from  the  intended  intervention  were  apparent
and  analyses  were  conducted  on  an  intention-to-treat  (ITT)
basis, although the statistical method(s) used to undertake these
analyses was not always clearly reported. Two trials were rated as
having some concerns for this domain. For one of these (Cooney
2010),  per  protocol  analyses  were  undertaken  and,  additionally,
some  minor  departures  from  the  intended  intervention  occurred
as a result of the experimental context. In the second, insufficient
information was reported on the analysis method(s) used (Spirito
2002).  One  trial  was  rated  as  having  high  risk  of  bias  for  this
domain (Cotgrove 1995). In this trial, some participants randomised
to  the  control  group  mistakenly  received  the  intervention  and

There  were  some  concerns  regarding  bias  in  the  measurement
of  the  outcome  for  around  half  (52.9%)  of  the  trials  included
in  this  review.  Typically,  this  was  because  repetition  of  SH  was
ascertained from self-reported information alone and participants
were  either  not  blind  to  treatment  allocation  and/or  participant
blinding was unlikely to have been possible given the differences
in therapeutic intensity between the intervention and control arms
(Asarnow 2017; Cooney 2010; Green 2011; Harrington 1998; Hazell
2009;  McCauley  2018;  Mehlum  2014;  Sinyor  2020;  Spirito  2002).
Two  trials  were  rated  as  having  high  risk  of  bias  for  this  domain
(Rossouw  2012;  Wood  2001a).  In  the  first  trial,  repetition  of  SH
was  determined  from  cut-scores  on  the  RTSHI  and  it  is  unclear
how this scale may relate to actual self-harming behaviour. In the
second, the definition of repetition of SH was based on there being
two or more further episodes, whilst in the two remaining trials of
this intervention approach (i.e. group-based psychotherapy; Green

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

2011; Hazell 2009), repetition was based on there being any further
episodes of SH.

Bias in selection of the reported result

Only two trials (11.8%) were rated as being at low risk of bias for
this domain. Of these, only one trial clearly reported that data had
been analysed in accordance with a prespecified analysis plan that
had been finalised before unblinded outcome data had been made
available  for  analysis  (Cottrell  2018),  whilst  for  the  second,  there
had been no major departures from the analysis plan as outlined in
either a published trial protocol or clinical trials register (Asarnow
2017).

Instead,  the  majority  (70.6%)  of  the  trials  included  in  this  review
were  rated  as  having  some  concerns  for  this  domain.  In  the
majority of cases, this was because trials were published prior to
the  International  Committee  of  Medical  Journal  Editors'  (ICMJE)
requirement  in  2015  that  all  trials  be  preregistered  in  a  publicly
available  clinical  trials  registry.  It  was,  therefore,  difficult  to
determine  whether  data  had  been  analysed  according  to  a
prespecified  plan,  although  there  were  no  apparent  departures
from  the  analyses  outlined  in  the  methods  section  of  these
trials (Cooney 2010; Cotgrove 1995; Donaldson 2005; Green 2011;
Harrington  1998;  Mehlum  2014;  Rossouw  2012).  For  two  trials
published subsequent to the ICMJE requirement, this domain was
also rated as having some concerns, as the information provided
within  the  clinical  trials  record  was  not  sufficiently  detailed  to
determine whether there had been departures from the proposed
analysis  plan  (Griffiths  2019;  Santamarina-Pérez  2020).  For  three
further  trials,  there  were  some  concerns  for  this  domain  as  data
on repetition of SH for one or more eligible time point(s) was not
reported (Hazell 2009; McCauley 2018; Wood 2001a); however, in all
three of these trials, it was unlikely that the results were selectively
reported for favourability.

Three trials were rated as being at high risk of bias for this domain
as,  although  repetition  of  SH  was  a  prespecified  outcome,  data
had  to  be  requested  from  the  trial  authors  (Ougrin  2011;  Spirito
2002) and one trials had not been preregistered with a clinical trials
register despite being published subsequent to 2015 (Sinyor 2020).

Overall bias

As a consequence, most trials (94.1%) were rated as either having
some concerns (k = 10; 58.8%) or were at high risk of bias ( k = 6;
35.3%).

Effects of interventions

See: Summary of findings 1 Comparison 1: Individual CBT-based
psychotherapy compared to TAU or other comparator for self-harm
in children and adolescents; Summary of findings 2 Comparison
2: DBT-A compared to TAU or another comparator for self-harm in
children and adolescents; Summary of findings 3 Comparison 3:
MBT-A  compared  to  TAU  or  another  comparator  for  self-harm  in
children and adolescents; Summary of findings 4 Comparison 7:
Family therapy compared to placebo for self-harm in children and
adolescents

Comparison 1: Individual CBT-based psychotherapy (e.g. CBT,
PST) versus treatment-as-usual (TAU) or other comparator

The  effectiveness  of  CBT-based  psychotherapy  (i.e.  up  to
10  treatment  sessions)  versus  alternative  psychotherapy  was

Cochrane Database of Systematic Reviews

assessed in two trials of children and adolescents (weighted mean
age: 16.1 ±  2.7 years; 77.8% female) presenting to clinical services
following  an  episode  of  SH.  In  the  first  trial,  the  comparator  was
supportive relationship therapy, which was designed to be as close
as  possible  to  TAU  for  this  population  (Donaldson  2005,  N  =  39).
In the second, the comparator was minimally-directive supportive
psychotherapy (Sinyor 2020, N = 24).

Primary outcome

1.1 Repetition of SH

two 

from 

show 

trials  did  not 

Data 
that  CBT-based
psychotherapy  reduces  repetition  of  SH  by  post-intervention
(i.e.  conclusion  of  the  acute  phase)  compared  to  alternative
psychotherapy  (OR  0.93,  95%  CI  0.12  to  7.24;  N  =  51,  k  =  2;  I2  =
29%;  Analysis  1.1).  The  overall  risk  of  bias  was  high  for  one  trial
(Sinyor  2020)  and  there  were  some  concerns  for  the  other  trial
(Donaldson  2005).  According  to  GRADE  criteria,  we  judged  the
evidence to be of low certainty.

For  the  second  of  these  trials  (Sinyor  2020),  whilst  time  to  SH
repetition  was  also  recorded,  correspondence  with  trial  authors
revealed that so few participants remained in the study until the
conclusion of the booster phase that the data for this outcome were
determined to be too unreliable.

Secondary outcomes

1.2 Treatment adherence

There was no evidence of an effect for CBT-based psychotherapy on
the proportion of participants who completed the acute treatment
phase (Analysis 1.2).

information  on  the  proportion  of
One  trial  also  reported 
participants who completed both the acute and booster phases of
treatment;  however,  there  was  no  evidence  of  an  effect  for  CBT-
based psychotherapy (1/12 versus 4/12; OR 0.18, 95% CI 0.02 to 1.95;
N = 24; k = 1; I2 = not applicable; Sinyor 2020).

There  was  no  evidence  of  an  effect  on  the  number  of  sessions
attended (Analysis 1.3). However, data on the number of treatment
sessions  attended  were  only  available  for  those  who  completed
the  three-  and  six-month  follow-up  assessments  in  one  trial
(Donaldson  2005),  whilst  only  data  on  the  number  of  treatment
sessions  attended  during  the  acute  phase  of  treatment  were
reported for the second trial as so few participants attended any
sessions during the booster phase in this trial (Sinyor 2020).

1.3 Depression

There  was  no  evidence  of  an  effect  of  CBT-based  psychotherapy
on  depression  scores  at  post-intervention  (Analysis  1.4),  or  at  12
months in one of these trials (mean 10.33, SD 11.45, n = 15 versus
mean 13.89, SD 8.28, n = 15; MD -3.56, 95% CI -10.71 to 3.59; N = 30;
k = 1; I2 = not applicable; Donaldson 2005).

For one of these trials (Sinyor 2020), depression was also measured
using the MADRS. Using these values did not materially affect this
result (mean 17.36, SD 13.12, n = 11 versus mean 22.30, SD 12.55, n =
10; MD -5.90, 95% CI -16.57 to 4.77; N = 21; k = 1; I2 = not applicable).

1.4 Hopelessness

No data available.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

1.5 General functioning

No data available.

1.6 Social functioning

No data available.

1.7 Suicidal ideation

There  was  also  no  evidence  of  an  effect  of  CBT-based
psychotherapy  on  suicidal  ideation  scores  at  post-intervention
(Analysis 1.5), or at 12 months in one trial (mean 24.89, SD 28.52, n
= 15 versus mean 33.33, SD 30.42, n = 15; MD -8.44, 95% CI -29.54 to
12.66; N = 30; k = 1; I2 = not applicable; Donaldson 2005).

1.8 Suicide

No participants died by suicide in either of these trials, including
by the 12-month follow-up assessment in one of them (Donaldson
2005).

Subgroup analyses

No included trial stratified randomisation by sex or repeater status.

Sensitivity analyses

Not applicable.

Comparison 2: Dialectical behaviour therapy (DBT) versus TAU
or another comparator

Four trials evaluated the effectiveness of a DBT program specially
adapted for adolescents (i.e. DBT-A), comprising individual, group-
based,  and  family  therapy  sessions,  in  children  and  adolescents
(weighted mean age: 15.2 ± 1.5 years; 90.4% female) with a history
of multiple episodes of SH compared to either TAU (Cooney 2010, N
= 29), EUC (Mehlum 2014, N = 77; Santamarina-Pérez 2020, N = 35),
or alternative psychotherapy (McCauley 2018, N = 173).

Primary outcome

2.1 Repetition of SH

Data  from  these  four  trials  showed  there  was  evidence  of  an
effect of DBT-A on repetition of SH at post-intervention (OR 0.46,
95%  CI  0.26  to  0.82;  N  =  270;  k  =  4;  I2  =  0%;  Analysis  2.1).
Although there were some concerns with regards to the overall risk
of bias for all four trials, according to the GRADE criteria, we judged
the evidence to be of high certainty.  There was no evidence of a
difference  by  comparator  (i.e.  TAU  versus  EUC  versus  alternative
psychotherapy).

However, there was no longer evidence of an effect for DBT-A, as
compared to alternative psychotherapy, on repetition of SH by 12
months in one of these trials (27/71 versus 30/58; OR 0.57, 95% CI
0.28 to 1.16; N = 129; k = 1; I2 = not applicable; McCauley 2018).

With  respect  to  frequency  of  repeat  SH  episodes,  there  was  no
evidence of an effect of DBT-A at the post-intervention assessment
(Analysis  2.2).  Once  again,  there  was  no  evidence  of  a  difference
based on comparator.

There was also no evidence of an effect for DBT-A, as compared to
alternative psychotherapy, on frequency of repeated SH by the 12-
month follow-up assessment in one of these trials (mean 2.54, SD
11.92, n = 71 versus mean 4.53, SD 18.30, n = 58; MD -1.99, 95% CI
-7.46 to 3.48; N = 129; k = 1; I2 = not applicable; McCauley 2018).

Cochrane Database of Systematic Reviews

Secondary outcomes

2.2 Treatment adherence

There  was  evidence  of  an  effect  for  DBT-A  when  compared  with
alternative  psychotherapy  on  the  proportion  of  children  and
adolescents  who  completed  treatment  in  one  trial  (39/86  versus
14/87; OR 4.33, 95% CI 2.12 to 8.82; N = 173; k = 1; I2 = not applicable;
McCauley 2018).

There  was  no  evidence  of  an  effect  for  DBT-A  on  the  number
of  individual  therapy  sessions  attended  (Analysis  2.3);  however,
there was evidence of an effect by comparator (test for subgroup
differences: Chi2 = 36.7, df = 2, P < 0.001, I2 = 94.5%). Specifically,
when  compared  to  either  TAU  or  alternative  psychotherapy,
participants  randomised  to  DBT-A  attended  a  greater  number  of
individual therapy sessions.

There  was  no  evidence  of  an  effect  for  DBT-A  on  the  number
of  group  therapy  sessions  attended  (Analysis  2.4).  There  was  no
evidence  of  a  difference  based  on  comparator.  There  was  also
no  evidence  that  children  and  adolescents  randomised  to  DBT-A
attended a greater number of family therapy sessions (Analysis 2.5);
however, there was evidence of a difference by comparator for this
outcome (test for subgroup differences: Chi2 = 5.4, df = 1, P = 0.02,
I2 = 81.5%).

Compared  with  TAU,  participants  randomised  to  DBT-A  attended
a greater number of family therapy sessions. Finally, there was no
evidence of an effect for DBT-A on the number of telephone therapy
sessions in two trials (Analysis 2.6), or on the number of medication
review meetings attended in one trial (mean 2.40, SD 2.20, n = 14
versus mean 1.60, SD 2.90, n = 15; MD 0.80, 95% CI -1.07 to 2.67; N
= 29; k = 1; Cooney 2010).

2.3 Depression

There  was  evidence  of  an  effect  for  DBT-A  as  compared  to  EUC
on depression scores at post-intervention in two trials (SMD -0.42,
95%  CI  -0.81  to  -0.03;  N  =  103;  k  =  2;  I2  =  0%;  Analysis  2.7).  Data
on  depression  was  also  measured  as  scores  on  the  depression
subscale of the MFQ in one of these trials (Mehlum 2014); however,
there  was  no  evidence  of  an  effect  for  DBT-A  according  to  this
measure (mean 10.2, SD 5.0, n = 39 versus mean 12.6, SD 6.6, n = 38;
MD -2.39, 95% CI -5.02 to 0.24; N = 77; k = 1; I2 = not applicable).

Data on depression scores, measured using both the MADRS and
the depression subscale of the MFQ were also available for one of
these trials by the 12-month assessment (Mehlum 2014); however,
there  was  no  evidence  of  an  effect  for  DBT-A  according  to  either
measure by this time point in this trial (MADRS: mean 15.09, SD 8.08,
n = 38 versus mean 15.73, SD 9.06, n = 37; MD -0.64, 95% CI -4.53 to
3.25; N = 75; k = 1; I2 = not applicable; SMFQ: mean 9.88, SD 5.53, n =
38 versus mean 9.19, SD 6.57, n = 37; MD 0.69, 95% CI -2.06 to 3.44;
N = 75; k = 1; I2 = not applicable).

2.4 Hopelessness

There was evidence of an effect for DBT-A on hopelessness scores at
the post-intervention assessment (SMD -0.62, 95% CI -1.07 to -0.16;
N = 100; k = 2; I2 =  13%; Analysis 2.8). There was no evidence of a
difference by comparator.

However,  there  was  no  longer  evidence  of  an  effect  for  DBT-A,
as  compared  to  EUC,  on  hopelessness  scores  by  the  12-month

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

assessment in one of these trials (mean 6.97, SD 5.66, n = 38 versus
mean 7.26, SD 6.57, n = 37; MD -0.29, 95% CI -3.07 to 2.49; N = 75; k
= 1; I2 = not applicable; Mehlum 2014).

2.5 General functioning

There  was  no  evidence  of  an  effect  for  DBT-A,  as  compared  to
EUC,  on  general  functioning  scores  at  post-intervention  in  two
trials  (Analysis  2.9).  The  means  obtained  by  correspondence  for
Santamarina-Pérez  2020  differ  modestly  from  those  published
(i.e. 65.00 versus 64.60 for the DBT-A arm and 54.29 versus 54.60 for
the comparator arm).

There  was  also  no  evidence  of  an  effect  for  DBT-A  on  general
functioning scores by the 12-month follow-up assessment in one
of these trials (mean 65.68, SD 11.81, n = 38 versus mean 64.22, SD
14.13, n = 37; MD 1.46, 95% CI -4.44 to 7.36; N = 75; k = 1; I2 = not
applicable; Mehlum 2014).

2.6 Social functioning

No data available.

2.7 Suicidal ideation

There  was  evidence  of  an  effect  of  DBT-A  on  suicidal  ideation  at
the post-intervention assessment in four trials (SMD -0.43, 95% CI
-0.68 to -0.18; N = 256; k = 4; I2 = 0%; Analysis 2.10). There was no
evidence of a difference based on comparator.

However, there was no longer evidence of an effect for DBT-A (as
compared  to  either  EUC  or  alterative  psychotherapy)  on  suicidal
ideation  scores  by  the  12-month  follow-up  assessment  in  two  of
these trials (Analysis 2.11). Once again, there was no evidence of a
difference based on comparator.

2.8 Suicide

Data obtained by correspondence with trial authors indicated there
were no suicides in either arm either at post-intervention or by the
12-month follow-up assessment in Cooney 2010, Mehlum 2014, or
Santamarina-Pérez  2020.  In  McCauley  2018,  one  participant  who
had  been  assigned  to  the  alternative  comparator  group  died  by
suicide by the 12-month follow-up assessment.

Correspondence  with  trial  authors  for  Mehlum  2014  further
indicated there had been no suicide deaths in either arm by the 24-
month follow-up assessment in this trial.

Subgroup analyses

No included trial stratified randomisation by sex or repeater status.

Sensitivity analyses

Four  analyses  within  this  comparison  were  associated  with
substantial levels of heterogeneity (Analysis 2.3, I2 = 92%; Analysis
2.4, I2 = 94%; Analysis 2.5, I2 = 88%; Analysis 2.9, I2 = 85%); however,
analyses did not indicate any individual study was associated with
excessive influence for any of these analyses.

Comparison 3: Mentalisation-based therapy versus TAU or
other comparator

Two  trials  investigated  the  effectiveness  of  mentalisation-based
therapy  for  adolescents  (MBT-A)  in  children  and  adolescents
(weighted mean age: 15.3 ± 1.3 years; 82.8% female) presenting to

Cochrane Database of Systematic Reviews

clinical services following SH (Griffiths 2019, N = 48; Rossouw 2012;
N = 80).

Primary outcome

3.1 Repetition of SH

Data from two trials did not show that MBT-A reduced repetition of
SH compared with TAU at post-intervention (OR 0.70, 95% CI 0.06
to 8.46; N = 85; k = 2; I2 = 68%; Analysis 3.1). There was substantial
heterogeneity  when  comparing  MBT-A  and  TAU  for  repetition  of
SH  at  post-intervention  (I2  =  68%),  and  the  pooled  estimate  was
imprecise.  As  a  consequence,  according  to  the  GRADE  criteria,
we  judged  the  evidence  to  be  of  very  low  certainty.  A  sensitivity
analysis using data for the proportion of participants who scored
above  the  cut-point  suggesting  likely  SH  on  the  Risk-Taking  and
Self-Harm  Inventory  (RTSHI;  Vrouva  2010)  for  both  trials  did  not
materially affect this result (Analysis 3.2).

There was also no evidence of an effect for MBT-A on repetition of
SH by the six-month follow-up assessment in one of these trials (2/2
versus  5/9;  OR  4.09,  95%  CI  0.15  to  108.94;  N  =  11;  k  =  1;  I2  =  not
applicable; Griffiths 2019).

Once  again,  a  post-hoc  sensitivity  analysis  using  data  for  the
proportion of participants who scored above the cut-point on the
RTSHI did not materially affect this result (17/22 versus 26/26; OR
0.06, 95% CI 0.00 to 1.16; N = 48; k = 1; I2 = not applicable; Griffiths
2019).

Secondary outcomes

3.2 Treatment adherence

There  was  no  evidence  of  an  effect  for  MBT-A  on  treatment
adherence,  as  measured  by  the  number  of  adolescents  who
completed all 12 months of treatment in one of these trials (20/40
versus  17/40;  OR  1.35,  95%  CI  0.56  to  3.27;  N  =  80;  k  =  1;  I2  =  not
applicable; Rossouw 2012).

One trial reported data on treatment adherence for the intervention
arm  only  (Griffiths  2019).  In  this  trial,  correspondence  with  trial
authors indicated: "50% [of] young people attended 50% or more
sessions. Additionally, there were six (27.3%) young people who did
not attend any sessions; a further five (22.7%) who attended at least
one but less than half of the sessions; four (18.2%) who attended
between 50-75% of sessions; and seven (31.8%) who attended 75%
or more."

3.3 Depression

There was no evidence of an effect for MBT-A on depression scores
at the post-intervention assessment in two trials (Analysis 3.3), or
by the six-month assessment in one of these trials (mean 20.1, SD
5.7, n = 22 versus mean 18.5, SD 7.0, n = 26; MD 1.60, 95% CI -1.99 to
5.19; N = 48; k = 1; I2 = not applicable; Griffiths 2019).

Depression was also measured dichotomously, as the proportion
of  participants  scoring  above  the  cut-point  on  the  depression
subscale  of  the  MFQ  in  one  trial  (Rossouw  2012).  Although  fewer
adolescents  in  the  intervention  arm  scored  above  this  cut-point,
there  was  no  evidence  of  an  effect  for  MBT-A  by  the  post-
intervention assessment (19/39 versus 25/37; OR 0.46, 95% CI 0.18
to 1.16; N = 76; k = 1; I2 = not applicable).

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

3.4 Hopelessness

No data available.

3.5 General functioning

No data available.

3.6 Social functioning

No data available.

3.7 Suicidal ideation

No data available.

3.8 Suicide

Cochrane Database of Systematic Reviews

4.3 Depression

There was no evidence of an effect of group-based psychotherapy
on depression scores at either the six-month (Analysis 4.3) or 12-
month (Analysis 4.4) assessments.

4.4 Hopelessness

No data available.

4.5 General functioning

There was no evidence of an effect of group-based psychotherapy
on general functioning scores by either the six-month (Analysis 4.5)
or 12-month (Analysis 4.6) assessments in two trials.

Correspondence  with  trial  authors  indicated  that  no  participant
died  by  suicide  by  the  6-month  follow-up  assessment  in  one
of  these  trials  (Griffiths  2019),  or  by  the  12-month  follow-up
assessment in the second of these trials (Rossouw 2012).

4.6 Social functioning

No data available.

4.7 Suicidal ideation

Subgroup analyses

No included trial stratified randomisation by sex or repeater status.

There was no evidence of an effect of group-based psychotherapy
on suicidal ideation scores at either the six-month (Analysis 4.7) or
12-month (Analysis 4.8) assessments.

Sensitivity analyses

4.8 Suicide

One  analysis  within  this  comparison  was  associated  with
substantial levels of heterogeneity (Analysis 3.3, I2 = 97%); however,
analyses did not indicate any individual study was associated with
excessive influence.

There were no suicide deaths in either arm in any of the three trials
of group-based psychotherapy by the final follow-up assessment.

Subgroup analyses

No included trial stratified randomisation by sex or repeater status.

Comparison 4: Group-based psychotherapy versus TAU or
other comparator

Sensitivity analyses

The effectiveness of group therapy was assessed in three trials in
children  and  adolescents  (weighted  mean  age:  14.4  ±    1.4  years;
87.4% female) presenting to clinical services following SH (Green
2011, N = 366; Hazell 2009, N = 68; Wood 2001a, N = 63).

One  analysis  within  this  comparison  was  associated  with
substantial levels of heterogeneity (Analysis 4.2, I2 = 77%); however,
analyses did not indicate any individual study was associated with
excessive influence.

Given that the Green 2011 and Hazell 2009 trials were based in a
large part on Wood 2001a, employed the same treatment manual
(Wood 2001b), and involved authors of the earlier trial in the design
of the intervention, we grouped these trials within a single analysis.

In all three trials, group therapy involved a variety of techniques,
including CBT, PST, DBT, and group psychodynamic psychotherapy.
The  intervention  consisted  of  six  weekly  acute  group  sessions,
followed by weekly or bi-weekly group therapy sessions continuing
until the adolescent felt ready to leave the service.

Primary outcome

4.1 Repetition of SH

There was no evidence of an effect for group-based psychotherapy
on  repetition  of  SH  by  the  six-month  (Analysis  4.1)  or  12-month
(Analysis 4.2) assessments.

As  no  trial  reported  information  on  repetition  of  SH  by  the
post-intervention  assessment  (i.e.  the  primary  outcome  of  this
review) we were unable to determine the quality of evidence for this
outcome according to the GRADE criteria.

Secondary outcomes

4.2 Treatment adherence

No data available.

Comparison 5: Enhanced assessment approaches versus TAU
or other comparator

One  cluster-RCT  examined  the  effectiveness  of  enhanced
assessment  for  the  treatment  of  SH  in  children  and  adolescents
(mean  age:  15.6  ±  1.3  years;  80.0%  female)  referred  for  a
psychological assessment following SH (Ougrin 2011, N = 70).

As  the  trial  authors  were  unable  to  provide  values  for  either  the
inter-cluster correlation coefficient or the design effect, and further,
there was no similar cluster-RCT of this intervention approach from
which  these  values  could  be  approximated,  we  were  unable  to
statistically account for the effects of clustering. Results presented
in this section may therefore overestimate the effectiveness of this
intervention.

Primary outcome

5.1 Repetition of SH

There  was  no  evidence  of  an  effect  for  enhanced  therapeutic
assessment on repetition of SH by the 12-month (4/35 versus 5/34;
OR 0.75, 95% CI 0.18 to 3.06; N = 69; k = 1; I2 = not applicable) or the
24-month (7/35 versus 9/34; OR 0.69, 95% CI 0.23 to 2.14; N = 69; k
= 1; I2 = not applicable) assessments.

As  this  trial  did  not  report  information  on  repetition  of  SH  by
the post-intervention assessment (i.e. the primary outcome of this

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

review) we were unable to determine the quality of evidence for this
outcome according to the GRADE criteria.

0.15; Spirito 2002), although insufficient information was available
to allow formal testing of this.

Secondary outcomes

5.2 Treatment adherence

There  was  an  effect  for  enhanced  therapeutic  assessment  on
treatment  adherence.  Children  and  adolescents  in  the  enhanced
therapeutic assessment arm were more likely to attend their first
aftercare appointment (29/35 versus 17/35; OR 5.12, 95% CI 1.70 to
15.39; N = 70; k = 1; I2 = not applicable).

5.3 Depression

No data available.

5.4 Hopelessness

No data available.

5.5 General functioning

There  was  no  evidence  of  an  effect  for  enhanced  therapeutic
assessment  on  general  functioning  at  post-intervention  (mean
64.6, SD 12.9, n = 35 versus mean 60.1, SD 9.9, n = 35; MD 4.50, 95%
CI -0.89 to 9.89; N = 70; k = 1; I2 = not applicable).

5.6 Social functioning

No data available.

5.7 Suicidal ideation

No data available.

5.8 Suicide

Correspondence with trial authors confirmed there were no suicide
deaths in either arm by the final 24-month follow-up assessment.

Subgroup analyses

As  this  trial  did  not  report  information  on  repetition  of  SH  by
the post-intervention assessment (i.e. the primary outcome of this
review), we were unable to determine the quality of evidence for
this outcome according to the GRADE criteria.

Secondary outcomes

6.2 Treatment adherence

There was no evidence of an effect for compliance enhancement
on the proportion of participants that completed the full course of
treatment  (17/29  versus  16/34;  OR  1.59,  95%  CI  0.59  to  4.33;  N  =
63; k = 1; I2 = not applicable), or on the average number of therapy
sessions attended (mean 7.70, SD 5.80, n = 29 versus mean 6.40, SD
4.40,  n  =  34;  MD  1.30,  95%  CI  -1.28  to  3.88;  N  =  63;  k  =  1;  I2  =  not
applicable).

6.3 Depression

No data available.

6.4 Hopelessness

No data available.

6.5 General functioning

No data available.

6.6 Social functioning

No data available.

6.7 Suicidal ideation

No data available.

6.8 Suicide

No included trial stratified randomisation by sex or repeater status.

There were no suicide deaths in either arm by the final follow-up
assessment.

Sensitivity analyses

Not applicable.

Comparison 6: Compliance enhancement approaches versus
TAU or other comparator

One  trial  investigated  the  effectiveness  of  standard  aftercare
planning  plus  an  added  compliance  enhancement  approach
(consisting of a series of four telephone calls at 1, 2, 4 and 8 weeks'
post-discharge)  to  standard  aftercare  planning  alone  in  children
and adolescents (mean age: not reported; 86.2% female) admitted
to  the  emergency  department  of  a  general  hospital  following  an
episode of SH (Spirito 2002, N = 76).

Primary outcome

6.1 Repetition of SH

There was no evidence of an effect for compliance enhancement
on repetition of SH by the six-month follow-up assessment (3/29
versus  5/34;  OR  0.67,  95%  CI  0.15  to  3.08;  N  =  63;  k  =  1;  I2  =  not
applicable).  Participants  in  the  compliance  enhancement  group
did, however, “engage in fewer repeat SH episodes” over this period
compared to participants in the control group (mean 0.10 versus

Subgroup analyses

No included trial stratified randomisation by sex or repeater status.

Sensitivity analyses

Not applicable.

Comparison 7: Family interventions versus TAU or other
comparator

Three trials compared the effectiveness of a family intervention to
either TAU (Cottrell 2018, N = 832; Harrington 1998, N = 162) or EUC
(Asarnow 2017, N = 42) in children and adolescents (weighted mean
age: 14.3 ± 1.4 years; 88.7% female) presenting to clinical services
following SH.

In one older trial, therapy was delivered in the adolescent's home
(Harrington 1998) whilst in the remaining two trials, therapy was
delivered in an outpatient setting (Asarnow 2017; Cottrell 2018).

Primary outcome

7.1 Repetition of SH

There was no evidence of an effect for family therapy interventions
on repetition of SH at post-intervention in two trials (OR 1.00, 95%

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

CI  0.49  to  2.07;  N  =  191;  k  =  2;  I2  =  0%;  Analysis  5.1).  There  was
no evidence of a difference based on comparator (i.e. TAU versus
EUC) for this outcome. According to GRADE criteria, we judged the
evidence to be of moderate certainty.

There  was  also  no  evidence  of  an  effect  for  family  therapy  on
repetition  of  SH  by  the  18-month  follow-up  assessment  in  one
further trial (118/415 versus 103/417; OR 1.21, 95% CI 0.89 to 1.65;
N = 832; k = 1; I2 = 0%; Cottrell 2018).

Two trials also reported data on time to SH repetition. There was
no evidence of an effect for family therapy, as compared to EUC, on
time  to  repetition  by  the  post-intervention  assessment  (Asarnow
2017). There was also no effect on time to SH repetition for family
therapy as compared to TAU by the 18-month assessment in one
further trial (HR 1.14, 95% CI 0.87 to 1.49; P = 0.33; Cottrell 2018).

Secondary outcomes

7.2 Treatment adherence

Treatment adherence was measured as the proportion of children
and  adolescents  who  completed  the  full  course  of  treatment  in
two trials (Cottrell 2018; Harrington 1998). There was evidence of
an effect for family therapy on treatment adherence by six months
(OR 1.99, 95% CI 1.55 to 2.57; N = 993; k = 2; I2 = 0%; Analysis 5.2).

7.3 Depression

There was no evidence of an effect for family therapy on depression
scores at either the 12-month (mean 33.2, SD 22.9, n = 248 versus
mean 33.9, SD 21.7, n = 189; MD -0.70, 95% CI -4.91 to 3.51; N = 437;
k = 1; I2 = not applicable), or 18-month (mean 30.6, SD 21.9, n = 204
versus mean 31.6, SD 19.0, n = 165; MD -1.00, 95% CI -5.18 to 3.18;
N = 369; k = 1; I2 = not applicable) assessments in one trial (Cottrell
2018).

7.4 Hopelessness

Cochrane Database of Systematic Reviews

(Cottrell 2018). There was no evidence of an effect for family therapy
on the proportion of participants with suicidal ideation at the 12-
month  (111/257  versus  98/202;  OR  0.81,  95%  CI  0.56  to  1.17;  N  =
459; k = 1; I2 = not applicable) or 18-month (85/212 versus 80/180;
OR  0.84,  95%  CI  0.56  to  1.25;  N  =  392;  k  =  1;  I2  =  not  applicable)
assessments in this trial.

7.8 Suicide

There were no deaths, including by suicide, in either arm by the 18-
month follow-up assessment in one trial (Cottrell 2018).

In the remaining trial, there was no evidence of a difference in effect
for suicide by the six-month follow-up assessment. One patient in
the  family  therapy  arm  died  by  suicide;  none  died  by  suicide  in
the control group (Harrington 1998). As the denominators for the
intervention and comparator arms for this outcome are not known,
however, we could not calculate ORs for this trial.

Subgroup analyses

Randomisation was stratified by sex in two of these trials; however,
for one of these trials we were did not receive these data from the
trial authors in time for publication of this review (Asarnow 2017).

For the second trial, data on repetition of SH disaggregated by sex
were reported in a secondary publication (Cottrell 2018). There was
no evidence of an effect for family therapy on repetition of SH by the
18-month assessment in either males (11/47 versus 7/48; OR 1.79,
95%  CI  0.63  to  5.10;  N  =  95;  k  =  1;  I2  =  not  applicable)  or  females
(107/368 versus 96/369; OR 1.17, 95% CI 0.84 to 1.61; N = 737; k =
1; I2 = not applicable) in this trial. There was also no evidence of
a difference by sex for this outcome (test for subgroup differences:
chi2 = 0.59, df = 1, P = 0.44).

Sensitivity analyses

Not applicable.

There  was  no  evidence  of  an  effect  for  family  therapy  on
hopelessness scores at either the six-month (mean 4.40, SD 3.30,
n = 74 versus mean 4.20, SD 3.60, n = 74; MD 0.20, 95% CI -0.91 to
1.32, N = 148; k = 1; I2 = not applicable; Harrington 1998), 12-month
(mean 4.90, SD 4.14, n = 255 versus mean 5.20, SD 4.14, n = 201; MD
-0.30, 95% CI -1.07 to 0.47; N = 456; k = 1; I2 = not applicable; Cottrell
2018), or 18-month (mean 4.60, SD 4.26, n = 213 versus mean 4.80,
SD 4.00, n = 179; MD -0.20, 95% CI -1.02 to 0.62; N = 392; k = 1; I2 =
not applicable; Cottrell 2018).

Comparison 8: Remote contact interventions versus TAU or
other comparator

One  trial  investigated  the  effectiveness  of  an  emergency  card
enabling  children  and  adolescents  (mean  age:  14.9  years,  SD  not
reported; 84.8% female) who were admitted to hospital following
an episode of SH to re-admit themselves to the paediatric ward of
the same hospital on demand if they felt suicidal over a 12-month
period in addition to TAU (Cotgrove 1995, N = 105).

7.5 General functioning

No data available.

7.6 Social functioning

No data available.

7.7 Suicidal ideation

There was no evidence of an effect for family therapy on suicidal
ideation scores at the six-month follow-up assessment in one trial
(mean 23.6, SD 40.0, n = 74 versus mean 28.7, SD 36.3, n = 75; MD
-5.10,  95%  CI  -17.37  to  7.17;  N  =  149;  k  =  1;  I2  =  not  applicable;
Harrington 1998).

In one further trial, information on the proportion of participants
with  clinically  significant  suicidal  ideation,  as  determined  from
cut-scores  on  the  BSSI,  was  reported  in  a  secondary  publication

Primary outcome

8.1 Repetition of SH

There  was  no  evidence  of  an  effect  for  emergency  cards  on
repetition  of  SH  by  the  12-month  follow-up  assessment  (3/47
versus  7/58;  OR  0.50,  95%  CI  0.12  to  2.04;  N  =  105;  k  =  1;  I2  =  not
applicable).

As  this  trial  did  not  report  information  on  repetition  of  SH  by
the post-intervention assessment (i.e. the primary outcome of this
review), we were unable to determine the quality of evidence for
this outcome according to the GRADE criteria.

Secondary outcomes

8.2 Treatment adherence

No data available.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

8.3 Depression

No data available.

8.4 Hopelessness

No data available.

8.5 General functioning

No data available.

8.6 Social functioning

No data available.

8.7 Suicidal ideation

No data available.

8.8 Suicide

No data available.

Subgroup analyses

No included trial stratified randomisation by sex or repeater status.

Sensitivity analyses

Not applicable.

Comparison 9: Tricyclic antidepressants versus placebo or
other comparator drug or dose

There were no eligible trials in which tricyclic antidepressants were
compared either to placebo or to other comparator drug or dose for
children and adolescents engaging in SH.

Comparison 10: Newer generation antidepressants versus
placebo or other comparator drug or dose

There were no eligible trials in which NGAs were compared either
to  placebo  or  to  other  comparator  drug  or  dose  for  children  and
adolescents engaging in SH.

Comparison 11: Any other antidepressants versus placebo or
other comparator drug or dose

There  were  no  eligible  trials  in  which  any  other  antidepressants
were compared either to placebo or to other comparator drug or
dose for children and adolescents engaging in SH.

Comparison 12: Antipsychotics versus placebo or other
comparator drug or dose

There were no eligible trials in which antipsychotics were compared
either to placebo or to other comparator drug or dose for children
and adolescents engaging in SH.

Comparison 13: Anxiolytics, including both benzodiazepines
and non-benzodiazepine anxiolytics, versus placebo or other
comparator drug or dose

There  were  no  eligible  trials  in  which  anxiolytics,  including
both  benzodiazepines  and  non-benzodiazepine  anxiolytics,  were
compared either to placebo or to other comparator drug or dose for
children and adolescents engaging in SH.

Cochrane Database of Systematic Reviews

Comparison 14: Mood stabilisers, including antiepileptics and
lithium, versus placebo or other comparator drug or dose

There  were  no  eligible  trials  in  which  mood  stabilisers,  including
antiepileptics  and  lithium,  were  compared  either  to  placebo  or
to  other  comparator  drug  or  dose  for  children  and  adolescents
engaging in SH.

Comparison 15: Other pharmacological agents versus placebo
or other comparator drug or dose

There were no eligible trials in which other pharmacological agents
were compared either to placebo or to other comparator drug or
dose for children and adolescents engaging in SH.

Comparison 16: Natural products versus placebo or other
comparator drug or dose

There  were  no  eligible  trials  in  which  natural  products  were
compared either to placebo or to other comparator drug or dose for
children and adolescents engaging in SH.

D I S C U S S I O N

This  review  included  17  trials,  six  of  which  have  been  completed
since the previous version of this review (Hawton 2015).

Previously,  we  commented  on  the  small  number  of  trials  in  this
population,  especially  given  the  size  of  the  problem  of  SH  and
its  increase  in  young  people  in  many  countries  (Bould  2019;
Lahti  2011;  Roh  2018;  Skinner  2012;  Stefanac  2019;  Sullivan
2015),  as  well  as  its  association  with  suicide  and  other  adverse
outcomes (e.g. alcohol and other substance misuse, and psychiatric
morbidity) in adulthood (Ohlis 2020). The reasons for this paucity
of  trials  are  unclear.  One  reason  may  be  that  conducting  such
trials in children and adolescents who are engaging in SH can be
particularly  challenging,  especially  in  very  young  individuals  for
whom parental consent will be required. However, there is a clear
need  for  more  and  better  quality  trials  that  can  inform  clinical
practice.

Summary of main results

The trials included in this review investigated the effectiveness of
various forms of psychosocial interventions. None of the included
trials evaluated the effectiveness of pharmacological agents in this
clinical population.

Individual CBT-based psychotherapy

On  the  basis  of  data  from  two  feasibility  trials,  there  is  probably
little to no effect of individual CBT-based psychotherapy (i.e. up to
10 acute sessions) compared with TAU on repetition of SH at post-
intervention.    There  was  also  no  evidence  of  effect  for  individual
CBT-based psychotherapy on any of the secondary outcomes.

Dialectical behaviour therapy (DBT)

On the basis of data from four trials, DBT for adolescents (DBT-A)
reduces repetition of SH at post-intervention compared with TAU
(Cooney 2010), EUC (Mehlum 2014; Santamarina-Pérez 2020), and
alternative psychotherapy (McCauley 2018).

Results for DBT-A on frequency of repeated SH by this time point
were less clear; although in contrast to our findings the trial authors
for  one  of  these  trials  analysed  the  longitudinal  slope  of  decline

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

in  the  mean  number  of  SH  episodes  per  participant  based  on
information  reported  at  the  baseline,  nine-week,  and  15-week
assessments, and reported an effect for DBT-A (Mehlum 2014). It is
difficult to rationalise these two sets of results. The results of our
analyses would, however, suggest that any differences in frequency
of SH repetition between the groups following treatment may not
be marked.

There was some evidence that those allocated to DBT-A attended
a  greater  number  of  individual  therapy  sessions  and  were  more
likely to experience some improvement by the end of the treatment
phase in some of the secondary outcomes included in this review,
including depression, hopelessness, and suicidal ideation scores.

Mentalisation-based therapy

We  are  uncertain  whether  MBT-A  reduced  repetition  of  SH  at  the
post-intervention assessment as compared with TAU on the basis
of data from two trials (Griffiths 2019; Rossouw 2012). However, this
was based on fewer adolescents scoring above the cut-point on the
Risk Taking and Self-Harm Inventory (RTSHI). It is unclear how this
scale may relate to actual SH behaviour.

There  was  no  apparent  effect  of  MBT-A  on  depression.  However,
in  contrast  to  our  findings,  the  authors  of  one  trial  reported
that  although  "[t]he  level  of  self-rated  depression  decreased  for
participants  in  both  groups...The  linear  rate  of  decrease  was
somewhat  greater  for  the  MBT-A  group  (p<0.04)  and  the  model
yielded  a  significant  difference  at  12  months"  (Rossouw  2012,  p.
1308). These results suggest there might be some effect for MBT-
A  over  usual  care  in  terms  of  this  outcome,  but  this  treatment
approach  requires  evaluation  in  further  trials  before  a  stronger
conclusion can be reached.

Group-based psychotherapy

Three trials investigated group-based therapy in adolescents with
a  history  of  multiple  SH  episodes  (Green  2011;  Hazell  2009;
Wood  2001a).  On  the  basis  of  data  from  these  three  trials,  there
is  probably  little  to  no  effect  of  group-based  psychotherapy
compared  with  TAU  on  repetition  of  SH.  However,  considerable
heterogeneity was found, with the results of the earlier two studies
showing effects in different directions (Hazell 2009; Wood 2001a),
whilst  the  results  of  the  third,  much  larger,  trial  indicated  no
superiority  of  group-based  psychotherapy  compared  with  TAU
(Green 2011). It is important to note, when interpreting this result,
that the definition of repetition in Wood 2001a was based on there
being  two  or  more  further  episodes,  whilst  in  the  two  remaining
trials of this intervention approach (i.e. Green 2011; Hazell 2009),
repetition was based on there being any further episodes of SH.

Enhanced assessment approaches

Given  the  known  poor  treatment  adherence  of  children  and
adolescents  who  engage  in  SH  (Granboulan  2001;  Taylor  1984),
efforts have been made to increase adherence through therapeutic
assessment  following  SH.  Based  on  data  from  a  single  trial,
there  is  probably  little  or  no  effect  of  an  enhanced  therapeutic
assessment  approach  compared  with  TAU  on  repetition  of  SH
at  12  or  24  months  (Ougrin  2011).  This  approach  may  increase
treatment adherence in terms of the number of participants who
attended their first treatment session. However, these results were
based on a single cluster-RCT, which may have overestimated the
effectiveness of this intervention.

Cochrane Database of Systematic Reviews

Compliance enhancement approaches

On the basis of data from a single trial, the evidence is uncertain
as  to  whether  compliance  enhancement  (consisting  of  standard
discharged planning together with a series of four telephone calls
at 1, 2, 4 and 8 weeks' post-discharge) has any effect on repetition
of SH when compared with TAU (Spirito 2002). However, this trial
was likely underpowered to evaluate these outcomes.

Family interventions

On  the  basis  of  data  from  three  trials,  there  is  probably  little  or
no effect for either a home-based (Harrington 1998) or clinic-based
(Asarnow  2017;  Cottrell  2018)  family  intervention  as  compared
with standard treatment on repetition of self-harm either at post-
intervention or by the 18-month follow-up assessment.

Remote contact interventions

On  the  basis  of  data  from  a  single  trial,  there  is  probably  little
or  no  effect  of  an  emergency  card  allowing  patients  to  re-admit
themselves  to  hospital  compared  with  TAU  on  repetition  of  SH
(Cotgrove 1995). However, the trial was underpowered to evaluate
this  outcome.  Few  adolescents  made  use  of  the  emergency  card
(10.6%);  however,  none  of  those  who  used  the  card  engaged  in
repeated SH.

Overall completeness and applicability of evidence

Completeness of evidence

There  have  been  relatively  few  trials  of  interventions  for  SH  in
children  and  adolescents,  especially  compared  with  the  number
of  trials  of  psychosocial  interventions  for  adults  (Hawton  2016).
Therefore,  our  conclusions  are  limited  to  a  small  range  of
interventions.  Additionally,  as  there  were  no  eligible  trials  of
pharmacological  interventions,  perhaps  due  to  concerns  about
safety  in  this  clinical  population,  our  findings  are  limited  to
psychosocial interventions.

Where it was unclear that the trials satisfied our inclusion criteria,
we  contacted  corresponding  trial  authors  for  clarification.  We
also contacted corresponding authors where data were either not
clearly reported, or where we required data reported in a different
format  to  allow  for  their  inclusion  in  a  meta-analysis.  However,
despite engaging in over 80 emails with corresponding authors we
were not always able to obtain all relevant data. This was due to
a  combination  of  non-response  to  our  enquiries  and  to  authors
being unable to access relevant data, either due to moving on to
later positions or as a result of working from home due to COVID-19
pandemic quarantine orders. This is a common problem in meta-
analyses (Selph 2014).

Unfortunately, presence of publication bias could not be formally
evaluated  as  no  meta-analysis  in  the  present  review  included  10
or more trials. Therefore, we could not rule out the possibility that
publication bias may have affected the studies within this review.
This is a problem that commonly affects clinical data (Easterbrook
1991).

Whilst all of the included trials reported information on repetition
of  SH,  publication  bias  may  have  been  more  common  for  the
secondary  outcomes  assessed  by  this  review.  However,  formal
testing  of  publication  bias  was  not  possible  due  to  the  small
number of trials.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Applicability of evidence

The majority of participants in these trials were female, reflecting
the  typical  pattern  for  SH  in  hospital-presenting  populations
(Hawton  2008).  Only  two  trials  stratified  randomisation  by  sex
(Asarnow 2017; Cottrell 2018). Given that there are some differences
in the motivations for SH reported by males as compared to females
(Claes 2007), further work is needed on the treatment needs and
preferences of males who engage in SH, as well as their experiences
of clinical services (Hassett 2017), and how these may differ from
females who engage in SH.

The majority of trials included either children and adolescents who
had  all  engaged  in  intentional  drug  overdoses  or  self-poisoning,
or  samples  where  the  majority  had,  again  reflecting  the  typical
pattern  observed  in  patients  who  present  to  general  hospitals
following  SH  (Hawton  2007).  However,  there  are  other  important
patient subgroups, such as those who engage in self-cutting, who
may  have  different  treatment  needs  (Hawton  2004).  None  of  the
trials included in this review specifically focused on these patients,
although  it  should  be  noted  that  method  switching  is  common
in  those  who  engage  in  repeat  episodes  of  SH  (Witt  2019b).  Nine
trials  focused  on  those  with  a  history  of  repeated  SH,  which  is  a
particular issue in this clinical population given its association with
subsequent  SH  repetition  (Hawton  2012a)  and  suicide  (Hawton
2020a).  However,  no  trial  investigated  impacts  of  psychosocial
interventions for those with an initial episode of SH versus those
engaging in repeated SH. We were therefore unable to undertake
subgroup analyses to investigate the impact of these interventions
by repeater status.

This  review  focused  exclusively  on  those  who  engaged  in  SH.
As  a  result,  we  have  excluded  trials  in  which  participants
were  diagnosed  with  conditions  such  as  borderline  personality
disorder  but  where  SH  was  not  required  for  trial  entry.  We  also
excluded  trials  in  which  participants  engaged  in  repetitive  self-
injurious  behaviour  in  the  context  of  an  intellectual  disability
or  developmental  disorder  (e.g.  an  autism  spectrum  disorder).
Readers  interested  in  the  use  of  psychosocial  interventions  for
these  patient  groups  are  instead  referred  to  the  relevant  reviews
(Chezan 2017; Wong 2020).

Quality of the evidence

Certainty of evidence, as assessed using the GRADE approach, was
generally  moderate  to  very  low  suggesting  that  further  research
is  likely  to  have  an  important  impact  on  our  confidence  in  the
estimates of treatment effectiveness, and may in fact change the
estimates.  This  is  particularly  likely  to  affect  results  for  those
interventions that so far have only been assessed in single trials.

Additionally, using the Cochrane 'Risk of bias' tool, version 2 (Sterne
2019), for almost all trials included in this review, there were some
concerns  of  a  high  risk  of  bias  in  relation  to  at  least  one  aspect
of  trial  design,  with  weaknesses  most  commonly  observed  with
respect to selection of the reported result and measurement of the
outcome.

For  most  trials  (70.6%),  insufficient  information  was  reported  to
determine  whether  data  were  analysed  in  accordance  with  a
prespecified  analysis  plan.  In  2015,  the  International  Committee
of Medical Journal Editors (ICMJE) recommended all clinical trials
should  be  preregistered  in  a  public  trials  registry  (Witt  2020b).
Whilst the majority (83.3%) of the six trials published subsequent

Cochrane Database of Systematic Reviews

to this recommendation were registered, in some cases insufficient
detail  was  provided  within  the  clinical  trial  register  to  determine
how  key  outcome(s)  were  defined.  This  made  it  difficult  to
determine  whether  there  had  been  any  substantive  changes  to
the  proposed  analysis  plan  and,  if  so,  the  reasons  for  any  such
departures. Future trials should provide sufficient detail within the
clinical trial register to determine how key outcome(s) are defined
and measured to aid in the determination as to whether there has
been any substantive changes to the proposed analysis plan and, if
so, the reasons for any such departures.

For  around  half  of  the  trials  (52.9%)  included  in  this  review,
there  were  some  concerns  relating  to  bias  in  the  measurement
of  repetition  of  SH.  This  was  typically  because  repetition  of  SH
was based on self-reported information. Given that up to one-fifth
of  SH  episodes  recorded  in  medical  and  clinical  records  are  not
reported by participants, prevalence estimates derived from self-
report  alone  may  underestimate  the  true  rate  of  SH  (Mars  2016).
By supplementing data on self-reported SH with information from
clinical  or  medical  records,  future  trials  could  compare  results
based  on  self-reported  information  with  those  obtained  from
objective sources to investigate what impact, if any this bias may
have had on the estimate of treatment effectiveness.

Additionally, participants and clinical personnel were, typically, not
blind to allocation owing to likely differences in treatment intensity
between  the  intervention  and  control  arms  (Witt  2020b).  Indeed,
due  to  safety  considerations,  unbinding  may  be  unavoidable  in
these types of trials. However, given that repetition of SH was based
on  self-reported  information  in  a  number  of  the  included  trials
(Asarnow  2017;  Cooney  2010;  Donaldson  2005;  Harrington  1998;
Hazell 2009; McCauley 2018; Mehlum 2014; Rossouw 2012; Sinyor
2020; Spirito 2002; Wood 2001a), this introduces potential bias.

Lastly, the trials included in this review were, in general, relatively
small to detect differences in proportions of patients who engage
in a repeat episode of SH, although it is acknowledged that some
of  the  trials  were  feasibility  studies  (e.g.  Cooney  2010;  Griffiths
2019; Sinyor 2020). Whilst sample sizes have increased over time,
most trials in this field are still underpowered. We have previously
calculated that trials in this field may need to recruit a minimum
of 1862 participants per arm to detect an effect for repetition of SH
with 80% power at the conventional alpha level (Witt 2020b). Future
trials should therefore supply a priori power calculations to justify
their sample size.

Potential biases in the review process

We  are  confident  we  have 
identified  all  relevant  trials  of
psychosocial  interventions  for  SH  in  children  and  adolescents.
However,  we  cannot  rule  out  the  possibility  that  some  relevant
outcome  data  may  be  missing  from  this  review.  Although  data
on  repetition  of  SH  were  available  for  all  of  the  included  trials,
limited data were available on secondary outcomes. Nevertheless,
by  using  the  random-effects  model  in  all  analyses,  our  results
possess greater generalisability than if we had used the fixed-effect
model (Erez 1996).

Agreements and disagreements with other studies or
reviews

This  review  is  an  update  of  the  2015  Cochrane  Review  on
in  children  and  adolescents  (Hawton
interventions  for  SH 

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

2015).  The  previous  review  included  11  trials  of  eight  different
approaches, finding that whilst there had been relatively few trials
on interventions for children and adolescents who have engaged
in SH, certain approaches warranted further evaluation. The results
in  this  update  largely  concur  with  the  previous  iteration.  There
appear to be limited positive findings regarding DBT-A on repetition
of  SH  by  the  end  of  the  treatment  phase.  Results  of  this  review
would also suggest that a comprehensive therapeutic assessment
may increase engagement with subsequent treatment.

We  identified  18  further  reviews  that  included  a  focus  on
interventions  for  SH  in  children  and  adolescents  that  have  been
completed since the previous version of this review was published.
Four  were  systematic  reviews  (Calear  2016;  Davasaambuu  2019;
included  meta-analyses
Devenish  2016; 
(Kothgassner 2020; Labelle 2015; Robinson 2018; Yuan 2019), and
the  remainder  were  narrative  reviews  (Asarnow  2019;  Berk  2016;
Brent 2019; Busby 2020; Cox 2017; Flaherty 2018; Glenn 2019; Joe
2018; Morken 2020).

Iyengar  2018),  four 

However, whilst these reviews generally indicated that delivering
some  form  of  psychotherapy  is  likely  to  be  more  effective  than
nothing  (e.g.  Iyengar  2018;  Kothgassner  2020;  Robinson  2018;
Yuan 2019), consistent with results found in adults (Hetrick 2016),
these  reviews  have  tended  to  statistically  pool  results  from  very
different  interventions  together  and  so  the  results  are  largely
meaningless for clinical practice as they provide little insight into
which  approach  may  be  most  beneficial  for  particular  clinically
relevant subgroups of patients.

Future  reviews  should  investigate  which  component(s)  of  these
typically  multi-component  intervention  approaches  are  most
effective.  Individual  participant  data  meta-analyses  would  also
assist  with  the  identification  of  clinically  relevant  subgroups  of
patients  who  may  benefit  from  certain  more  intensive  forms  of
intervention.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

Presentations  of  children  and  adolescents  to  clinical  services
following  SH  are  common,  yet  there  have  been  relatively  few
systematic  investigations  into  interventions  that  may  prevent
recurrence. We found only 17 trials of psychosocial interventions
in  this  clinical  population.  We  found  none  of  pharmacological
treatments.

Given  the  evidence  for  its  benefit  for  adults  who  engage  in  SH,
individual CBT-based psychotherapy needs to be further developed
and  evaluated  in  children  and  adolescents.  However,  treatment
adherence with this approach may be challenging in this age group.
One  small  feasibility  study  included  in  this  review,  for  example,
found that few adolescents completed the acute treatment phase,
and  even  fewer  attended  any  of  the  booster  sessions  offered
(Sinyor  2020).  We  also  found  some  positive  effects  of  DBT-A,  but
methodological  factors  limit  confidence  in  the  generalisability
  We  recommend  further  evaluation  of  these
of  the  results. 
approaches to assess the impact of these interventions in different
samples and settings. Given the multi-component nature of these
intervention approaches, greater use of head-to-head trials, which
allow  for  dismantling  of  the  effect  size(s)  between  one  or  more
component(s), should be considered.

Cochrane Database of Systematic Reviews

Given  the  high  incidence  of  family  problems  in  children  and
adolescents who engage in SH, the lack of evidence for efficacy of
family therapy approaches found in this review is both surprising
and  disappointing.  On  the  strength  of  the  evidence  from  three
trials, including one recent larger trial, there is also little support
for group-based therapy for adolescents with a history of multiple
episodes of SH. Additionally, it is notable that the authors of one
of these trials reports an incident in which one participant posted
confidential  information  about  another  participant  on  an  online
blog (Hazell 2009), highlighting the potential risks associated with
group-based therapy in this clinical population

An  argument  for  intervention  following  an  episode  of  SH  is
that  it  may  improve  other  outcomes  even  if  it  does  not  reduce
SH.  Secondary  outcomes  were  examined  variably  across  the
included trials. There was only limited evidence that experimental
interventions  might  lead  to  better  outcomes  in  these  other
domains. DBT-A improved depression, hopelessness, and suicidal
ideation in the short term. Both DBT-A and therapeutic assessment
appeared to improve treatment adherence (at least for individual
therapy).  Conspicuously,  other  treatments  that  might  have  been
expected  to  improve  depression,  such  as  individual  CBT-based
psychotherapy and MBT-A did not perform any better than TAU.

Indeed,  few  psychosocial  interventions  appear  to  perform  better
than  TAU.  However,  TAU  was  not  well  described  in  most  clinical
trials  we  examined.  TAU  also  varies  greatly  across  clinical
settings  (Witt  2018b).  A  positive  step  forward  would  be  the
operationalisation  of  TAU  to  inform  both  clinical  practice  and
research.  It  is  possible  that  TAU  has  an  advantage  over  some  of
these  specific  interventions  because  it  offers  more  flexibility  to
tailor treatment to the specific needs of the patients.

treatment  whilst,  additionally,  enabling 

Results  of  this  review  would  also  suggest  that  a  comprehensive
increase  engagement  with
therapeutic  assessment  may 
subsequent 
the
identification  of  psychosocial  needs  that  should  be  addressed
during treatment. Although this finding is based on a single cluster-
randomised trial which may overestimate the effectiveness of the
intervention, this result suggests that a comprehensive therapeutic
psychosocial  assessment  might  be  a  useful  part  of  a  clinical
intervention. This is in keeping with official guidance (NICE 2011).

Implications for research

Given  that  SH  results  from  a  complex  interplay  between  genetic,
biological,  psychiatric,  psychosocial,  social,  cultural,  and  other
factors,  the  development  of  interventions  for  SH  in  children
and  adolescents  could  benefit  from  being  based  on  detailed
investigation of these factors, including those that might reduce the
risk  of  further  SH,  as  well  as  having  benefits  for  other  outcomes.
Ideally,  the  development  of  new  treatments  should  ensure  their
feasibility and suitability for the young people for whom they are
designed; children and adolescents with experience of SH and their
carers should be involved in this process.

Additionally,  trials  of  interventions  for  children  and  adolescents
who  engage  in  SH  should  include  a  range  of  outcome  measures,
not  just  SH  and  suicide,  but  also  acceptability,  adherence,  and
attitudes  to  treatment  by  young  people,  their  caregivers,  and
service providers, as these may help to identify contributors to any
apparent  benefit  or  lack  of  impact.  In  particular,  the  inclusion  of
outcomes  that  matter  to  those  who  engage  in  SH  is  required  to

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

further  inform  intervention  development  (Owens  2020).  It  is  also
important that adverse effects of treatment, both short- and long-
term,  are  carefully  evaluated,  such  as  the  release  of  confidential
information described in the Hazell 2009 trial. Use of an agreed set
of outcome measures would also assist in evaluation across trials.
Investigation of the mechanisms through which treatments might
work is also desirable to assist with the identification of clinically
relevant subgroups of patients who may benefit from certain, more
intensive, forms of intervention.

Heed  should  also  be  paid  to  the  principles  of  development
and  evaluation  of  treatments  as  laid  out  in  the  UK  Medical
Research  Council  guidance  regarding  complex  interventions.
Additionally,  from  a  service  planning  perspective,  future  trials
should  also  include  economic  evaluations  in  order  to  determine
which interventions may be most feasible to routinely implement
throughout a health service (Bustamante-Madsen 2018).

Elizabeth McCauley, Lars Mehlum, Dennis Ougrin, Trudie Rossouw,
Erica  V.  Rozmid,  Pilar  Santamarina-Pérez,  Mark  Sinyor,  Anthony
Spirito, and Rabia Zaheer.

The  authors  and  the  CCMD  Editorial  Team  are  also  grateful
to  the  following  peer  reviewers  for  their  time  and  comments:
Sarah Knowles, Nuala Livingstone, Jean Sellar-Edmunds, and Peter
Szatmari.  They  would  also  like  to  thank  Cochrane  Copy  Edit
Support for the team's help and Phil Roberts from the University of
York for graphic design support in the production of Figure 2.

This  project  has  previously  been  supported  by  the  National  Co-
ordinating Centre for NHS Service Delivery and Organisation R&D
(NCCSDO). KH is funded by Oxford Health NHS Foundation Trust.
He  is  a  National  Institute  for  Health  Research  (NIHR)  Senior
Investigator and personal funding from NIHR helped support this
update.

A C K N O W L E D G E M E N T S

The NIHR is the largest single funder of the CCMD Group.

The  authors  thank  the  following  trial  authors  for  providing  us
with unpublished data: Molly Adrian, Joan Asarnow, Emily Cooney,
Andrew  Cotgrove,  Jonathon  Green,  Helen  Griffiths,  Philip  Hazell,

The views expressed are those of the authors and not necessarily
those of the NHS, the NIHR or the Department of Health and Social
Care.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Asarnow 2017 {published data only}

therapy vs. treatment as usual in adolescents following self-
harm. Clinical Trials 2018;15:197-206.

Asarnow JR, Berk M, Hughes JL, Anderson NL. The SAFETY
Program: a treatment-development trial of a cognitive-
behavioral family treatment for adolescent suicide
attempters. Journal of Clinical Child and Adolescent Psychology
2015;44:194-203.

Wright-Hughes A, Graham E, Farrin A, Collinson M, Boston P,
Eisler I, et al. Self-Harm Intervention: Family Therapy (SHIFT),
a study protocol for a randomised controlled trial of family
therapy versus treatment as usual for young people seen after a
second or subsequent episode of self-harm. Trials 2015;16:501.

*  Asarnow JR, Hughes JL, Babeva KN, Sugar CA. Cognitive-
behavioral family treatment for suicide attempt prevention: a
randomized controlled trial. Journal of the American Academy
Child and Adolescent Psychiatry 2017;56:506-14.

Cooney 2010 {published and unpublished data}

Cooney E, Davis K, Thompson P, Wharewera-Mika J, Stewart J.
Feasibility of Evaluating DBT for Self-Harming Adolescents: A
Small Randomised Controlled Trial. Auckland, New Zealand:
Te Pou o Te Whakaaro Nui and The National Centre of Mental
Health Research, Information and Workforce Development,
2010.

Cotgrove 1995 {published data only}

Cotgrove A, Zirnisky L, Black D, Weston D. Secondary prevention
of attempted suicide in adolescence. Journal of Adolescence
1995;18:569-77.

Cottrell 2018 {published and unpublished data}ISRCTN59793150

Cottrell DJ, Wright-Hughes A, Collinson M, Boston P, Eisler I,
Fortune S, et al. A pragmatic randomised controlled trial
and economic evaluation of family therapy versus treatment
as usual for young people seen after second or subsequent
episodes of self-harm: the Self-Harm Intervention – Family
Therapy (SHIFT) trial. Health Technology Assessment
2018;22:1-222. [DOI: 10.3310/hta22120]

*  Cottrell DJ, Wright-Hughes A, Collinson M, Boston P, Eisler I,
Fortune S, et al. Effectiveness of systemic family therapy
versus treatment as usual for young people after self-harm: a
pragmatic, phase 3, multicentre, randomised controlled trial.
Lancet Psychiatry 2018;5:203-16.

Cottrell DJ, Wright-Hughes A, Eisler I, Fortune S, Green J,
House AO, et al. Longer-term effectiveness of systemic family
therapy compared with treatment as usual for young people
after self-harm: an extended follow-up of pragmatic randomised
controlled trial. eClinical Medicine 2020;18:100246.

Holliday R, Brennan C, Cottrell D. Understanding adolescents'
experiences of self-harm: secondary analysis of family therapy
sessions from the SHIFT trial. Archives of Suicide Research
2020;24:190-203.

Tubeuf S, Saloniki E-C, Cottrell D. Parental health spillover
in cost-effectiveness analysis: evidence from self-harming
adolescents in England. PharmacoEconomics 2019;37:513–30.

Wright-Hughes A, Graham E, Cottrell D, Farrin A. Routine
hospital data – is it good enough for trials? An example using
England’s Hospital Episode Statistics in the SHIFT trial of family

Donaldson 2005 {published data only}

*  Donaldson D, Spirito A, Esposito-Smythers C. Treatment
for adolescents following a suicide attempt: results of a pilot
trial. Journal of the American Academy of Child and Adolescent
Psychiatry 2005;44:113-20.

Donaldson D, Spirito A, Overholser J. Treatment of adolescent
suicide attempters. In: Spirito A, Overholser JC, editors(s).
Evaluating and Treating Adolescent Suicide Attempters:
From Research to Practice. San Diego, CA: Academic Press,
2003:295-321.

Green 2011 {published data only}

Ayodeji E, Green J, Roberts C, Trainor G, Rothwell J,
Woodham E, et al. The influence of personality disorder on
outcome in adolescent self-harm. British Journal of Psychiatry
2015;207:313-9.

*  Green JM, Wood AJ, Kerfoot MJ, Trainor G, Roberts C,
Rothwell J, et al. Group therapy for adolescents with repeated
self harm: randomised controlled trial with economic
evaluation. British Medical Journal 2011;342:d682.

Griffiths 2019 {published data only}

Griffiths H, Duffy F, Duffy L, Brown S, Hockaday H, Eliasson E,
et al. Efficacy of mentalization-based group therapy for
adolescents: the results of a pilot randomised controlled trial.
BMC Psychiatry 2019;19:167.

Harrington 1998 {published data only}

Aglan A, Kerfoot M, Pickles A. Pathways from adolescent
deliberate self-poisoning to early adult outcomes: a six-
year follow-up. Journal of Child Psychology and Psychiatry
2008;49:508-15.

Byford S, Harrington R, Torgerson D, Kerfoot M, Dyer E,
Harrington V, et al. Cost-effectiveness analysis of a home-based
social work intervention for children and adolescents who have
deliberately poisoned themselves: results of a randomised
controlled trial. British Journal of Psychiatry 1999;174:56-62.

Chitsabesan P, Harrington R, Harrington V, Tomenson B.
Predicting repeat self-harm in children: how accurate can
we expect to be? European Child and Adolescent Psychiatry
2003;12:23-9.

Harrington R, Kerfoot M, Dyer E, McNiven F, Gill J, Harrington V,
et al. Deliberate self-poisoning in adolescence: why does a brief
family intervention work in some cases and not others? Journal
of Adolescence 2000;23:13-20.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

*  Harrington R, Kerfoot M, Dyer E, McNiven F, Gill J,
Harrington V, et al. Randomized trial of a home-based family
intervention for children who have deliberately poisoned
themselves. Journal of the American Academy of Child and
Adolescent Psychiatry 1998;37:512-8.

Ougrin 2011 {published and unpublished data}

Ougrin D, Boege I, Stahl D, Banarsee R, Taylor E. Randomised
controlled trial of therapeutic assessment versus usual
assessment in adolescents with self-harm: 2-year follow-up.
Archives of Diseases in Childhood 2013;98:772-6.

Harrington R, Pickles A, Aglan A, Harrington V, Burroughs H,
Kerfoot M. Early adult outcomes of adolescents who
deliberately poisoned themselves. Journal of the American
Academy of Child and Adolescent Psychiatry 2006;45:337-45.

Hazell 2009 {published data only}

Hazell PL, Martin G, McGill K, Kay T, Wood A, Trainor G, et
al. Group therapy for repeated deliberate self-harming
adolescents: failure of replication of a randomized trial. Journal
of the American Academy of Child and Adolescent Psychiatry
2009;48:662-70.

McCauley 2018 {published data only}

Adrian M, McCauley E, Berk MS, Asarnow JR, Korslund K,
Avina C, et al. Predictors and moderators of recurring self-harm
in adolescents participating in a comparative treatment trial of
psychological interventions. Journal of Child Psychology and
Psychiatry 2019;60:1123-32.

McCauley E, Adrian M, Curtis A. 5.5. Youth suicide: how gender,
sexual orientation, and gender-nonconforming status shape
risk and inform intervention strategies. Journal of the American
Academy of Child and Adolescent Psychiatry 2018;57:S128.

*  McCauley E, Berk MS, Asarnow JR, Adrian M, Cohen J,
Korslund K, et al. Efficacy of dialectical behavior therapy for
adolescents at high risk for suicide: a randomized clinical trial.
JAMA Psychiatry 2018;75:777-85.

Mehlum 2014 {published and unpublished data}

Haga E, Aas E, Grøholt B, Tørmoen AJ, Mehlum L. Cost-
effectiveness of dialectical behaviour therapy vs. enhanced
usual care in the treatment of adolescents with self-harm. Child
and Adolescent Psychiatry and Mental Health 2018;12:22.

Mehlum L, Ramberg M, Tørmoen AJ, Haga E, Diep LM,
Stanley BH. Dialectical behavior therapy compared with
enhanced usual care for adolescents with repeated suicidal
and self-harming behavior: outcomes over a one-year follow-
up. Journal of the American Academy of Child and Adolescent
Psychiatry 2016;55:295-300.

*  Mehlum L, Tømoen AJ, Ramberg M, Haga E, Diep LM, Laberg S,
et al. Dialectical behavior therapy for adolescents with repeated
suicidal and self-harming behavior - a randomized trial. Journal
of the American Academy of Child and Adolescent Psychiatry
2014;53:1082-91.

Ramleth R-K, Groholt B, Diep LM, Walby FA, Mehlum L. The
impact of borderline personality disorder and sub-threshold
borderline personality disorder on the course of self-reported
and clinician-rated depression in self-harming adolescents.
Borderline Personality Disorder and Emotion Dysregulation
2017;4:22.

Ougrin D, Zundel T, Kyriakopoulos M, Banarsee R, Stahl D,
Taylor E. Adolescents with suicidal and nonsuicidal self harm:
clinical characteristics and response to therapeutic assessment.
Psychological Assessment 2012;24:11-20.

*  Ougrin D, Zundel T, Ng A, Banarsee R, Bottle A, Taylor E. Trial
of therapeutic assessment in London: randomised controlled
trial of therapeutic assessment versus standard psychosocial
assessment in adolescents presenting with self harm. Archives
of Disease in Childhood 2011;96:148-53.

Rossouw 2012 {published and unpublished data}

Rossouw T. Self-harm in young people: is MBT the answer? In:
Midgley N, Vrouva I, editors(s). Minding the Child: Mentalization-
Based Interventions with Children, Young People and their
Families. New York, NY: Routledge, 2012:131-44.

Rossouw T. W1-02-02. Mentalisation based treatment for
adolescents with self harm: an RCT. European Child and
Adolescent Psychiatry 2015;24:S113.

*  Rossouw TI, Fonagy P. Mentalization-based treatment for self-
harm in adolescents: a randomized controlled trial. Journal
of the American Academy of Child and Adolescent Psychiatry
2012;51:304-13.

Santamarina-Pérez 2020 {published and unpublished data}

Santamarina P, Mendez-Blanco I, Picado M, Font E, Moreno E,
Martínez E, et al. 3.65. Dialectical behavior therapy versus
supportive therapy for adolescents with suicidal behavior: a
randomized controlled trial. Journal of the American Academy of
Child and Adolescent Psychiatry 2017;56:S226.

Santamarina-Pérez P, Cela R, Méndez-Blanco I, Font-Martínez E,
Picado-Rossi M, Martínez-Mallén E, et al. P.2.f.013. Efficacy
of dialectical behavior therapy compared to supportive
therapy in adolescents with suicidal behavior. European
Neuropsychopharmacology 2017;27:S853.

*  Santamarina-Pérez P, Mendez I, Singh MK, Berk M, Picado M,
Font E, et al. Adapted dialectical behavior therapy for
adolescents with a high risk of suicide in a community clinic:
a pragmatic randomized controlled trial. Suicide and Life
Threatening Behavior 2020;50:652-67.

Sinyor 2020 {published data only}

*  Sinyor M, Williams M, Mitchell R, Zaheer R, Bryan CJ,
Schaffer A, et al. Cognitive behavioral therapy for suicide
prevention in youth admitted to hospital following an episode
of self-harm: a pilot randomized controlled trial. Journal of
Affective Disorders 2020;266:686-94.

Williams M, Tien H, Schaffer A, Ellis J, Cheung A, Goldstein B,
et al. T68. Hope and borderline-personality disorder as
predictors of study drop-out among inpatient youth receiving
psychotherapy treatment for an episode of deliberate self-
harm. Biological Psychiatry 2018;83:S155.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Spirito 2002 {published data only}

English 2019 {published data only}

*  Spirito A, Boergers J, Donaldson D, Bishop D, Lewander W.
An intervention trial to improve adherence to community
treatment by adolescents after a suicide attempt. Journal of
Child and Adolescent Psychiatry 2002;41:435-42.

English O, Wellings C, Banerjea P, Ougrin D. Specialized
therapeutic assessment-based recovery-focused treatment for
young people with self-harm: pilot study. Frontiers in Psychiatry
2019;10:895.

Spirito A, Stanton C, Donaldson D, Boergers J. Treatment-
as-usual for adolescent suicide attempters: implications
for the choice of comparison groups in psychotherapy
research. Journal of Clinical Child and Adolescent Psychology
2002;31:41-7.

Esposito-Smythers 2017 {published data only}

Esposito-Smythers C, Hadley W, Curby TW, Brown LK.
Randomized pilot trial of a cognitive-behavioral alcohol, self-
harm, and HIV prevention program for teens in mental health
treatment. Behaviour Research and Therapy 2017;89:49-56.

Wood 2001a {published data only}

*  Wood A, Trainor G, Rothwell J, Moore A, Harrington R.
Randomized trial of group therapy for repeated deliberate self-
harm in adolescents. Journal of the American Academy of Child
and Adolescent Psychiatry 2001;40:1246-53.

Esposito-Smythers 2019 {published data only}

Esposito-Smythers C, Wolff JC, Liu RT, Hunt JI, Adams L, Kim K,
et al. 2019. Family-focused cognitive behavioral treatment for
depressed adolescents in suicidal crisis with co-occurring risk
factors: a randomized trial 2019;60:1133-41.

Wood A, Trainor G. Developmental Group Psychotherapy
for Adolescents: A Manual for Mental Health Professionals.
Manchester, UK: University of Manchester, 2001.

References to studies excluded from this review

Gillespie 2019 {published data only}

Gillespie C, Joyce M, Flynn D, Corcoran P. Dialectical behaviour
therapy for adolescents: a comparison of 16-week and 24-week
programmes delivered in a public community setting. Child and
Adolescent Mental Health 2019;24:266-73.

Alavi 2013 {published and unpublished data}

Kaess 2020a {published and unpublished data}

*  Alavi A, Sharifi B, Ghanizadeh A, Dehbozorgi G. Effectiveness
of cognitive-behavioral therapy in decreasing suicidal ideation
and hopelessness of the adolescents with previous suicidal
attempts. Iranian Journal of Pediatrics 2013;23:467-72.

Fischer G, Brunner R, Parzer P, Resch F, Kaess M. Short term
psychotherapeutic treatment in adolescents engaging in
non-suicidal self-injury: a randomized controlled trial. Trials
2013;14:294.

Alavi AS, Sharifi B, Ghanizadeh A, Dehbozorgi G. Cognitive-
behavioral therapy in decreasing suicidal ideation and
hopelessness in depressed adolescents with previous suicidal
attempt. Neuropsychiatrie de l’Enfance et de l’Adolescence
2012;60S:S172-3.

*  Kaess M, Edinger A, Fischer-Waldschmidt G, Parzer P,
Brunner R, Resch F. Effectiveness of a brief psychotherapeutic
intervention compared with treatment as usual for adolescent
nonsuicidal self-injury: a single-centre, randomised controlled
trial. European Child and Adolescent Psychiatry 2020;29:881-91.

Czyz 2019 {published data only}

Kennard 2018 {published and unpublished data}

Czyz EK, King CA, Biermann BJ. Motivational interviewing-
enhanced safety planning for adolescents at high suicide risk:
a pilot randomized controlled trial. Journal of Clinical Child and
Adolescent Psychology 2019;48:250-62.

Diamond 2012 {published data only}

Diamond GS, Levy S. Attachment-oriented family therapy
as an outpatient follow-up care for adolescents after
attempted suicide [Bindungsorientierte familientherapie als
ambulante nachsorge für jugendliche nach suizidversuch].
Psychotherapie im Dialog 2012;13:41-5.

Diamond 2019 {published data only}

*  Diamond GS, Kobak RR, Ewing ESK, Levy SA, Herres JL,
Russon JM, et al. A randomized controlled trial: attachment-
based family and nondirective supportive treatments for youth
who are suicidal. Journal of the American Academy of Child and
Adolescent Psychiatry 2019;58:721-31.

Lifshitz C, Tsvieli N, Bar-Kalifa E, Abbott C, Diamond GS,
Kobak RR, et al. Emotional processing in attachment-based
family therapy for suicidal adolescents. Psychotherapy Research
2021;31(2):267-79. [DOI: 10.1080/10503307.2020.1745315]

Brent DA, Kennard BD. 22.4. Impact of a brief inpatient
intervention and suicide safety planning app to decrease
suicidal behavior after hospital discharge. Journal of the
American Academy of Child and Adolescent Psychiatry
2018;57:S33.

Kennard BD, Biernesser C, Wolfe KL, Foxwell AA, Craddock-
Lee SJ, Rial KV, et al. Developing a brief suicide prevention
intervention and mobile phone application: a qualitative report.
Journal of Technology in Human Services 2015;33:345-57.

*  Kennard BD, Goldstein T, Foxwell AA, McMakin DL, Wolfe K,
Biernesser C, et al. As Safe As Possible (ASAP): a brief app-
supported inpatient intervention to prevent postdischarge
suicidal behavior in hospitalized, suicidal adolescents. American
Journal of Psychiatry 2018;175:864-72.

King 2019 {published data only}

King C, Arango A, Kramer A, Busby D, Czyz E, Foster CE, et
al. 6.35. Effect of a Youth-Nominated Support Team on 10-
to 12-year mortality outcomes of suicidal adolescents: an
RCT. Journal of the American Academy of Child and Adolescent
Psychiatry 2018;57:s260.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

*  King CA, Arango A, Kramer A, Busby D, Czyz E, Foster CE, et al.
Association of the Youth-Nominated Support Team intervention
for suicidal adolescents with 11- to 14-year mortality outcomes.
JAMA Psychiatry 2019;76:492-8.

Latimer 2014 {published data only}

Greenfield B, Larson C, Hetchman L, Rousseau C, Platt R. A
rapid-response outpatient model for reducing hospitalization
rates among suicidal adolescents. Psychiatric Services
2002;53:1574-9.

*  Latimer EA, Gariépy G, Greenfield B. Cost-effectiveness of a
rapid response team intervention for suicidal youth presenting
at an emergency department. Canadian Journal of Psychiatry
2014;59:310-8.

LoParo 2018 {published and unpublished data}

LoParo D, Mack SA, Patterson B, Negi LT, Kaslow NJ. The efficacy
of cognitively-based compassion training for African American
suicide attempters. Mindfulness 2018;9:1941-54.

Mubarak 2017 {published data only}

Mubarak AR, Zeitz J, Slee P. Effectiveness of an intervention
programme for teenage girls with self-harm in Adelaide, South
Australia. In: Child and Adolescent Wellbeing and Violence
Prevention in School. London, UK: Routledge, 2017:209-16.

NCT02726035 {unpublished data only}

NCT02726035. Evaluation of naltrexone as a treatment for self-
injurious behavior. clinicaltrials.gov/ct2/show/NCT02726035
(first received 1 April 2016).

Perera Ramani 2011 {published and unpublished data}

Perera Ramani EA, Kathriarachchi ST. Problem-solving
counselling as a therapeutic tool on youth suicidal behavior
in the suburban population in Sri Lanka. Indian Journal of
Psychiatry 2011;53:30-5.

Pineda 2013 {published and unpublished data}

Pineda J, Dadds MR. Family intervention for adolescents
with suicidal behavior: a randomized controlled trial and
mediation analysis. Journal of the American Academy of Child
and Adolescent Psychiatry 2013;52:851-62.

Rees 2015 {published data only}

Rees CS, Hasking P, Breen LJ, Lipp OV, Marmotte C. Group
mindfulness based cognitive therapy vs group support for self-
injury among young people: study protocol for a randomised
controlled trial. BMC Psychiatry 2015;15:154.

Rengasamy 2019 {published and unpublished data}

Rengasamy M, Phelps-Tschang J, Simpson M, Tew Jr JD,
Sparks G. 6.50. Reduction of adolescent suicide attempts after
telephone-based intervention. Journal of the American Academy
of Child and Adolescent Psychiatry 2018;57:S265.

*  Rengasamy M, Sparks G. Reduction of postdischarge suicidal
behavior among adolescents through a telephone-based
intervention. Psychiatric Services 2019;70:545-52.

Cochrane Database of Systematic Reviews

Rowe 2018 {published data only}ISRCTN11230559

Rowe SL, French RS, Henderson C, Ougrin D, Slade M,
Moran P. Decisional support for young people who self-harm:
protocol for a feasibility trial. British Medical Journal Open
2016;6:e012161.

*  Rowe SL, Patel K, French RS, Henderson C, Ougrin D, Slade M,
et al. Web-based decision aid to assist help-seeking choices
for young people who self-harm: outcomes from a randomized
controlled feasibility trial. Journal of Medical Internet Research
Mental Health 2018;5:e10-13.

Stallard 2016 {published data only}

Stallard P, Porter J, Grist R. Safety, acceptability, and use of a
smartphone app, BlueIce, for young people who self-harm:
protocol for an open phase I trial. Journal of Medical Internet
Research: Research Protocols 2016;5:e217.

Tracey 2018 {published data only}

Tracey M, Rowney G, Pignatiello A, Monga S, Korczak D.
Feasibility of a manualized family-based suicide prevention
strategy to reduce adolescent suicide risk among emergency
department referred youth: a quality improvement project.
Paediatrics and Child Health 2018;23:e54.

Wharff 2019 {published and unpublished data}

Wharff EA, Ginnis KB, Ross AM, White EM, White MT, Forbes PW.
Family-based crisis intervention with suicidal adolescents:
a randomized clinical trial. Pediatric Emergency Care
2019;35:170-5.

Xavier 2019 {published data only}

Xavier A, Otero P, Blanco V, Vázquez FL. Efficacy of a problem-
solving intervention for the indicated prevention of suicidal risk
in young Brazilians: randomized controlled trial. Suicide and
Life-Threatening Behavior 2019;49:1746-61.

Yen 2019 {published and unpublished data}

Yen S, Spirito A, Weinstock LM, Tezanos K, Kolobaric A,
Miller I. Coping long term with active suicide in adolescents:
results from a pilot randomized controlled trial. Clinical Child
Psychology and Psychiatry 2019;24:847-59.

Yen 2020 {published and unpublished data}

Yen S, Ranney ML, Krek M, Peters JR, Mereish E,
Tezanos KM, et al. Skills to enhance positivity in suicidal
adolescents: results from a pilot randomized clinical trial.
Journal of Positive Psychology 2020;15(3):348-61. [DOI:
10.1080/17439760.2019.1615105]

References to ongoing studies

ACTRN12617000668303p {unpublished data only}

ACTRN12617000668303p. Testing the efficacy of an Emotion
Regulation Group Therapy for adolescent non-suicidal self-
injury in Aotearoa New Zealand [A randomised control trial on
the effect of Emotion Regulation Group Therapy on non-suicidal
self-injury in adolescent]. www.anzctr.org.au/Trial/Registration/
TrialReview.aspx?ACTRN=12617000668303 (first received 1 May
2017).

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ACTRN12618000085279p {unpublished data only}

NCT03550521 {unpublished data only}

ACTRN12618000085279p. Improving care for adolescents during
an inpatient admission following self-harm and suicidal acts [A
pilot randomised trial of standard care versus structured care
during an inpatient admission following self-harm and suicidal
acts in adolescents]. www.anzctr.org.au/Trial/Registration/
TrialReview.aspx?ACTRN=12618000085279 (first received 29
December 2017).

Andreasson 2017 {published and unpublished data}

Andreasson K, Krogh J, Bech P, Frandsen H, Buus N, Stanley B,
et al. MYPLAN – mobile phone application to manage crisis
of persons at risk of suicide: study protocol for a randomized
controlled trial. Trials 2017;18:171.

De Silva 2018 {published and unpublished data}

De Silva ANLM, Dawson AH, Gawarammana IB, Tennakoon S,
Rajapakse T. Study protocol: a pilot randomized controlled trial
to evaluate the acceptability and feasibility of a counseling
intervention, delivered by nurses, for those who have
attempted self-poisoning in Sri Lanka. Pilot and Feasibility
Studies 2018;4:150.

ISRCTN10541045 {unpublished data only}ISRCTN10541045

ISRCTN10541045. A comparison of usual care versus usual care
plus a smartphone self-harm prevention app (BlueIce) in young
adolescents aged 12-17 who self-harm: Beating Adolescent Self-
Harm (BASH) - Version 1. www.isrctn.com/ISRCTN10541045
(first received 15 July 2019).

NCT03550521. Interrupting self-harm study [A mixed
methods investigation of brief mindfulness training and self-
injury attentional bias among self-injuring adolescents].
clinicaltrials.gov/ct2/show/NCT03550521 (first received 8 June
2018).

NCT03709472 {unpublished data only}

NCT03709472. Computer assisted family intervention to treat
self-harm disparities in Latinas and sexual/gender minority
youth (CA CIFFTA). clinicaltrials.gov/ct2/show/NCT03709472
(first received 17 October 2018).

NCT04131179 {unpublished data only}

NCT04131179. Multicenter study to evaluate the clinical
and cost effectiveness of a Youth Culturally Adapted
Therapy (YCMAP) [Youth Culturally adapted Manual-Assisted
Psychological therapy (Y-CMAP) in adolescents Pakistani
patients with a history of self harm]. clinicaltrials.gov/ct2/show/
NCT04131179 (first received 18 October 2019).

NCT04243603 {unpublished data only}

NCT04243603. Effects of internet-based ERITA added to
TAU in young people with non-suicidal self-injury (TEENS)
feasibility trial [Treatment effects of internet-based Emotion
Regulation Individual Therapy for Adolescents (ERITA) added
to treatment as usual in young people with non-suicidal self-
injury]. clinicaltrials.gov/ct2/show/results/NCT04243603 (first
received 28 January 2020).

Kaess 2019 {published data only}

R000011786 {unpublished data only}

Edinger A, Koenig J, Bauer S, Moessner M, Fischer-
Waldschmidt G, Herpertz SC, et al. Development of an online
intervention for the care of self-harming adolescents and
young adults [Entwicklung einer online-Intervention für
die versorgung von sich selbstverletzenden jugendlichen
und jungen erwachsenen]. Praxis der Kinderpsychologie und
Kinderpsychiatrie 2020;69:141-55.

*  Kaess M, Koenig J, Bauer S, Moessner M, Fischer-
Waldschmidt G, Mattern M, et al. Self-injury: Treatment,
Assessment, Recovery (STAR): online intervention for
adolescent non-suicidal self-injury - study protocol for a
randomized controlled trial. Trials 2019;20:425.

Ligier 2016 {published and unpublished data}

*  Ligier F, Kabuth B, Guillemin F. MEDIACONNEX: a multicenter
randomised trial based on short message service to reduce
suicide attempt recurrence in adolescents. BMC Psychiatry
2016;16:251.

NCT02762734. Prevention of recurrence of suicide attempt by
adolescent by sending SMS: MEDIACONNEX. clinicaltrials.gov/
ct2/show/NCT02762734 (first received 5 May 2016).

NCT03353961 {unpublished data only}

NCT03353961. Internet delivered Emotion Regulation Individual
Therapy for Adolescents (ERITA) with nonsuicidal self-Injury: a
randomized controlled study. www.clinicaltrials.gov/ct2/show/
NCT03353961 (first received 1 October 2020).

R000011786-UMIN000010065. Randomized controlled trial
of eye movement desensitization and reprocessing (EMDR)
and interpersonal psychotherapy (IPT) for non-suicidal
self injury in adolescent and young adult females: JNSSIAP
study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?
recptno=R000011786 (first received 18 February 2013).

Additional references

Albrecht 2014

Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI.
Benzodiazepine use and aggressive behaviour: a systematic
review. Australian and New Zealand Journal of Psychiatry
2014;48:1096-114.

Allen 2008

Allen JG, Fonagy P, Bateman AW. Mentalizing in Clinical
Practice. Washington DC, USA: American Psychiatric Publishing,
2008.

Andover 2012

Andover MS, Morris BW, Wren A, Bruzzese ME. The co-
occurrence of non-suicidal self-injury and attempted suicide
among adolescents: distinguishing risk and psychosocial
correlates. Child and Adolescent Psychiatry and Mental Health
2012;6:11.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Angold 1995

Boyce 1989

Angold A, Costello EJ, Messer SC, Pickles A. The development
of a short questionnaire for use in epidemiological studies in
depression in children and adolescents. International Journal of
Methods in Psychiatric Research 1995;5:237-49.

APA 2000

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-
IV-TR). Washington, DC: American Psychiatric Association, 2000.

Asarnow 2019

Asarnow JR, Mehlum L. Practitioner review: treatment for
suicidal and self-harming adolescents - advances in suicide
prevention care. Journal of Child Psychology and Psychiatry
2019;60:1046-54.

Beck 1961

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An
inventory for measuring depression. Archives of General
Psychiatry 1961;4:561.

Boyce P, Parker G. Development of a scale to measure
interpersonal sensitivity. Australian and New Zealand Journal of
Psychiatry 1989;23:341-51.

Brausch 2019

Brausch AM, Woods SE. Emotion regulation deficits and
nonsuicidal self-injury prospectively predict suicidal ideation in
adolescents. Suicide & Life-threatening Behavior 2019;49:868-80.

Brennan 1998

Brennan KA, Clark CL, Shaver PR. Self-report measurement
of adult attachment: an integrative overview. In: Simpson
JA, Rholes WS, editors(s). Attachment Theory and Close
Relationships. New York, NY: Guilford Press, 1998.

Brenning 2014

Brenning K, Van Petegem S, Vanhalst J, Soenens B. The
psychometric qualities of a short version of the Experiences in
Close Relationships Scale – Revised Child version. Personality
and Individual Differences 2014;68:118-23.

Beck 1974

Brent 2019

Beck AT, Weissman A, Lester D, Trexler L. The measurement of
pessimism: the Hopelessness Scale. Journal of Consulting and
Clinical Psychology 1974;42:861-5.

Beck 1988

Beck AT, Steet RA, Ranieri WF. Scale for Suicide Ideation:
psychometric properties of a self-report version. Journal of
Clinical Psychology 1988;44:499-505.

Bennardi 2016

Bennardi M, McMahon E, Corcoran P, Griffin E, Arensman E.
Risk of repeated self-harm and associated factors in children,
adolescents, and young adults. BMC Psychiatry 2016;16:421.

Berk 2016

Berk MS, Hughes J. Cognitive behavioral approaches for
treating suicidal behavior in adolescents. Current Psychiatry
Reviews 2016;12:4-13.

Bird 1993

Bird HR, Shaffer D, Fisher P, Gould MS. The Columbia
Impairment Scale (CIS): pilot findings on a measure of global
impairment for children and adolescents. International Journal
of Methods in Psychiatric Research 1993;3:167-76.

Bohus 2007

Bohus M, Limberger MF, Frank U, Chapman AL, Kuhler T,
Stieglitz RD. Psychometric properties of the Borderline
Symptom List (BSL). Psychopathology 2007;40:126-32.

Bould 2019

Bould H, Mars B, Moran P, Biddle L, Gunnell D. Rising suicide
rates among adolescents in England and Wales. Lancet
2019;394:116-7.

Brent DA. Master clinician review: saving Holden Caulfield:
suicide prevention in children and adolescents. Journal of
the American Academy of Child and Adolescent Psychiatry
2019;58:25-35.

Brunner 2002

Brunner J, Parhofer KG, Schwandt P, Bronisch T. Cholesterol,
essential fatty acids, and suicide. Pharmacopsychiatry
2002;35:1-5.

Busby 2020

Busby DR, Hatkevich C, McGuire TC, King CA. Evidence-based
interventions for youth suicide risk. Current Psychiatry Reports
2020;22:5.

Bustamante-Madsen 2018

Bustamante-Madsen L, Eddleston M, Schultz-Hansen K,
Konradsen F. Quality assessment of economic evaluations of
suicide and self-harm interventions. Crisis 2018;39:82-95.

Cairns 2019

Cairns R, Karanges EA, Wong A, Brown JA, Robinson J,
Pearson S-A, et al. Tends in self-poisoning and psychotropic
drug use in people aged 5 – 19 years: a retrospective cohort
study in Australia. BMJ Open 2019;9:e026001. [DOI: 10.1136/
bmjopen-2018-026001]

Calear 2016

Calear AL, Christensen H, Freeman A, Fenton K, Busby Grant J,
Van Spijker B, et al. A systematic review of psychosocial
suicide prevention interventions for youth. European Child and
Adolescent Psychiatry 2016;25:467-82.

Carter 2016

Carter G, Page A, Large M, Hetrick S, Milner AJ, Bendit N, et
al. Royal Australian and New Zealand College of Psychiatrists
clinical practice guideline for the management of deliberate

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

self-harm. Australian and New Zealand Journal of Psychiatry
2016;50:939-1000.

Chezan 2017

Chezan LC, Gable RA, McWhorter GZ, White SD. Current
perspectives on interventions for self-injurious behavior of
children with autism spectrum disorder: a systematic review of
the literature. Journal of Behavioral Education 2017;26:293-329.

Chorpita 2000

Chorpita BF, Yim L, Moffitt C, Umemoto LA, Francis SE.
Assessment of symptoms of DSM-IV anxiety and depression
in children: a revised child anxiety and depression scale.
Behaviour Research and Therapy 2000;38:835-55.

Curtin 2002a

Curtin F, Elbourne D, Altman DG. Meta-analysis combining
parallel and cross-over clinical trials. III. The issue of carry-over.
Statistics in Medicine 2002;21:2161-73.

Curtin 2002b

Curtin F, Altman DG, Elbourne D. Meta-analysis combining
parallel and cross-over clinical. I. Continuous outcomes.
Statistics in Medicine 2002;21:2131-44.

D'Zurilla 2010

D'Zurilla TJ, Nezu AM. Problem-solving therapy. In: Dobson KS,
editors(s). Handbook of Cognitive-Behavioral Therapies. 3rd
edition. New York, NY: Guilford Press, 2010.

Cipriani 2013a

Davasaambuu 2019

Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the
prevention of suicide in mood disorders: updated systematic
review and meta-analysis. BMJ 2013;346:f3646.

Cipriani 2013b

Cipriani A, Reid K, Young AH, Macritchie K, Geddes J.
Valproic acid, valproate and divalproex in the maintenance
treatment of bipolar disorder. Cochrane Database of
Systematic Reviews 2013, Issue 10. Art. No: CD003196. [DOI:
10.1002/14651858.CD003196.pub2]

Claes 2007

Claes L, Wandereycken W, Vertommen H. Self-injury in
female versus male psychiatric patients: a comparison of
characteristics, psychopathology and aggression regulation.
Personality and Individual Differences 2007;42:611-21.

Courtney 2019

Courtney DB, Duda S, Szatmari P, Henderson J, Bennett K.
Systematic review and quality appraisal of practice guidelines
for self-harm in children and adolescents. Suicide & Life-
threatening Behavior 2019;49:707-23.

Cox 2014

Cox GR, Callahan P, Churchill R, Hunot V, Merry SN, Parker AG,
et al. Psychological therapies versus antidepressant
medication, alone and in combination, for depression
in children and adolescents. Cochrane Database of
Systematic Reviews 2014, Issue 11. Art. No: CD008324. [DOI:
10.1002/14651858.CD008324.pub3]

Cox 2017

Cox G, Hetrick S. Psychosocial interventions for self-harm,
suicidal ideation and suicide attempt in children and young
people: What? How? Who? and Where? Evidence Based Mental
Health 2017;20:35-40.

Crowell 2012

Crowell SE, Beauchaine TP, Hsiao RC, Wasilev CA, Yaptangco M,
Linehan MM. Differentiating adolescent self-injury from
adolescent depression: possible implications for borderline
personality development. Journal of Abnormal Child Psychology
2012;40:45-57.

Davasaambuu S, Itzhaky L, Ellis SP, Cisneros S, Scolaro K,
Lemberansky J, et al. Systematic review and meta-
analysis of randomized clinical trials of nonpharmacologic
interventions to reduce suicide risk among adolescents.
Neuropsychopharmacology 2019;44:S103-4.

De Beurs 2018

De Beurs D, Vancayseele N, Van Borkulo C, Portzky G, Van
Heeringen K. The association between motives, perceived
problems and current thoughts of self-harm following an
episode of self-harm: a network analysis. Journal of Affective
Disorders 2018;240:262-70.

Deeks 2019

Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 10:
Analysing data and undertaking meta-analyses. In: Higgins
JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et
al, editor(s). Cochrane Handbook for Systematic Reviews of
Interventions version 6.0 (updated July 2019). Cochrane, 2019.
Available from www.training.cochrane.org/handbook.

Devenish 2016

Devenish B, Berk L, Lewis AJ. The treatment of suicidality in
adolescents by psychosocial interventions for depression:
a systematic literature review. Australian and New Zealand
Journal of Psychiatry 2016;50:726-40.

Diamond 2014

Diamond GS, Diamond GM, Levy SA. Attachment Based Family
Therapy for Depressed Adolescents. Washington DC, USA:
American Psychological Association, 2014.

Diggins 2017

Diggins E, Kelley R, Cottrell D, House A, Owens D. Age-related
differences in self-harm presentations and subsequent
management of adolescents and young adults at the
emergency department. Journal of Affective Disorders
2017;208:399-405.

Donner 2002

Donner A, Klar N. Issues in the meta-analysis of cluster
randomized trials. Statistics in Medicine 2002;21:2971-80.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Easterbrook 1991

First 1997

Easterbrook PJ, Gopalan R, Berlin JA, Matthews DR. Publication
bias in clinical research. Lancet 1991;337:867-72.

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in
meta-analysis detected by a simple, graphical test. BMJ
1997;315:629-34.

Elbourne 2002

Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV,
Vail A. Meta-analyses involving cross-over trials: methodological
issues. International Journal of Epidemiology 2002;31:140-9.

EMA 2005

European Medicines Agency. European Medicines Agency
finalises review of antidepressants in children and adolescents.
www.ema.europa.eu/en/news/european-medicines-agency-
finalises-review-antidepressants-childrenand-adolescents
(accessed 7 July 2020).

Endicott 2006

Endicott J, Nee J, Yang R, Wohlberg C. Pediatric Quality of
Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q):
reliability and validity. Journal of the American Academy of Child
and Adolescent Psychiatry 2006;45:401-7.

Engles 2003

Engles JM, Diehr P. Imputation of missing longitudinal data:
a comparison of methods. Journal of Clinical Epidemiology
2003;56:968-76.

Epstein 1983

Epstein NB, Baldwin LM, Bishop DS. The McMaster Family
Assessment Device. Journal of Marital and Family Therapy
1983;9:171-80.

Erez 1996

Erez A, Bloom MC, Wells MT. Using random rather than fixed
effects models in meta-analysis: implications for situation
specificity and validity generalization. Personnel Psychology
1996;49:275-306.

EuroQol Group 1990

The EuroQol Group. EuroQol - a new facility for the
measurement of health-related quality of life. Health Policy
1990;16:199-208.

FDA 2004

US Food and Drug Administration. Relationship between
psychotropic drugs and pediatric suicidality: review and
evaluation of clinical data. www.fda.gov/ohrms/dockets/
ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf
(accessed prior to 10 Feb 2021).

FDA 2019

US Food and Drug Administration. FDA approves new
nasal spray medication for treatment-resistant depression.
www.fda.gov/news-events/press-announcements/fda-
approves-new-nasal-spray-medication-treatment-resistant-
depression-available-only-certified (accessed 18 March 2020).

First MB, Gibbon M, Spitzer RL, Benjamin LS. User’s Guide for
the Structured Clinical Interview for DSM-IV Axis II Personality
Disorders: SCID-II. 1st edition. Washington, DC: American
Psychiatric Association Publishing, 1997.

Flaherty 2018

Flaherty HB. Treating adolescent nonsuicidal self-injury: a
review of psychosocial interventions to guide clinical practice.
Child and Adolescent Social Work Journal 2018;35:85-95.

Fleiss 1994

Fleiss JL. Measures of effect size for categorical data. In: Cooper
H, Hedges LV, editors(s). The Handbook of Research Synthesis.
New York, NY: Russell Sage Foundation, 1994.

Fonagy 2019

Fonagy P, Campbell C, Rossouw T, Bateman A. Mentalization-
based therapy for adolescents. In: Evidence-Based Treatment
Approaches for Suicidal Adolescents: Translating Science into
Practice. Washington, DC: American Psychiatric Publishing,
2019.

Fortune 2016

Fortune S, Cottrell D, Fife S. Family factors associated with
adolescent self-harm: a review. Journal of Family Therapy
2016;38:226-56.

Friedlander 2006

Friedlander ML, Escudero V, Horvath AO, Heatherington L,
Cabero A, Martens MP. System for observing family therapy
alliances: a tool for research and practice. Journal of Counseling
Psychology 2006;53:214-25.

Furlong 2001

Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health
Utilities Index (HUI) system for assessing health-related quality
of life in clinical studies. Annals of Medicine 2001;33:375-84.

Gardner 2019

Gardner W, Pajer K, Cloutier P, Zemek R, Currie L, Hatcher S,
et al. Changing rates of self-harm and mental disorders by
sex in youths presenting to Ontario emergency departments:
repeated cross-sectional study. Canadian Journal of Psychiatry
2019;64:789-97.

Geulayov 2018

Geulayov G, Casey D, McDonald KC, Foster P, Pritchard K,
Wells C, et al. Incidence of suicide, hospital-presenting non-
fatal self-harm, and community-occurring non-fatal self-harm
in adolescents in England (the Iceberg Model of Self-Harm): a
retrospective study. Lancet Psychiatry 2018;5:167-74.

Gibbons 2007

Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK,
Erkens JA, et al. Early evidence on the effects of regulators'
suicidality warnings on SSRI prescriptions and suicide in
children and adolescents. American Journal of Psychiatry
2007;164:1356-63.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gilbert 2020

Gilbert AC, DeYoung LLA, Barthelemy CM, Jenkins GA,
MacPherson HA, Kim KL, et al. The treatment of suicide and
self-injurious behaviors in children and adolescents. Current
Treatment Options in Psychiatry 2020;7:39-52.

Gjelsvik 2014

Gjelsvik B, Heyerdahl F, Lunn D, Hawton K. Change in access to
prescribed medication following an episode of deliberate self-
poisoning: a multilevel approach. PLOS One 2014;9:e98086.

Glenn 2019

Glenn CR, Esposito EC, Porter AC, Robinson DJ. Evidence base
update of psychosocial treatments for self-injurious thoughts
and behaviors in youth. Journal of Clinical Child and Adolescent
Psychology 2019;48:357-92.

Goldberg 1972

Goldberg DP. The Detection of Psychiatric Illnesss by
Questionnaire. London, UK: Oxford University Press, 1972.

Good 2006

Good CR. Adjunctive quetiapine targets self-harm behaviors in
adolescent females with major depressive disorder. Journal of
Child and Adolescent Psychopharmacology 2006;16:235-6.

Goodman 1998

Goodman R, Meltzer H, Bailey V. The Strengths and Difficulties
Questionnaire: a pilot study on the validity of the self-
report version. European Child and Adolescent Psychiatry
1998;7:125-30.

Gowers 1999

Gowers SG, Harrington RC, Whitton A, Lelliott P, Beevor A,
Wing J, et al. Brief scale for measuring the outcomes of
emotional and behavioural disorders in children: the Health
of the Nation Outcome Scales for Children and Adolescents
(HoNOSCA). British Journal of Psychiatry 1999;174:413-6.

GRADEpro GDT 2015 [Computer program]

GRADEpro GDT. Version accessed 26 June 2020. Hamilton (ON):
McMaster University (developed by Evidence Prime). Available
at www.gradepro.org.

Granboulan 2001

Granboulan V, Roudot-Thoraval F, Lemerle S, Alvin P.
Predictive factors of post-discharge follow-up care among
adolescent suicide attempters. Acta Psychiatrica Scandinavica
2001;104:31-6.

Gratz 2004

Gratz KL, Roemer L. Multidimensional assessment of emotion
regulation and dysregulation: development, factor structure,
and initial validation of the Difficulties in Emotion Regulation
Scale. Journal of Psychopathology and Behavioral Assessment
2004;26:41-54.

Griffin 2018

Griffin E, McMahon E, McNicholas F, Corcoran P, Perry IJ,
Arensman E. Increasing rates of self-harm among children,
adolescents and young adults: a 10-year national registry study

Cochrane Database of Systematic Reviews

2007-2016. Social Psychiatry and Psychiatric Epidemiology
2018;53:663-71.

Grist 2018

Grist R, Porter J, Stallard P. Acceptability, use, and safety of a
mobile phone app (BlueIce) for young people who self-harm:
qualitative study of service users’ experience. Journal of Medical
Internet Research Mental Health 2018;5:e16.

Guy 1976

Guy W. Assessment Manual for Psychopharmacology. Rockville,
MD: US Department of Heath, Education, and Welfare Public
Health Service Alcohol, Drug Abuse, and Mental Health
Administration, 1976.

Ha 2013

Ha C, Sharp C, Ensink K, Fonagy P, Cirino P. The measurement of
reflective function in adolescents with and without borderline
traits. Journal of Adolescence 2013;36:1215-23.

Hassett 2017

Hassett A, Isbister C. Young men's experiences of accessing
and receiving help from Child and Adolescent Mental Health
Services following self-harm. SAGE Open 2017;1:1-14.

Hawton 2003

Hawton K, Hariss L, Hall S, Simkin S, Bale E, Bond A. Deliberate
self-harm in Oxford, 1990-2000: a time of change in patient
characteristics. Psychological Medicine 2003;33:987-96.

Hawton 2004

Hawton K, Harriss L, Simkin S, Bale E, Bond A. Self-cutting:
patient characteristics compared with self-poisoners. Suicide
and Life-Threatening Behavior 2004;34:199-208.

Hawton 2007

Hawton K, Bergen H, Casey D, Simkin S, Palmer B, Cooper J, et
al. Self-harm in England: a tale of three cities. Multicentre study
of self-harm. Social Psychiatry and Psychiatric Epidemiology
2007;42:513-21.

Hawton 2008

Hawton K, Harriss L. The changing gender ratio in occurrence of
deliberate self-harm across the lifecycle. Crisis 2008;29:4-10.

Hawton 2010

Hawton K, Bergen H, Simkin S, Cooper K, Water K, Gunnell D,
et al. Toxicity of antidepressants: rates of suicide relative to
prescribing and non-fatal overdose. British Journal of Psychiatry
2010;196:354-8.

Hawton 2012a

Hawton K, Bergen H, Kapur N, Cooper J, Steeg S, Ness J, et
al. Repetition of self-harm and suicide following self-harm
in children and adolescents: findings from the Multicentre
Study of Self-Harm in England. Journal of Child Psychology and
Psychiatry 2012;53:1212-9.

Hawton 2012b

Hawton K, Saunders KEA, O'Connor R. Self-harm and suicide in
adolescents. Lancet 2012;379:2373-82.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hawton 2012c

Higgins 2019a

Hawton K, Bergen H, Waters K, Ness J, Cooper J, Steeg S, et
al. Epidemiology and nature of self-harm in children and
adolescents: findings from the Multicentre Study of Self-
harm in England. European Child & Adolescent Psychiatry
2012;21:369-77.

Hawton 2013

Hawton K, Saunders KEA, Topiwala A, Haw C. Psychiatric
disorders in patients presenting to hospital following self-
harm: a systematic review. Journal of Affective Disorders
2013;151:821-30.

Hawton 2016

Hawton K, Witt KG, Taylor Salisbury TL, Arensman E, Gunnell D,
Hazell P, et al. Psychosocial interventions for self-harm in
adults. Cochrane Database of Systematic Reviews 2016, Issue 5.
Art. No: CD012189. [DOI: 10.1002/14651858.CD012189]

Hawton 2020a

Hawton K, Bale L, Brand F, Townsend E, Ness J, Waters K, et al.
Mortality in children and adolescents following presentation
to hospital after non-fatal self-harm in the Multicentre Study
of Self-harm: a prospective observational cohort study. Lancet
Child & Adolescent Health 2020;4(2):111-20. [DOI: 10.1016/
S2352-4642(19)30373-6]

Hawton 2020b

Hawton K, Hill NTM, Gould M, John A, Lascelles K, Robinson J.
Clustering of suicides in children and adolescents. Lancet Child
and Adolescent Health 2020;4:58-67.

Healy 2003

Healy D. Lines of evidence on the risks of suicide with
selective serotonin reuptake inhibitors. Psychotherapy and
Psychosomatics 2003;72:71-9.

Higgins JPT, Eldridge S, Li T, editor(s). Chapter 23: Including
variants on randomized trials. In: Higgins JPT, Thomas J,
Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions version
6.0 (updated July 2019). Cochrane, 2019. Available from
www.training.cochrane.org/handbook.

Higgins 2019b

Higgins JPT, Li T, Deeks JJ, editor(s). Chapter 6: Choosing
effect measures and computing estimates of effect. In: Higgins
JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch
VA (editors). Cochrane Handbook for Systematic Reviews of
Interventions version 6.0 (updated July 2019). Cochrane, 2019.
Available from www.training.cochrane.org/handbook.

Hopewell 2009

Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K.
Publication bias in clinical trials due to statistical significance
or direction of trial results. Cochrane Database of
Systematic Reviews 2009, Issue 1. Art. No: MR000006. [DOI:
10.1002/14651858.MR000006.pub3]

Hunt 2013

Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M.
Psychosocial interventions for people with both severe
mental illness and substance misuse. Cochrane Database of
Systematic Reviews 2013, Issue 10. Art. No: CD001088. [DOI:
10.1002/14651858.CD001088.pub3]

Husain 2014

Husain N, Afsar S, Ara J, Fayyaz H, Ur Rahman R, Tomenson B, et
al. Brief psychological intervention after self-harm: randomised
controlled trial from Pakistan. British Journal of Psychiatry
2014;204:462-70.

Iyengar 2018

Heerde 2019

Heerde JA, Hemphill SA. Are bullying perpetration and
victimization associated with adolescent deliberate self-harm?
A meta-analysis. Archives of Suicide Research 2019;23:353-81.

Iyengar U, Snowden N, Asarnow JR, Moran P, Tranah T, Ougrin D.
A further look at therapeutic interventions for suicide attempts
and self-harm in adolescents: an updated systematic review of
randomized controlled trials. Frontiers in Psychiatry 2018;9:583.

Hetrick 2012

James 2008

Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN.
Newer generation antidepressants for depressive disorder
in children and adolescents. Cochrane Database of
Systematic Reviews 2012, Issue 11. Art. No: CD004851. [DOI:
10.1002/14651858.CD004851.pub3]

Hetrick 2016

Hetrick SE, Robinson J, Spittal MJ, Carter G. Effective
psychological and psychosocial approaches to reduce
repetition of self-harm: a systematic review, meta-analysis and
meta-regression. BMJ Open 2016;6:e011024.

Higgins 2011

Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and
collecting data. In: Higgins JP, Green S, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
Available from training.cochrane.org/handbook/archive/v5.1.

James AC, Taylor A, Winmill L, Alfoadari K. A preliminary
community study of dialectical behavior therapy (DBT) with
adolescent females demonstrating persistent, deliberate self-
harm (DSH). Child and Adolescent Mental Health 2008;13:7.

Joe 2018

Joe S, Scott ML, Banks A. What works for adolescent black
males at risk of suicide: a review. Research on Social Work
Practice 2018;28:340-5.

John 2018

John A, Glendenning AC, Marchant A, Montgomery P, Stewart A,
Wood S, et al. Self-Harm, suicidal behaviours, and cyberbullying
in children and young people: systematic review. Journal of
Medical Internet Research 2018;20:e129.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jones 2012

Jones C, Hacker D, Cormac I, Meaden A, Irving CB.
Cognitive behavioural therapy versus other psychosocial
treatments for schizophrenia. Cochrane Database of
Systematic Reviews 2012, Issue 4. Art. No: CD008712. [DOI:
10.1002/14651858.CD008712.pub2]

Jung 2018

Jung KY, Kim T, Hwang SY, Lee TR, Yoon H, Shin TG, et al.
Deliberate self-harm among young people begins to increase
at the very early age: a nationwide study. Journal of Korean
Medical Science 2018;33:e191.

Kaess 2020b

self-harm behaviours in adolescents. Canadian Psychology
2015;56:368-78.

Lahti 2011

Lahti A, Räsänen P, Riala K, Keränen S, Hakko H. Youth suicide
trends in Finland, 1969-2008. Journal of Child Psychology and
Psychiatry, and Allied Disciplines 2011;52:984-91.

Liberati 2009

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC,
Ioannidis JP, et al. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration. PLOS
Medicine 2009;6:e1000100.

Kaess M, Eppelmann L, Brunner R, Parzer P, Resch F, Carli V, et
al. Life events predicting the first onset of adolescent direct self-
injurious behavior — a prospective multicentre study. Journal of
Adolescent Health 2020;66:195-201.

Linehan 1993

Linehan MM. Skills Training Manual for Treating Borderline
Personality Disorder. New York, NY: Guildford Press, 1993.

Kandemir 2008

Linehan 2006

Kandemir H, Yumru M, Kul M, Kandemir SB. Behavioural
disinhibition, suicidal ideation, and self-mutilation
related to clonazepam. Journal of Child and Adolescent
Psychopharmacology 2008;18:409.

Kaufman 2009

Kaufman AS, Kaufman NL. Kaufman Brief Intelligence Test —
Second Edition (KBIT-2). Circle Pines, MN: American Guidance
Service, 2009.

Kazdin 1983

Kazdin AE, French NH, Unis AS, Esveldt-Dawson K, Sherick RB.
The Hopelessness Scale for Children: psychometric
characteristics and concurrent validity. Journal of Consulting
and Clinical Psychology 1983;51:504-10.

Kerry 1998

Kerry SM, Bland JM. Analysis of a trial randomised in clusters.
BMJ 1998;316:54.

Kinchin 2017

Kinchin I, Doran CM, Hall WD, Meurk C. Understanding the true
economic impact of self-harming behaviour. Lancet Psychiatry
2017;4:900-1.

Klonsky 2011

Klonsky ED. Non-suicidal self-injury in United States adults:
prevalence, socio-demographics, topography and functions.
Psychological Medicine 2011;41:1981-6.

Kothgassner 2020

Kothgassner OD, Robinson K, Goreis A, Ougrin D, Plener PL.
Does treatment method matter? A meta-analysis of the past 20
years of research on therapeutic interventions for self-harm and
suicidal ideation in adolescents. Borderline Personality Disorder
and Emotion Dysregulation 2020;7:9.

Linehan MM, Comtois KA, Brown MZ, Heard HL, Wagner A.
Suicide Attempt Self-Injury Interview (SASII): development,
reliability, and validity of a scale to assess suicide attempts
and intentional self-injury. Psychological Assessment
2006;18:303-12.

Liu 2018

Liu RT, Scopelliti KM, Pittman SK, Zamora AS. Childhood
maltreatment and non-suicidal self-injury: a systematic review
and meta-analysis. Lancet Psychiatry 2018;5:51-64.

Lu 2014

Lu C, Zhang F, Lakoma MD, Madden JM, Rusinak D, Penford RB,
et al. Changes in antidepressant use by young people and
suicidal behavior after FDA warnings and media coverage: a
quasi-experimental study. BMJ 2014;348:g3596.

Lynch 2006

Lynch TR, Chapman AL, Rosenthal MZ, Kuo JR, Linehan MM.
Mechanisms of change in dialectical behavior therapy:
theoretical and empirical observations. Journal of Clinical
Psychology 2006;62:459-80.

Ma 2018

Ma C-H, Chang S-S, Tsai H-J, Gau SS-F, Chen I-M, Lian S-C, et al.
Comparative effect of antipsychotics on risk of self-harm among
patients with schizophrenia. Acta Psychiatrica Scandinavica
2018;137:296-305.

Madge 2008

Madge N, Hewitt A, Hawton K, De Wilde EJ, Corcoran P, Fekete S,
et al. Deliberate self-harm within an international community
sample of young people: comparative findings from the Child &
Adolescent Self-harm in Europe (CASE) study. Journal of Child
Psychology and Psychiatry, and Allied Disciplines 2008;49:667-77.

Madge 2011

Labelle 2015

Labelle R, Pouliot L, Janelle A. A systematic review and meta-
analysis of cognitive behavioural treatments for suicidal and

Madge N, Hawton K, McMahon EM, Corcoran P, De Leo D, De
Wilde EJ, et al. Psychological characteristics, stressful life
events and deliberate self-harm: findings from the Child and

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Adolescent Self-harm in Europe (CASE) Study. European Child &
Adolescent Psychiatry 2011;20:499-508.

Mann 2013

Mann JJ. The serotonergic system in mood disorders and
suicidal behaviour. Philosophical Transactions of The Royal
Society (B Biological Sciences) 2013;368:20120537.

Mars 2016

Mars B, Cornish R, Heron J, Boyd A, Crane C, Hawton K, et al.
Using data linkage to investigate inconsistent reporting of self-
harm and questionnaire non-response. Archives of Suicide
Research 2016;20:113-41.

Marshall 2000

Microsoft Excel RoB2 Macro [Computer program]

Version 6. Risk of Bias 2 Development Group, 22 August 2019.
Available at: sites.google.com/site/riskofbiastool/welcome/
rob-2-0-tool/current-version-of-rob-2.

Mikolajczak 2009

Mikolajczak M, Petrides KV, Hurry J. Adolescents choosing
self-harm as an emotion regulation strategy: the protective
role of trait emotional intelligence. British Journal of Clinical
Psychology 2009;48:191-3.

Miller 2007

Miller AL, Rathus JH, Linehan MM. Dialectical Behavior Therapy
with Suicidal Adolescents. New York, NY: Guilford Press, 2007.

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M.
Unpublished rating scales: a major source of bias in randomised
controlled trials of treatments for schizophrenia. British Journal
of Psychiatry 2000;176:249-52.

Miller 2014

Miller M, Swanson SA, Azrael D, Pate V, Strumer T.
Antidepressant dose, age, and the risk of deliberate self-harm.
JAMA Internal Medicine 2014;174(6):899-909.

Maslach 1986

Milner 2016

Maslach C, Jackson SE. Maslach Burnout Inventory Manual.
Palo Alto, CA: Consulting Psychologists Press, 1986.

Maydeu-Olivares 1996

Maydeu-Olivares A, D’Zurilla TJ. A factor analytic study of the
Social Problem-Solving Inventory: an integration of theory and
data. Cognitive Therapy and Research 1996;20:115-33.

McGill 2018

McGill K, Hiles S, Handley TE, Page A, Lewin TJ, Whyte I, et
al. Is the reported increase in young female hospital-treated
intentional self-harm real or artefactual? Australian and New
Zealand Journal of Psychiatry 2018;53:663-72.

McMahon 2013

Milner A, Spittal MJ, Kapur N, Witt K, Pirkis J, Carter G.
Mechanisms of brief contact interventions in clinical
populations: a systematic review. BMC Psychiatry 2016;16:194.

Moher 1998

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.
Does quality of reports of randomised trials affect estimates
of intervention efficacy reported in meta-analyses? Lancet
1998;352:609-13.

Montgomery 1979

Montgomery SA, Åsberg M. A new depression scale designed
to be sensitive to change. British Journal of Psychiatry
1979;134:382-9.

McMahon EM, Corcoran P, Keeley H, Perry IJ, Arensman E.
Adolescents exposed to suicidal behavior of others: prevalence
of self-harm and associated psychological, lifestyle, and
life event factors. Suicide & Life-threatening Behavior
2013;43:634-45.

Morgan 2017

Morgan C, Webb RT, Carr MJ, Kontopantelis E, Green J, Chew-
Graham C, et al. Incidence, clinical management, and mortality
risk following self harm among children and adolescents. BMJ
Open 2017;359:j4351.

McMahon 2014

Morken 2020

McMahon EM, Keeley H, Cannon M, Arensman E, Perry IJ,
Clarke M, et al. The iceberg model of suicide and self-harm in
Irish adolescents: a population-based study. Social Psychiatry
and Psychiatric Epidemiology 2014;49:1929-35.

Morken IS, Dahlgren A, Lunde I, Toven S. The effects of
interventions preventing self-harm and suicide in children and
adolescents: an overview of systematic reviews. F1000Research
2020;8:890.

MHRA 2003

Müller 2016

Medicines and Healthcare Products Regulatory
Authority (MHRA). Selective Serotonin Reuptake
Inhibitors (SSRIs): overview of regulatory status and
CSM advice relating to major depressive disorder (MDD)
in children and adolescents including a summary of
available safety and efficacy data. www.mhra.gov.uk/
Safetyinformation/Safetywarningsalertandrecalls/
Safetywarningsandmessagesformedicines/CON019494
(accessed 18 September 2014).

Müller A, Claes L, Brähler E, De Zwaan M. Prevalence and
correlates of self-harm in the German general population. PLOS
One 2016;11:e0157928.

NCCMH 2004

National Collaborating Centre for Mental Health. Clinical
Guideline 16. Self-Harm: The Short-Term Physical and
Psychological Management and Secondary Prevention of Self-
Harm in Primary and Secondary Care. London, UK: National
Institute for Clinical Excellence, 2004.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Nezu 2010

Plöderl 2019

Nezu AM, Nezu CM, D'Zurilla TJ. Problem-solving therapy. In:
Kazantzis N, Reinecke MA, Freeman A, editors(s). Cognitive and
Behavioral Theories in Clinical Practice. New York, NY: Guilford
Press, 2010.

Plöderl M, Hengartner MP. Antidepressant prescription rates
and suicide attempt rates from 2004 to 2016 in a nationally
representative sample of adolescents in the USA. Epidemiology
and Psychiatric Sciences 2019;28:589-91.

NICE 2011

Poznanski 1985

National Institute for Health and Clinical Excellence. Self-
harm: Longer-Term Management [National Institute for Health
and Care Excellence clinical guideline 133]. Accessed 26 June
2020 from: www.nice.org.uk/guidance/cg133/evidence/full-
guideline-pdf-184901581. London, UK: National Institute for
Health and Clinical Excellence, 2011.

O'Connor 2012

O'Connor RC, Rasmussen S, Hawton K. Distinguishing
adolescents who think about self-harm from those who engage
in self-harm. British Journal of Psychiatry 2012;200:330-5.

Ohlis 2020

Ohlis A, Bjureberg J, Lichtenstein P, D’Onofrio BM, Fruzzetti AE,
Cederlöf M, et al. Comparison of suicide risk and other
outcomes among boys and girls who self-harm. European Child
and Adolescent Psychiatry 2020;29(12):1741-6. [DOI: 10.1007/
s00787-020-01490-y]

Osman 1998

Osman A, Downs WR, Kopper BA, Barrios FX, Besett FX,
Linehan MM, et al. The Reasons for Living Inventory for
Adolescents (RFL-A): development and psychometric
properties. Journal of Clinical Psychology 1998;54:1063-78.

Ougrin 2012

Poznanski EO, Freeman LN, Mokros HB. Children's Depression
Rating Scale - Revised. Psychopharmacology Bulletin
1985;21:979-89.

Radloff 1991

Radloff LS. The use of the Center for Epidemiologic Studies
Depression Scale in adolescents and young adults. Journal of
Youth and Adolescence 1991;20:149-66.

Review Manager 2020 [Computer program]

Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic
Cochrane Centre, The Cochrane Collaboration, 2020.

Reynolds 1985

Reynolds WM. Suicidal Ideation Questionnaire: Professional
Manual. Odessa, FL: Psychological Assessment Resources, 1985.

Reynolds 1988

Reynolds WM. Suicidal Ideation Questionnaire: Professional
Manual. Odessa, FL: Psychological Assessment Resources, 1988.

Rhodes 2014

Rhodes AE, Boyle MH, Bridge JA, Sinyor M, Links TS, Tonmyr L,
et al. Antecedents and sex/gender differences in youth suicidal
behavior. World Journal of Psychiatry 2014;4:120-32.

Ougrin D, Zundel T, Kyriakopoulos M, Banarsee R, Stahl D,
Taylor E. Adolescents with suicidal and nonsuicidal self-harm:
clinical characteristics and response to therapeutic assessment.
Psychological Assessment 2012;24:11-20.

Robinson 2018

Robinson J, Bailey E, Witt K, Stefanac N, Milner A, Currier D, et
al. What works in youth suicide prevention? A systematic review
and meta-analysis. eClinical Medicine 2018;4:P52-91.

Owens 2020

Roh 2018

Owens C, Fox F, Redwood S, Davies R, Foote L, Salisbury N, et
al. Measuring outcomes in trials of interventions for people
who self-harm: qualitative study of service users' views. British
Journal of Psychiatry Open 2020;6:e22.

Perera 2018

Perera J, Wand T, Bein KJ, Chalkley D, Ivers R, Steinbeck KS, et
al. Presentations to NSW emergency departments with self-
harm, suicidal ideation, or intentional poisoning, 2010-2014.
Medical Journal of Australia 2018;208:348-53.

Platt 1971

Platt JJ, Spivack G, Bloom M. Means-End Problem Solving
Procedure (MEPS): Manual and Tentative Norms. Philadelphia,
PA, USA: Department of Health Services, Hahnemann Medical
College and Hospital, 1971.

Plener 2016

Plener PL, Brunner R, Fegert JM, Groschwitz RC, In-Albon T,
Kaess M, et al. Treating nonsuicidal self-injury (NSSI) in
adolescents: consensus based German guidelines. Child and
Adolescent Psychiatry and Mental Health 2016;10:46.

Roh BR, Jung EH, Hong HJ. A comparative study of suicide
rates among 10-19-year-olds in 29 OECD countries. Psychiatry
Investigations 2018;15:376-83.

Rossouw 2018

Rossouw T. Mentalization-based therapy for adolescents:
managing storms in youth presenting with self-harm and
suicidal states. In: Steele H, Steele M, editors(s). Handbook of
Attachment-Based Interventions. New York, NY: Guilford Press,
2018.

Royal College of Psychiatrists 2014

Royal College of Psychiatrists. Managing Self-Harm in Young
People (Guideline number CR192). London, UK: Royal College of
Psychiatrists, 2014.

Sadowski 1991

Sadowski C, Kelley ML. Social problem solving in suicidal
adolescents. Journal of Consulting and Clinical Psychology
1991;61:121-7.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sanacora 2017

Sterne 2019

Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS,
Schatzberg AF, et al, American Psychiatric Association
(APA) Council of Research Task Force on Novel Biomarkers
and Treatments. A consensus statement on the use of
ketamine in the treatment of mood disorders. JAMA Psychiatry
2017;74:399-405.

Schünemann 2019

Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA,
Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’
tables and grading the certainty of the evidence. In: Higgins
JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et
al, editor(s). Cochrane Handbook for Systematic Reviews of
Interventions version 6.0 (updated July 2019). Cochrane, 2019.
Available from www.training.cochrane.org/handbook.

Selph 2014

Selph SS, Ginsburg AD, Chou R. Impact of contacting study
authors to obtain additional data for systematic reviews:
diagnostic accuracy studies for hepatic fibrosis. Systematic
Reviews 2014;3:107.

Shaffer 1985

Shaffer D, Gould MS, Brasic P, Ambrosini P, Fisher P,
Bird H, et al. A Children's Global Assessment Scale (CGAS).
Psychopharmacology Bulletin 1985;21:747-8.

Sharp 2014

Sharp C, Steinberg L, Temple J, Newlin E. An 11-item measure to
assess borderline traits in adolescents: refinement of the BPFSC
using IRT. Personality Disorders 2014;5:70-8.

Sheen 2002

Sheen CL, Dillon JF, Bateman DN, Simpson KJ, MacDonald TM.
Paracetamol toxicity: epidemiology, prevention and costs
to the health-care system. Quarterly Journal of Medicine
2002;95:609-19.

Sinclair 2011

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS,
Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in
randomised trials. BMJ 2019;366:I4898.

Stiffman 2000

Stiffman AR, Horwitz SM, Hoagwood K, Compton W, Cottler L,
Bean DL, et al. The Service Assessment for Children and
Adolescents (SACA): adult and child reports. Journal of
the American Academy of Child and Adolescent Psychiatry
2000;39:1032-9.

Sublette 2006

Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA, Mann JJ.
Omega-3 polyunsaturated essential fatty acid status as a
predictor of future suicide risk. American Journal of Psychiatry
2006;163:1100-02.

Sullivan 2015

Sullivan EM, Annest JL, Simon TR, Luo F, Dahlberg LL. Suicide
trends among persons aged 10-24 years — United States,
1994-2012. Morbidity and Mortality Weekly Report. Surveillance
Summaries: MMWR 2015;64:201-5.

Tanskanen 2001

Tanskanen A, Hibbeln JR, Hintikka J, Haatainen K,
Honkalampi K, Viinamaki H. Fish consumption, depression,
and suicidality in a general population. Archives of General
Psychiatry 2001;58:512-3.

Taylor 1984

Taylor EA, Stansfeld SA. Children who poison themselves.
II. Prediction of attendance for treatment. British Journal of
Psychiatry 1984;145:132-5.

Taylor 2011

Taylor LMW, Oldershaw A, Richards C, Davidson K, Schmidt U,
Simic M. Development and pilot evaluation of a manualized
cognitive-behavioural treatment package for adolescent self-
harm. Behavioural and Cognitive Psychotherapy 2011;39:619-25.

Sinclair JMA, Gray A, Rivero-Arias O, Saunders KEA, Hawton K.
Healthcare and social services resource use and costs of self-
harm patients. Social Psychiatry and Psychiatric Epidemiology
2011;46:263-71.

Torgerson 2004

Torgerson D. The use of Zelen's design in randomised trials.
British Journal of Obstetrics and Gynaecology 2004;111:2.

Skinner 2012

Tyrer 2012

Skinner R, McFaull S. Suicide among children and adolescents
in Canada: trends and sex differences, 1980-2008. Canadian
Medical Association Journal 2012;184:1029-34.

Tyrer P. Why benzodiazepines are not going away: commentary
on benzodiazepines for anxiety disorders. Advances in
Psychiatric Treatment 2012;18:259-62.

Spielberger 1988

Van Heeringen 2014

Spielberger CD. State-Trait Anger Expression Inventory. Odess,
FL, USA: Psychological Assessment Resources, 1988.

Van Heeringen K, Mann JJ. The neurobiology of suicide. Lancet
Psychiatry 2014;1:63-72.

Stefanac 2019

Viechtbauer 2020

Stefanac N, Hetrick S, Hulbert C, Spittal MJ, Witt K, Robinson J.
Are young female suicides increasing? A comparison of sex-
specific rates and characteristics of youth suicides in Australia
over 2004-2014. BMC Public Health 2019;19:1389.

Viechtbauer W, Cheung MW-L. Outlier and influence diagnostics
for meta-analysis. Research Synthesis Methods 2020;1:112-25.

Vrouva 2010

Vrouva I, Fonagy P, Fearon PRM, Roussow T. The Risk-Taking
and Self-Harm Inventory for adolescents: development

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

and psychometric evaluation. Psychological Assessment
2010;22:853-65.

Washburn 2012

Washburn JJ, Richardt SL, Styer DM, Gebhardt M, Juzwin KR,
Yourek A, et al. Psychotherapeutic approaches to non-suicidal
self-injury in adolescents. Child and Adolescent Psychiatry and
Mental Health 2012;6:14.

Weissman 1999

Weissman MM, Staff MHS. Social Adjustment Scale - Self-Report
(SAS-SR) User's Manual. North Tonawanda, NY: Multi-Health
Systems, 1999.

Westbrook 2008

Westbrook D, Kennerley H, Kirk J. An Introduction to Cognitive
Behaviour Therapy: Skills and Applications. London, UK: SAGE
Publications, 2008.

Whitely 2020

Whitely M, Raven M, Jureidini J. Antidepressant prescribing and
suicide/self-harm by young Australians: regulatory warnings,
contradictory advice, and long-term trends. Frontiers in
Psychiatry 2020;11:478.

methods used at repeat episodes of non-fatal self-harm and
suicide: a systematic review. Journal of Affective Disorders
2019;245:250-64.

Witt 2020a

Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW, Loo C,
et al. Ketamine for suicidal ideation in adults with psychiatric
disorders: a systematic review and meta-analysis of treatment
trials. Australian and New Zealand Journal of Psychiatry
2020;54:29-45.

Witt 2020b

Witt K, Townsend E, Arensman E, Gunnell D, Hazell P, Taylor
Salisbury T, et al. Psychosocial interventions for people
who self-harm: methodological issues involved in trials
to evaluate effectiveness. Archives of Suicide Research
2020;24(sup2):S32-93. [DOI: 10.1080/13811118.2019.1592043]

Witt 2020c

Witt  KG, Hawton  K, Hetrick  SE, Taylor Salisbury  TL,
Townsend  E, Hazell  P. Psychosocial interventions for self-harm
in adults. Cochrane Database of Systematic Reviews 2020, Issue
7. Art. No: CD013668. [DOI: 10.1002/14651858.CD013668]

Witt 2021

WHO 2014a

World Health Organization. Preventing Suicide: A Global
Imperative. Geneva, Switzerland: World Health Organization,
2014.

Witt  KG, Hetrick  SE, Rajaram  G, Hazell  P, Taylor Salisbury  TL,
Townsend  E, et al. Pharmacological interventions for self-harm
in adults. Cochrane Database of Systematic Reviews 2021, Issue
1. Art. No: CD013669. [DOI: 10.1002/14651858.CD013669.pub2]

WHO 2014b

Wong 2020

World Health Organization Collaborating Centre for Drug
Statistics and Methodology. Guidelines for ATC Classification
and DDD Assignment. Oslo, Norway: World Health Organization,
2014.

Wong J, Bahji A, Khalid-Khan S. Psychotherapies for adolescents
with subclinical and borderline personality disorder: a
systematic review and meta-analysis. Canadian Journal of
Psychiatry 2020;65:5-15.

Wilkinson 2018

Wood 2001b

Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW,
Feder A, et al. The effect of a single dose of intravenous
ketamine on suicidal ideation: a systematic review and
individual participant data meta-analysis. American Journal of
Psychiatry 2018;175:150-8.

Witt 2018

Witt K, Pache de Moraes D, Taylor Salisbury T, Arensman E,
Gunnell D, Hazell P, et al. Treatment as usual (TAU) as a
control condition in trials of cognitive behavioural-based
psychotherapy for self-harm: impact of content and quality on
outcomes in a systematic review. Journal of Affective Disorders
2018;235:434-47.

Witt 2019a

Witt K, Milner A, Spittal MJ, Hetrick S, Robinson J, Pirkis J, et
al. Population attributable risk of factors associated with the
repetition of self-harm behaviour in young people presenting
to clinical services: a systematic review and meta-analysis.
European Child & Adolescent Psychiatry 2019;28:5-18.

Witt 2019b

Witt K, Daly C, Arensman E, Pirkis J, Lubman D. Patterns
of self-harm methods over time and the association with

Wood A, Trainor G. Developmental Group Psychotherapy
for Adolescents: A Manual for Mental Health Professionals.
Manchester, UK: University of Manchester, 2001.

Yuan 2019

Yuan SNV, Kwok KHR, Ougrin D. Treatment engagement in
specific psychological treatment vs. treatment as usual for
adolescents with self-harm: systematic review and meta-
analysis. Frontiers in Psychology 2019;10:104.

Zahl 2004

Zahl DL, Hawton K. Repetition of deliberate self-harm and
subsequent suicide risk: long-term follow-up study of 11 583
patients. British Journal of Psychiatry 2004;185:70-5.

Zanarini 2007

Zanarini MC. In: Childhood prevalence of borderline personality
disorder. 54th Annual Meeting of the American Academy of
Child and Adolescent Psychiatry. Boston, MA, 2007.

Zelen 1979

Zelen M. A new design for randomized clinical trials. New
England Journal of Medicine 1979;300:1242-5.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Zigmond 1983

Zigmond AS, Snaith RP. The Hospital Anxiety and Depression
Scale. Acta Psychiatrica Scandinavica 1983;67:361-70.

References to other published versions of this review

Hawton 2015

Hawton K, Witt KG, Taylor Salisbury TL, Arensman E, Gunnell D,
Townsend E, et al. Interventions for self-harm in children and

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Cochrane Database of Systematic Reviews

adolescents. Cochrane Database of Systematic Reviews 2015,
Issue 12. Art. No: CD012013. [DOI: 10.1002/14651858.CD012013]

Witt 2020d

Witt KG, Hawton K, Hetrick SE, Taylor Salisbury TL, Townsend E,
Hazell P. Interventions for self-harm in children and
adolescents. Cochrane Database of Systematic Reviews 2020,
Issue 7. Art. No: CD013667. [DOI: 10.1002/14651858.CD013667]

* Indicates the major publication for the study

Asarnow 2017 

Study characteristics

Methods

Single-blind RCT. Participants were individually randomised via a computerised algorithm, stratified by
sex and self-harm type (i.e. NSSI-only versus SA), to either 12 weeks of a family intervention or EUC.

Follow-up period: 12 months.

N lost to follow-up: 12/42 (28.6%) for repetition of SH according to self-report, 0/42 (0%) for repetition of
SH according to either self or parent-report

Participants

Number of total participants: 42 adolescents were randomised; 20 were allocated to the intervention
arm (family intervention) and 22 were allocated to EUC.

Interventions

Profile of participants: mean age 14.6 ± 1.8 years (range 11 to 18 years). The majority (88.1%) were fe-
male. Half (54.8%) were diagnosed with major depression.

Source of participants: patients presenting to the ED following an episode of SH

Inclusion criteria: i) 11 to 18 years of age; ii) recent (past three months) episode of SH; iii) history of
repetitive SH (≥ 3 lifetime SH episodes); iv) living in a stable family situation (e.g. no plans for residen-
tial placement); v) at least one parent willing to participate in treatment

Exclusion criteria: i) symptoms interfering with participation in assessments or intervention (e.g. psy-
chosis, substance dependence); ii) insufficient language ability

Intervention: Safe Alternatives for Teens and Youths (SAFETY), a 12-week family-centred intervention,
consisting of weekly (duration not reported) individual and family therapy sessions. The intervention
combines elements from CBT (e.g. problem-solving, chain analysis, cognitive restructuring, behav-
ioural activation, 'hope box'), DBT (e.g. emotion regulation, distress tolerance), safety planning, fami-
ly therapy, and a crisis card intervention. Sessions were delivered by two therapists (information on ex-
pertise and experience not reported), one of which delivered the individual therapy to the young per-
son and the second of which delivered the family therapy component.

Comparator: EUC, including an in-clinic psychoeducation and therapy session for parents, telephone
counselling, and TAU

Length of treatment: 12 weeks

Location: Los Angeles, CA, USA

Outcomes

Primary outcome(s): i) repetition of SH according to self-report (supplemented by parental report,
where necessary) using the C-SSRS.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Asarnow 2017  (Continued)

Cochrane Database of Systematic Reviews

Secondary outcomes: i) ED visits, hospitalisation, and other service use according to self-report using a
modified version of the Service Assessment for Children and Adolescents (SACA; Stiffman 2000); ii) de-
pression, as measured by the CES-D

Notes

Source of funding: "…this publication was supported by grants from the National Institute of Mental
Health [R34 MH078082] and the American Foundation for Suicide Prevention (AFSP)" (p.513).

Conflict(s) of interest: "Dr. Asarnow has received grant or research support from the National Institute
of Mental Health, the American Foundation for Suicide Prevention, the American Psychological Associ-
ation (APA) Committee on Division/APA Relations, and the Society of Clinical Child and Adolescent Psy-
chology (Division 53 of the APA). She has served as a consultant on quality improvement interventions
for depression and suicidal/self-harm behavior. Dr. Hughes has received grant or research support from
the American Foundation for Suicide Prevention. She has served as a consultant on quality improve-
ment interventions for depression and suicidal/self-harm behavior in youth. Dr. Sugar has received re-
search support from the National Institutes of Health (NIH) through multiple divisions including the Na-
tional Institute of Mental Health (NIMH), the National Institute of General Medical Sciences (NIGMS), the
National Institute of Child Health and Human Development (NICHD), the National Institute of Allergy
and Infectious Diseases (NIAID), and the National Institute of Diabetes and Digestive and Kidney Dis-
eases (NIDDK); the Health Resources and Services Administration (HRSA); the US Department of Vet-
erans Affairs; and the John Templeton Foundation. She has served on technical expert panels for the
Centers for Medicare and Medicaid Services and Data Safety and Monitoring Boards for both academic
institutions and Kaiser Permanente. Dr. Babeva reports no biomedical financial interests or potential
conflicts of interest" (Asarnow 2017, p.513).

Cooney 2010 

Study characteristics

Methods

Single-blind RCT. Participants were individually assigned via a computer-generated sequence to either
manualised DBT-A or TAU.

Follow-up period: 6 months

N lost to follow-up: 0/29 (0%) for repetition of SH at post-intervention

Participants

Number of total participants: 29 adolescents were randomised; 14 were allocated to manualised DBT-A
and 15 were allocated to TAU.

Profile of participants: mean age 15.9 ± 1.1 years (range 14.0 to 17.8 years). Three-quarters (n = 22;
75.9%) were female. The majority (80.0%) were diagnosed with major depression. Two-thirds (n = 20;
68.9%) were diagnosed with any anxiety disorder. Almost all (n = 27; 93.1%) were diagnosed with co-
morbid psychiatric disorders.

Source of participants: patients referred to clinical services following a suicide attempt or an episode of
intentional self-injury within the preceding three months

Inclusion criteria: i) 13 to 19 years of age; ii) ≥ 1 suicide attempt or episode of intentional self-injury with-
in the three months preceding the baseline assessment; iii) in regular contact with at least one adult
who was willing and able to attend treatment sessions as required; iv) proficient in English

Exclusion criteria: i) diagnosed with an intellectual disability; ii) diagnosed with a psychotic disorder

Interventions

Intervention: DBT-A comprising weekly individual therapy sessions (50-60 minutes), weekly group skills
training (110 minutes), family therapy sessions (duration not reported), and telephone counselling, as
required. Sessions were delivered by trained therapists with experience in delivering DBT-A (expertise
not reported).

Comparator: TAU comprising weekly individual and family sessions provided by a multidisciplinary
treatment team, medication management, and hospital or respite care, as required

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cooney 2010  (Continued)

Length of treatment: 26 weeks

Location: Auckland, New Zealand

Outcomes

Primary outcome(s): i) repetition of SH according to self-report using the Suicide Attempt-Self-Injury In-
terview (SASII; Linehan 2006); ii) frequency of repeat SH according to self-report using the SASII

Secondary outcome(s): i) treatment adherence, as measured by the number of therapy sessions attend-
ed; ii) hopelessness, as measured by the Reasons for Living Inventory for Adolescents (RFL-A; Osman
1998); iii) suicidal ideation, as measured by the BSSI; iv) emotion regulation skills, as measured by the
Difficulties in Emotion Regulation Scale (DERS; Gratz 2004). Therapist burnout was also measured using
the Maslach Burnout Inventory (MBI; Maslach 1986).

Notes

Source of funding: no details on funding reported

Conflict(s) of interest: “Dr. Emily Cooney and Dr. Kirsten Davis are both directors of a training compa-
ny (DBTNZ) that is affiliated with Behavioral Tech LLC, the training organisation mandated by the de-
veloper of dialectical behaviour therapy. DBTNZ provides training in this therapy within New Zealand.
Dr. Emily Cooney, Dr. Kirsten Davis and Pania Thompson are all employed by the Kari Centre child and
adolescent mental health service within the Auckland District Health Board. This service provides a
DBT programme as a treatment for young people with emotion dysregulation and repeated self-har-
m” (Cooney 2010, p. 4).

Cotgrove 1995 

Study characteristics

Methods

RCT (unclear whether clinical personnel or outcome assessors were blinded). Participants were individ-
ually assigned via an open number table to either 12 months of using an emergency green card in addi-
tion to TAU or TAU alone.

Follow-up period: 12 months

N lost to follow-up: 0/105 (0%) for repetition of SH at post-intervention

Participants

Number of total participants: 105 adolescents were randomised; 47 were allocated to receive a emer-
gency green card in addition to TAU and 58 were allocated to TAU.

Profile of participants: mean age 14.9 ± NR years (range 12.2 to 16.7 years). The majority (n = 89; 84.8%)
were female. Few were diagnosed with a psychiatric disorder (n = 6; 5.7%); however, the nature of
these diagnoses was not reported.

Source of participants: patients admitted to hospital following SH

Inclusion criteria: i) 16 years of age or under

Exclusion criteria: i) information on original suicide attempt missing; ii) "insufficient follow-up da-
ta" (Cotgrove 1995, p. 572)

Interventions

Intervention: emergency green card in addition to TAU. The green card acted as a passport to re-ad-
mission into a paediatric ward at the local hospital. No information on who delivered the intervention,
their expertise, or their experience was reported.

Comparator: TAU. No further details reported

Length of treatment: 12 months

Location: North London, UK

Outcomes

Primary outcome(s): i) repetition of SH according to clinical and hospital notes

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cotgrove 1995  (Continued)

Cochrane Database of Systematic Reviews

Secondary outcome(s): i) use of the emergency green card according to clinical and hospital notes

Notes

Source(s) of funding: no details on funding reported

Conflict(s) of interest: no details on conflicts of interest reported

Cottrell 2018 

Study characteristics

Methods

Single-blind, multicentre RCT. Participants were individually randomised via a computer-generated
minimisation procedure to either a family intervention or TAU.

Follow-up period: 18 months

N lost to follow-up: 0/832 (0%) for repetition of SH

Participants

Number of total participants: 832 adolescents were randomised; 415 were allocated to the intervention
arm (family intervention) and 147 were allocated to TAU.

Profile of participants: mean age 14.3 ± 1.4 years (range 11 to 18 years). The majority (88.6%) were fe-
male, and had a history of multiple episodes of SH (n = 739; 88.8%). No information on psychiatric diag-
noses at baseline was reported.

Source of participants: patients referred to Child and Adolescent Mental Health Services (CAMHS) fol-
lowing an episode of SH

Inclusion criteria: i) 11 to 17 years of age; ii) living with a primary caregiver willing to take part in the tri-
al; iii) ≥ 2 episodes of SH prior to CAMHS referral (i.e. the index episode)

Exclusion criteria: i) at serious risk of suicide; ii) ongoing child protection investigation; iii) pregnant at
time of trial entry; iii) already receiving usual treatment by a specific specialist service within CAMHS;
iv) resident in a short-term foster home; v) diagnosed with moderate to severe learning disabilities; vi)
involved in another trial within the six months preceding trial entry; vii) sibling currently participating
in any trial or treatment involving family therapy within CAMHS; viii) insufficient language proficiency
for either the young person or their caregiver

Location: Greater Manchester, Yorkshire, and London, UK

Intervention: Self-Harm Intervention: Family Therapy (SHIFT), a manualised six-month family-centred
intervention, consisting of six to eight monthly sessions (1.25 hours) of family therapy sessions in addi-
tion to TAU. Sessions were delivered by therapists (number and expertise not reported) who received
initial training  (duration not reported) and ongoing monthly supervision (2 hours).

Comparator: TAU by local CAMHS teams. Therapy was consistent with NICE guidelines, and could con-
sist of a wide range of treatment techniques and modalities, as necessary.

Length of treatment: six months

Concomitant medications: a minority of participants (n = 41; 4.9%) were prescribed concomitant med-
ications, most commonly antidepressants (n = 28; 68.3%), followed by medications to manage symp-
toms associated with attention deficit hyperactivity disorder (n = 6; 14.6%), sedatives (n = 5; 12.2%), an-
tipsychotics (n = 2; 4.9%), and anxiolytics (n = 1; 2.4%).

Interventions

Outcomes

Primary outcome(s): repetition of self-harm leading to hospital attendance at 18 months

Secondary outcome(s): i) suicidal ideation, measured by the BSSI; ii) quality of life, as measured by
Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q; Endicott 2006); iii)
parental quality of life, as measured by the General Health Questionnaire-12 (GHQ-12; Goldberg 1972);
depression, measured by the CDRS; v) overall mental health, measured by the Strengths and Difficul-

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cottrell 2018  (Continued)

Cochrane Database of Systematic Reviews

ties Questionnaire (SDQ; Goodman 1998); hopelessness, as measured by the Hopelessness Scale for
Children; vii) family functioning, as measured by the McMaster Family Assessment Device (MFAD; Ep-
stein 1983) and an idiosyncratic and Family Questionnaire; viii) self-reported self-harm, as measured
by the SASII; ix) engagement with therapy, as measured by the System for Observing Family Therapy Al-
liances (Friedlander 2006). Trial authors also measured a number of health economics indices, includ-
ing the three level version of the European Quality of life, 5 Dimension (EQ-5D-3L; EuroQol Group 1990),
the Health Utilities Index, Mark 3 (HUI-3; Furlong 2001), and an idiosyncratic health economics ques-
tionnaire.

Notes

Source(s) of funding: “This research was funded by the National Institute for Health Research (NIHR)
Health Technology Assessment (HTA) programme (project number 07/03)” (p. 215).

Conflict(s) of interest: “DJC, AW-H, MC, PB, IE, SF, EHG, JG, AOH, DWO, MS, FL, JR, ST and AJF report
grants from the National Institute for Health Research…DJC, PB and IE are co-authors of the SHIFT
manual" (p. 215).

Donaldson 2005 

Study characteristics

Methods

RCT (unclear whether clinical personnel or outcome assessors were blinded). Participants were individ-
ually assigned via a random numbers table to either PST or supportive relationship therapy designed to
resemble TAU.

Follow-up period: 3 and 6 months. Data on functioning for a sub-sample of participants was also report-
ed at 12 months.

N lost to follow-up: 8/39 (20.5%) for repetition of SH at post-intervention

Participants

Number of total participants: 39 adolescents were randomised; 21 were allocated to the intervention
(problem-solving therapy), and 18 to TAU.

Interventions

Profile of participants: mean age 15.0 ± 1.7 years (range 12 to 17 years). The majority (n = 32; 82.1%)
were female. Around one-half (n = 15; 48.4%) had multiple episodes of SH prior to trial entry. Around
one-half (n = 20; 51.3%) were diagnosed with an SUD (n = 6; 19.4% with Alcohol Use Disorder specifical-
ly), followed by major depression (n = 9; 29.0%).

Source of participants: patients presenting to a general paediatric ED or inpatient unit of an affiliated
child psychiatric hospital following a suicide attempt.

Inclusion criteria: i) 12 to 17 years of age; ii) primary language was English; iii) outpatient care indicated;
iv) indicated intent to die at presentation

Exclusion criteria: i) diagnosed with any psychosis on mental status examination; ii) intellectual func-
tioning precluded outpatient care according to clinical judgement

Intervention: individual PST. The intervention comprised two phases: i) six bimonthly individual ses-
sions and one adjunct family session (acute phase; three months); ii) three monthly individual sessions,
two further family therapy sessions and two crisis sessions (booster phase; three months). Sessions
were delivered by seven therapists with masters' or doctoral-level expertise and who received initial
training (duration not reported).

Comparator: supportive relationship therapy, designed to analogue TAU. Therapy focused on address-
ing the adolescent’s mood and behaviour, including unstructured sessions which addressed reported
symptoms and problems, and fostered the development of specific skills not otherwise addressed dur-
ing treatment. Therapy was delivered by masters'-level therapists.

Concomitant medication(s): "Half of the participants were prescribed medication by their treating psy-
chiatrist or physician upon intake. Approximately 50% were prescribed an selective serotonin reuptake

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Donaldson 2005  (Continued)

Cochrane Database of Systematic Reviews

inhibitor (SSRI) alone, 33% an SSRI plus another medication, 6% an atypical antidepressant, and 11% a
mood stabilizer" (Donaldson 2005, p. 114).

Length of treatment: 6 months

Location: Northeast USA

Outcomes

Primary outcome(s): i) repetition of SH according to self- and collateral informant (parental) report

Secondary outcome(s): i) suicide, according to collateral informant (parent) report; iii) suicidal ideation,
as measured by the SIQ; iii) depression, as measured by the CES-D; iv) problem-solving, as measured
by the Social Problem Solving Inventory-Revised (SPSI-R; Maydeu-Olivares 1996) and the Means-Ends
Problem-Solving Procedure (MEPS; Platt 1971); v) treatment adherence, as measured by the number of
sessions attended; vi) anger, as measured by the State-Trait Anger Expression Inventory (STAXI; Spiel-
berger 1988)

Notes

Source(s) of funding: "This project was supported by NIMH (MH05749), the American Foundation for Sui-
cide Prevention, and the Harvard Pilgrim Research Foundation” (Donaldson 2005, p. 113).

Conflict(s) of interest: no details on conflicts of interest provided

Green 2011 

Study characteristics

Methods

Unblinded RCT. Participants were individually assigned via a minimisation algorithm to either group-
based therapy or TAU.

Follow-up period: 6 and 12 months

N lost to follow-up: "Loss to follow-up was low (< 4%)" (Green 2011, p. 1).

Participants

Number of total participants: 366 adolescents were randomised; 183 were allocated to group-based
therapy, and 183 to TAU.

Interventions

Profile of participants: mean age not reported (range 12 to 17 years). The majority (n = 324; 88.5%) were
female. All (n = 366; 100%) had multiple episodes of SH prior to trial entry. The majority were diagnosed
with major depression (n = 227; 62.0%); one-third were diagnosed with a behavioural disorder (n = 122;
33.3%).

Source of participants: patients presenting to local CAMHS

Inclusion criteria: i) between 12 years and 16 years 11 months of age; ii) presenting to child and adoles-
cent services with ≥ 2 episodes of SH in the 12 months preceding trial entry

Exclusion criteria: i) insufficient language ability; ii) diagnosed with severe low weight anorexia nervosa;
iii) diagnosed with psychosis; iv) attends a special learning disability school; v) currently in secure care

Intervention: manualised, group-based developmental psychotherapy. Up to 32 sessions (mean 10.2
± 10.1; duration not reported) involving elements of CBT, DBT, and group psychotherapy. Sessions
were delivered by therapists with a minimum of three years post-qualifying experience in youth mental
health (expertise not reported) and who also received initial training in delivering developmental group
psychotherapy and ongoing monthly supervision (duration not reported).

Comparator: TAU according to the clinical judgement of the adolescent's child and adolescent mental
health service team. TAU, however, excluded any type of group-based intervention.

Length of treatment: 6 weeks (acute phase). Weekly booster sessions continued for as long as required
(maximum theoretical length of treatment unclear).

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Green 2011  (Continued)

Location: Manchester and Chester, UK

Outcomes

Primary outcome(s): i) repetition of SH according to self- and collateral informant (parental) report

Secondary outcome(s): i) suicide, according to medical and/or health service records; iii) suicidal
ideation as measured by the SIQ; iv) depression as measured by the Mood and Feelings Questionnaire
(MFQ; Angold 1995); v) general functioning as measured by the Health of the Nation Outcome Scale for
Children and Adolescents (HoNOSCA; Gowers 1999); vi) health economics information

Notes

Source(s) of funding: "This study was funded by the Health Foundation and sponsored by the University
of Manchester" (Green 2011, p. 11).

Conflict(s) of interest: no details on conflicts of interest reported

Griffiths 2019 

Study characteristics

Methods

Single-blind RCT. Participants were individually randomised via a randomised-permuted block proce-
dure, to either 12 weeks of manualised MBT-A in addition to TAU or TAU alone.

Follow-up period: 36 weeks

N lost to follow-up: N/A

Participants

Number of total participants: 53 adolescents were randomised; 26 were allocated to MBT-A plus TAU,
and 27 to TAU alone. However, only 48 (90.6%) had data at baseline. Of these 48 participants, 22 had
been allocated to MBT-A plus TAU and 26 to TAU.

Profile of participants: mean age 15.6 ± 1.3 years (range 12 to 18 years). The majority (79.2%) were fe-
male. One-third (n = 16; 33.3%) were diagnosed with BPD. No further information on psychiatric diag-
noses at baseline were reported.

Source of participants: patients presenting to local CAMHS

Inclusion criteria: i) 12-18 years of age; ii) SH in the six months preceding trial entry; iii) currently receiv-
ing CAMHS treatment; iv) competent and willing to provide written, informed consent

Exclusion criteria: i) diagnosed with a severe learning disability or pervasive developmental disorder; ii)
experiencing an acute psychotic episode; iii) diagnosed with an eating disorder in the absence of self-
harm; iv) non-English speaking; v) current involvement in other ongoing treatment research

Location: Edinburgh and Lothian, UK

Intervention: manualised MBT-A (12 sessions, 1.25 hours' duration) delivered by MBT-trained clinical
psychologists. Sessions consisted of mentalisation, emotion regulation, attachment therapy, and were
delivered in a group-based format (up to 10 children and adolescents per group). Sessions were deliv-
ered by experienced clinical psychologists (expertise not reported) who received initial training (dura-
tion not reported) and were supervised by an accredited MBT-A therapist.

Comparator: TAU delivered according to national and local protocols and guidelines, and could consist
of any combination of in- or out-patient psychological/psychosocial intervention, and pharmacothera-
py, if required

Length of treatment: 12 weeks

Interventions

Outcomes

Primary outcome(s): i) self-harm, as measured by the self-harm subscale of the RTSHI, as well as self-
harm related hospital use as identified from ED electronic records

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Griffiths 2019  (Continued)

Cochrane Database of Systematic Reviews

Secondary outcome(s): i) risk-taking, as measured by the RTSHI; ii) emotional distress, as measured by
the Revised Child Anxiety and Depression Scale (RCADS; Chorpita 2000); iii) mentalisation, as measured
by the self-reported Reflective Function Questionnaire for Youth (RFQY; Ha 2013), iv) emotion regula-
tion, as measured by the DERS (Gratz 2004); v) interpersonal sensitivity, as measured by the Interper-
sonal Sensitivity Measure (ISM; Boyce 1989); vi) borderline traits, as measured by the 11-item short-ver-
sion of the Borderline Personality Features Scale for Children (BPFSC; Sharp 2014); vii) attachment, as
measured by the Experiences in Close Relationships Scale - Revised Child version (ECRS-RC; Brenning
2014)

Notes

Source(s) of funding: “Funding was received from the Edinburgh and Lothian Health Foundation” (Grif-
fiths 2019, p. 11).

Conflict(s) of interest: "The authors declare that they have no competing interests" (Griffiths 2019, p.
12).

Harrington 1998 

Study characteristics

Methods

Single-blind RCT. Participants were individually assigned using a sequence of opaque, sealed envelopes
to either manualised, home-based family therapy or TAU.

Follow-up period: 6 months

N lost to follow-up: 13/162 (4.9%) for repetition of SH at post-intervention

Participants

Number of total participants: 162 adolescents were randomised; 85 were allocated to manualised,
home-based family therapy, and 77 to TAU.

Profile of participants: mean age 14.5 ± 1.1 years (range 10 to 16 years). The majority (n = 145; 89.5%)
were female. All (n = 162; 100%) had multiple episodes of self-poisoning prior to trial entry. The majori-
ty were diagnosed with major depression (n = 109; 67.3%).

Inclusion criteria: i) 16 years or younger; ii) engaged in an episode of self-poisoning; iii) living with their
family

Exclusion criteria: i) engaged in self-cutting or hanging; ii) in social service care; iii) under current in-
vestigation of physical or sexual abuse; iv) diagnosed with a contraindicated psychiatric condition
(e.g. psychosis); v) currently in inpatient treatment; vi) parent or child diagnosed with a learning dis-
ability; vii) parent or child seriously suicidal

Interventions

Intervention: manualised, home-based family therapy delivered by two masters-level psychiatric social
workers. Sessions consisted of one assessment session (duration not reported) and 4 home visits (du-
ration not reported) in addition to TAU. Sessions were delivered by two master's-level child psychiatric
social workers with previous experience in youth mental health and who received initial training (dura-
tion not reported) and ongoing weekly supervision (duration not reported).

Control: TAU. No further details reported

Length of treatment: not reported

Location: Manchester, UK

Outcomes

Primary outcome(s): i) repetition of SH according to self- and collateral informant (parental) report

Secondary outcome(s): i) suicide (unclear how ascertained); ii) suicidal ideation, as measured by the
SIQ; iii) treatment adherence as measured by the number of sessions attended; iv) hopelessness, as
measured by the BHS; v) problem-solving, as measured by the Generation of Alternative Solutions sub-
scale of the Social Problem Solving Inventory (SPSI; Sadowski 1991); vi) family functioning as mea-

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Harrington 1998  (Continued)

Cochrane Database of Systematic Reviews

sured by the McMaster Family Assessment Device (MFAD; Epstein 1983). Parental general health was al-
so measured using the General Health Questionnaire-9 (GHQ-9; Goldberg 1972).

Notes

Source(s) of funding: "This research was supported by the Department of Health, London" (Harrington
1998, p. 517).

Conflict(s) of interest: no details on conflicts of interest reported

Hazell 2009 

Study characteristics

Methods

Single-blind RCT. Participants were individually assigned using a computer generated random number
table to either group-based therapy in addition to TAU or TAU alone.

Follow-up period: 12 months.

N lost to follow-up: 0/72 (0%) for repetition of SH at post-intervention.

Participants

Number of total participants: 72 adolescents were randomised; 35 were allocated to the intervention
(group-based therapy in addition to TAU), and 37 to TAU.

Profile of participants: mean age 14.5 ± 1.1 years (range 12 to 16 years). The majority (n = 65; 90.3%)
were female. All (n = 72; 100%) had multiple episodes of SH prior to trial entry. Over half were diag-
nosed with major depression (n = 41; 56.9%), followed by conduct/oppositional defiance disorder (n =
5; 6.9%), and alcohol use disorder (n = 3; 4.1%).

Source of participants: patients referred to CAMHS

Inclusion criteria: i) 12 to 16 years of age; ii) referred to CAMHS within the catchment area; iii) ≥ 2
episodes of SH in the year preceding trial entry, with one of these occurring within the past three
months
Exclusion criteria: i) required intensive treatment owing to an imminent risk of SH; ii) diagnosed with
acute psychosis; iii) diagnosed with an intellectual disability or other disorder that would indicate the
patient was unlikely to benefit from group therapy sessions; iv) current level of SH risk precluded par-
ticipation in group therapy sessions

Interventions

Intervention: manualised, group-based therapy in addition to TAU delivered by clinicians with experi-
ence working in community-based adolescent mental health services. Sessions consisted of CBT, social
skills training, interpersonal psychotherapy, and group psychotherapy. Sessions were delivered by two
clinical psychologists with experience in delivering group therapy to adolescents and who received ini-
tial training (duration not reported) and six-monthly supervision (duration not reported).

Comparator: TAU consisting of individual counselling, family sessions, medication
assessment and review, and other care co-ordination

Length of treatment: 12 months

Location: Newcastle, NSW, Australia, and Brisbane North and Logan, Queensland,
Australia

Outcomes

Primary outcome(s): i) repetition of SH according to self-report

Secondary outcome(s): i) suicide as ascertained from medical and/or health service records; ii) suicidal
ideation, as measured by the SIQ; iii) depression, as measured by MFQ; iv) symptomatology, as mea-
sured by the SDQ; v) psychiatric functioning as measured by the relevant sub-scales of the HoNOSCA;
vi) general functioning, as measured by the C-GAS

Notes

Source(s) of funding: no details on sources of finding reported

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hazell 2009  (Continued)

Cochrane Database of Systematic Reviews

Conflict(s) of interest: "Prof. Hazell has received research funding from Celltach and Eli Lilly; has served
as a consultant to Eli Lilly, Janssen-Cilag, Novartis, and Shire; and has participated in the speakers’ bu-
reaus of Eli Lilly, Janssen-Cilag, and Pfizer. The other authors report no conflicts of interest” (Hazell
2009, p. 669).

McCauley 2018 

Study characteristics

Methods

Single-blind, multicentre RCT. Participants were individually randomised via a computer-generated
adaptive procedure to either six months of DBT-A or alternative comparator (Individual and Group Sup-
portive Therapy)

Follow-up period: 1 year

N lost to follow-up: 0/173 (0%) for repetition of SH

Participants

Number of total participants: 173 adolescents were randomised; 86 were allocated to the intervention
(DBT-A), and 37 to alternative psychotherapy (Individual and Group Supportive Therapy).

Profile of participants: mean age 14.9 ± 1.5 years (range 12 to 18 years). The majority (n = 163; 94.2%)
were female. All (n = 173; 100%) had multiple episodes of SH prior to trial entry. The majority (n = 145;
83.8%) were diagnosed with major depression, followed by any anxiety disorder (n = 93; 54.1%), and
BPD (n = 92; 53.2%).

Inclusion criteria: i) 12 to 18 years of age; ii) ≥ 1 lifetime suicide attempt; ii) elevated past-month suici-
dal ideation (score of ≥ 24 on the SIQ-JR); iii) engaged in self-injury repetition (≥ 3 lifetime self-harm
episodes, including one in the 12 weeks preceding trial entry); iv) meets ≥ 3 or more criteria for BPD ac-
cording to the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II; First 1997)

Exclusion criteria: i) IQ < 70 on the Kauffman Brief Intelligence Test (Kaufman 2009); ii) diagnosed with
psychosis, mania, anorexia, or life-threatening condition; iii) insufficient English language fluency
(young person); iv) insufficient English or Spanish language fluency (carer/parent)

Location: Seattle and Los Angeles, USA

Intervention: manualised DBT, comprising weekly individual psychotherapy sessions (duration not re-
ported), multifamily group skills training (duration not reported), telephone coaching, and weekly ther-
apist team consultation. Sessions were delivered by therapists (expertise and experience not reported)
who received initial training (multi-day) and weekly supervision (duration not reported).

Comparator: alternative psychotherapy (manualised Individual and Group Supportive Therapy) con-
sisting of ≤ 7 sessions (duration not reported) of individual sessions, group psychotherapy, parent ses-
sions (as needed),
and weekly therapist team consultation. Participants were also provided with numbers for 24-hour cri-
sis telephone counselling.

Length of treatment: six months

Primary outcome(s): i) SA, NSSI and SH, as measured using the SASII; ii) suicidal ideation, as measured
by the SIQ-JR

Source(s) of funding: The study was funded by grants 5RO1MH090159 (Dr Linehan and McCauley, princi-
pal investigators at University of Washington, Seattle Children’s Hospital) and R01MH93898 (Drs Berk
and Asarnow, principal investigators at Los Angeles sites) from the NIMH.

Conflict(s) of interest: “Drs McCauley Berk, Adrian, Cohen, Korslund, Hughes, and Avina reported receiv-
ing grant support from the National Institute of Mental Health (NIMH), National Institutes of Health. Dr
Asarnow reported receiving grant support from the American Psychological Association and the Soci-

Interventions

Outcomes

Notes

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McCauley 2018  (Continued)

Cochrane Database of Systematic Reviews

ety of Clinical Child and Adolescent Psychology and serving as a consultant on quality improvement in-
terventions for depression and suicidal/self-harm behaviour. Dr Harned reported receiving grant sup-
port and personal fees from the Behavioral Tech LLC outside the work represented in this article. Dr
Linehan reported receiving royalties from Guilford Press for books she has written on dialectical behav-
iour therapy, royalties for training materials from Behavioral Tech LLC, and compensation for dialec-
tical behaviour therapy workshops, online programs, and books. No other disclosures reported" (Mc-
Cauley 2018, p. 8).

Mehlum 2014 

Study characteristics

Methods

Single-blind RCT. Participants were individually randomised via a permuted block randomisation pro-
cedure with an undisclosed and variable blocking factor to either manualised DBT-A or EUC.

Follow-up period: 16 weeks (post-intervention)

N lost to follow-up: 0/77 (0%) for repetition of SH at post-intervention

Participants

Number of total participants: 77 adolescents were randomised; 39 were allocated to DBT-A, and 38 to
EUC.

Profile of participants: mean age 15.6 ± 1.5 years (range 12.0 to 18.0 years). The majority (n = 68; 88.3%)
were female. All (n = 77; 100%) had multiple episodes of SH prior to trial entry. Just over half (n = 46;
59.7%) were diagnosed with any depressive disorder, followed by any anxiety disorder (n = 33; 42.9%),
BPD (n = 20; 26.0%), any eating disorder (n = 15; 20.5%), and any SUD (n = 2; 2.6%).

Source of participants: patients referred to CAMHS

Inclusion criteria: i) a history of ≥ 2 episodes of SH prior to trial entry, at least one of these within the 16
weeks preceding trial entry; iii) meets ≥ 2 criteria for BPD according to the DSM-IV (in addition to the
SH criterion) or, alternatively, ≥ 1 criterion for BPD plus ≥ 2 subthreshold-level criteria; iv) sufficient lan-
guage ability

Exclusion criteria: i) diagnosed with bipolar disorder (except bipolar II), schizophrenia, schizoaffective
disorder, psychotic disorder not otherwise specified, intellectual disability, or Asperger's syndrome

Location: Oslo, Norway

Intervention: manualised DBT, comprising weekly individual psychotherapy sessions (duration not re-
ported), multifamily group skills training (duration not reported), and telephone coaching, as required.
Sessions were delivered by eight therapists (mix of psychiatrists, clinical psychologists, and education-
al psychologists) with no previous experience in delivering DBT-A. Therapists received an initial training
session (80 hours) and 12 months of supervision.

Comparator: EUC consisting of weekly sessions (duration not reported) of individual psychotherapy (ei-
ther CBT or psycho-dynamically oriented) in addition to pharmacological treatment, if required.

Concomitant medications: nine (11.7%) were receiving concomitant medications, however, specific in-
formation was not reported.

Length of treatment: 19 weeks

Interventions

Outcomes

Primary outcome(s): i) number of self-reported episodes of SH; ii) suicide ideation, as measured by the
SIQ-JR; iii) depression, as measured by the SMFQ and MADRS.

Secondary outcome(s): i) SH, as determined from hospital admissions and ED presentations; ii) hope-
lessness, as measured by the BHS; iii) depression, as measured by the MADRS; iv) BPD symptom severi-
ty, as measured by Borderline Symptom List (BSL; Bohus 2007)

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mehlum 2014  (Continued)

Notes

Ougrin 2011 

Study characteristics

Methods

Source(s) of funding: "The study was funded by grants from the Norwegian Directorate of Health, the
South Eastern Health Authority, the Extra-Foundation for Health and Rehabilitation, and the University
of Oslo" (Mehlum 2014, p. 1090).

Conflict(s) of interest: "Drs Mehlum, Ramberg, Haga, Larsson, Stanley, Miller, Sund, Grøholt, and Mss.
Tømoen, Diep, and Laberg report no biomedical financial interests or potential conflicts of inter-
est" (Mehlum 2014, p. 1090).

Double-blind cluster-RCT via a web-based, permuted block randomisation procedure. Randomisation
was stratified by centre. Each centre was allocated to either enhanced assessment or TAU.

Follow-up period: 3 months

N lost to follow-up: 1/70 (1.4%) for repetition of SH at post-intervention

Participants

Number of total participants: 70 adolescents were randomised; 35 were allocated to enhanced thera-
peutic assessment, and 35 to TAU.

Profile of participants: mean age 15.6 ± 1.3 years (range 12 to 18 years). The majority (n = 56; 80.0%)
were female. Over half (58.6%) had multiple episodes of SH prior to trial entry. The majority (n = 42;
60.0%) were diagnosed with any mood disorder. Almost one-quarter (n = 17; 24.3%) were not diag-
nosed with a psychiatric disorder, however.

Source of participants: patients admitted to the ED following SH

Inclusion criteria: i) 12 to 18 years of age; ii) not currently engaged with psychiatric services; iii) engaged
in SH and referred for a psychosocial assessment

Exclusion criteria: i) diagnosed with psychosis; ii) intoxicated; iii) diagnosed with a moderate to severe
learning disability; iii) insufficient language ability; iv) at immediate risk of violence or suicide necessi-
tating inpatient psychiatric treatment

Location: London, UK

Interventions

Intervention: manualised enhanced therapeutic assessment, consisting of a single, one-hour, standard
psychosocial history and risk assessment, construction of a diagram (based on cognitive analytic ther-
apy paradigm), identification of a target problem, consideration of motivation for change, and writing
of an 'understanding letter'. Sessions were delivered by 26 therapists (mix of doctors, nurses, psychol-
ogists, and social workers) (experience not reported) who received initial training (duration not report-
ed) and weekly supervision.

Comparator: TAU following NICE recommendations

Length of treatment: three months

Outcomes

Primary outcome(s): i) treatment attendance, obtained from electronic records and CAMHS

Secondary outcome(s): i) treatment completion, as measured by attendance at four or more treatment
sessions during the three-month follow-up period; ii) number of treatment sessions attended; iii) psy-
chopathology, as measured by the SDQ; iv) general functioning, as measured by the C-GAS

Notes

Source(s) of funding: "The study was funded from the following three sources: Psychiatry Research Fund
(Institute of Psychiatry, King’s College London), Maudsley Charitable Funds (South London and Mauds-
ley NHS Trust) and West London Research Consortium" (Ougrin 2011, p. 153).

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ougrin 2011  (Continued)

Cochrane Database of Systematic Reviews

Conflict(s) of interest: "...(1) DO has support from Psychiary Research Trust, Maudsley Charitable Funds
and West London Research Consortium for the submitted work; (2) AN, DO and TZ have royalties paid
to them by Hodder Arnold Publishing that might have an interest in the submitted work; (3) the au-
thors’ spouses, partners, or children have no financial relationships that may be relevant to the submit-
ted work; and (4) DO, TZ, AN, RB, AB and ET have no non-financial interests that may be relevant to the
submitted work" (Ougrin 2011, p. 153).

Rossouw 2012 

Study characteristics

Methods

Double-blind, RCT. Participants were individually randomised via an adaptive minimisation algorithm
to either 12 months of manualised MBT-A or TAU.

Follow-up period: 3, 6, 9, and 12 months.

N lost to follow-up: 9/80 (11.2%) for repetition of SH at post-intervention.

Participants

Number of total participants: 80 adolescents were randomised; 40 were allocated to manualised MBT-A
and 40 to TAU.

Profile of participants: mean age 15.1 ± 1.3 years (range 12 to 17 years). The majority (n = 68; 85.0%)
were female. Almost all (n = 77; 96.3%) were diagnosed with major depression, followed by BPD (n = 58;
72.5%), and SUD (n = 57; 71.2%).

Source of participants: patients presenting to community health services or EDs following an episode of
SH

Inclusion criteria: i) 12 to 17 years of age; ii) ≥ 1 episode of SH within the month preceding trial entry

Exclusion criteria: i) diagnosed with psychosis; ii) diagnosed with a severe learning disability (IQ < 65);
iii) diagnosed with a pervasive developmental disorder; iv) diagnosed with an eating disorder in the ab-
sence of SH; v) diagnosed with a chemical dependence

Location: London, UK

Intervention: Manualised MBT-A, consisting of weekly (duration not reported) individual sessions and
monthly (duration not reported) family therapy sessions. Sessions were delivered by 22 therapists (mix
of different expertise) with experience in youth mental health and who received initial training (6 days)
and weekly supervision.

Comparator: TAU delivered by qualified child and mental health professionals according to NICE guid-
ance

Length of treatment: 12 months

Primary outcome(s): i) repetition of SH, as measured by SH scale of the RTSHI; ii) depression, as mea-
sured by the SMFQ; iii) BPD features, as measured by the Childhood Interview for DSM-IV Borderline
Personality Disorder (CI-BPD; Zanarini 2007); iv) mentalisation skills as measured by the unpublished
How I Feel scale; v) attachment as measured by the Experiences of Close Relationships scale (CDR;
Brennan 1998)

Interventions

Outcomes

Notes

Source(s) of funding: No details reported

Conflict(s) of interest: "Dr. Fonagy is the Chief Executive of the Anna Freud Centre, London, which reg-
ularly offers training courses in mentalization based treatment (MBT) and National Clinical Lead for
the Department of Health’s Improved Access to Psychological Therapies for Children and Young Peo-
ple Programme. He has received grant income from the National Institute of Clinical Excellence, the UK
Mental Health Research Network, the British Academy, the Wellcome Trust, the National Institute of
Health Research (Senior Investigator Award and Research for Patient Benefit Pro-gramme), the Pulitzer

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rossouw 2012  (Continued)

Cochrane Database of Systematic Reviews

Foundation, the Department for Children, Schools, and Families, the Central and East London Compre-
hensive Local Research Network (CLRN) Programme, the NHS Health Technology Assessment (HTA)
programme, the Department of Health’s IAPT Programme, and the Hope for Depression Foundation. Dr.
Rossouw reports no biomedical, financial interests, or potential conflicts of interest" (Rossouw 2012, p.
1312).

Santamarina-Pérez 2020 

Study characteristics

Methods

Single-blind RCT. Participants were individually randomised using a computer-generated list of random
numbers and following a simple randomisation procedure to either manualised DBT-A or EUC.

Follow-up period: 16 weeks

N lost to follow-up: 5/35 (14.3%) for repetition of SH at post-intervention (following correspondence)

Participants

Number of total participants: 35 adolescents were randomised; 18 were allocated to manualised DBT-
A and 17 to EUC.

Interventions

Profile of participants: mean age 15.2 ± 1.3 years (range 12 to 17 years). The majority (n = 31; 88.6%)
were female. All (n = 35; 100%) had engaged in multiple episodes of SH. The majority (n = 29; 82.9%)
were diagnosed with major depression, followed by any anxiety disorder (n = 19; 54.3%), and bipolar
disorder (n = 5; 14.3%).

Source of participants: patients treated at community child and adolescent outpatient clinic

Inclusion criteria: i) 12 years 0 months to 17 years 11 months years of age; ii) engaged in repetitive NSSI
and/or SA in the 12 months preceding trial entry and at current high risk of suicide, as assessed by the
C-SSRS; iii) at least one parent or guardian willing to participate in family sessions

Exclusion criteria: i) IQ < 70 according to the Wechsler Intelligence Test; ii) acute psychopathology re-
quiring inpatient treatment at the time of requirement; iii) diagnosed with low-weight anorexia ner-
vosa as determined by the DSM-IV-TR; iv) diagnosed with substance dependence (though concurrent
substance abuse was not an exclusion criterion) as determined by the DSM-IV-TR

Location: Barcelona, Spain

Intervention: manualised DBT-A consisting of at least one biweekly (60-minute) individual therapy ses-
sion, one weekly (60-minute) session of group-based skills training attended separately by the adoles-
cents and their families, one weekly (duration not reported) consultation team meeting for therapists,
and telephone counselling, as required. Sessions were delivered by three therapists (expertise not re-
ported) with experience in youth mental health and with a minimum of two years' experience in deliv-
ering DBT-A and who received two (three days each) further training sessions and ongoing supervision
(duration not reported).

Comparator: EUC consisting of at least biweekly (60-minute) individual CBT-based therapy, psychoed-
ucation plus one weekly (60-minute) session of group-based skills training attended separately by the
adolescents and their families

Concomitant medications: antidepressants (DBT-A: n = 12, 66.7%; EUC: n = 10, 58.8%), antipsychotics
(DBT-A: n = 10, 55.6%; EUC: n = 12, 70.6%), lithium (DBT-A: n = 1; 5.6%; EUC: n = 2, 11.8%). Number of
psychiatric medications (DBT-A: mean 1.8, SD 1.2; EUC: mean 1.8, 1.1)

Length of treatment: 16 weeks

Outcomes

Primary outcome(s): i) self-reported frequency of NSSI/SAs

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Santamarina-Pérez 2020  (Continued)

Cochrane Database of Systematic Reviews

Secondary outcome(s): i) treatment adherence, as measured by the number of therapy sessions attend-
ed; ii) general functioning, as measured C-GAS; iii) suicidal ideation, as measured by the SIQ-JR; iii) de-
pression, as measured by the BDI

Notes

Source(s) of funding: Not reported

Conflict(s) of interest: None reported

Sinyor 2020 

Study characteristics

Methods

Single-blind RCT. Participants were individually randomised, using a random number generator, to ei-
ther acute individual CBT-based psychotherapy (plus three booster sessions over a nine-month period)
or alternative psychotherapy (minimally-directive supportive psychotherapy).

Participants

Number of total participants: 24 adolescents were randomised; 12 were allocated to individual CBT-
based psychotherapy and 17 to alternative psychotherapy (minimally-directive supportive psychother-
apy).

Interventions

Profile of participants: mean age 18.0 ± 2.9 years (range 16 to 26 years). The majority (n = 17; 70.8%)
were female, and were diagnosed with major depression (n = 21; 87.5%), followed by any anxiety disor-
der (n = 19; 79.2%), SUD (n = 12; 50.0%), BPD (n = 7; 29.2%), and bipolar disorder (n = 10; 41.7%).

Source of participants: patients admitted to hospital following an episode of SH

Inclusion criteria: i) 16 to 26 years of age; ii) admitted to hospital following an episode of SH iii) sufficient
language ability

Exclusion criteria: i) current or previous psychotic symptoms

Location: Toronto, Canada

Intervention: Brief, individual CBT-based psychotherapy comprising up to 10 weekly (45 minutes) ses-
sions of narrative assessment, cognitive restructuring, derivation of strategies to foster emotion regu-
lation, crisis response planning, and relapse prevention in addition to TAU. The acute phase lasted 15
weeks, and was followed by up to three booster sessions delivered over 12 months. Sessions were de-
livered by masters'-level social workers with experience in youth mental health and who received ini-
tial training (duration not reported).

Comparator: alternative psychotherapy consisting of 10 weekly (45 minutes) sessions of minimally-di-
rective supportive psychotherapy in addition to TAU

Concomitant medication(s): SSRI (intervention: n = 8, 66.7%; comparator: n = 7; 58.3%), other NGA (in-
tervention: n = 6, 50.0%; comparator: n = 3; 25.0%), anticonvulsants (intervention: n = 3, 25.0%; com-
parator: n = 3; 25.0%), antipsychotics (n = 1; 8.3%; comparator: n = 2, 16.7%), anxiolytics, including ben-
zodiazepines (intervention: n = 5, 41.7%; comparator: n = 3; 25.0%), lithium (intervention: n = 1; 8.3%;
comparator: n = 1; 8.3%)

Length of treatment: 15 weeks (acute phase) plus nine months (booster phase)

Outcomes

Primary outcome(s): i) treatment retention to 12 months/final visit, defined as ≥ 70% retention

Secondary outcome(s): i) repetition of SH, as measured by the C-SSRS; ii) depression, as measured by
the MADRS and the BDI; iii) global impairment, as measured by the Columbia Impairment Scale (CIS;
Bird 1993); iv) symptom severity, as measured by the Clinical Global Impression Severity (CGI-S) and
Improvement (CGI-I) subscales (Guy 1976)

Notes

Source(s) of funding: "This work was supported by a grant from the Innovation Fund of the Alternative
Funding Plan from the Academic Health Sciences Centres of Ontario. The work was also supported in

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sinyor 2020  (Continued)

Cochrane Database of Systematic Reviews

part by Academic Scholars Awards and the Departments of Psychiatry at the University of Toronto and
Sunnybrook Health Sciences Centre" (Sinyor 2020, p. 693).

Conflict(s) of interest: "All authors report no financial relationships with commercial interests of rel-
evance to this study. Dr Sinyor reports that he has received grant support from the Innovation Fund
of the Alternative Funding Plan from the Academic Health Sciences Centres of Ontario, the American
Foundation for Suicide Prevention, the Ontario Ministry of Research and Innovation, and the University
of Toronto, Department of Psychiatry Excellence Fund. Dr Bryan reports that he has received grant sup-
port from the Department of Defense, Department of the Air Force, National Institute of Mental Health,
Bob Woodruff Foundation, and the Boeing company; and consulting fees from Oui Therapeutics and
Neurostat Analytical Solutions" (Sinyor 2020, p. 693).

Spirito 2002 

Study characteristics

Methods

RCT (further details on randomisation or blinding not reported). Participants were individually ran-
domised to either a compliance enhancement intervention or TAU.

Follow-up period: 3 months

N lost to follow-up: 0/63 (0%) for repetition of SH at post-intervention

Participants

Number of total participants: 63 adolescents were randomised; 29 were allocated to compliance en-
hancement and 34 to TAU.

Interventions

Profile of participants: mean age 15.0 ± 1.4 years (range 12 to 18 years). The majority (n = 57; 90.5%)
were female. Diagnoses were reported for 46 (73.0%) of the sample. Of these, half had not been diag-
nosed with a psychiatric disorder (n = 23; 50.0%). For the remainder, around one-fifth (n = 10; 21.7%)
were diagnosed with a SUD, followed by any mood disorder (n = 7; 15.2%), and major depression
specifically (n = 6; 13.0%).

Source of participants: patients presenting to hospital following a SA

Inclusion criteria: i) 12 to 18 years of age; ii) engaged in SA necessitating medical care in either an ED or
paediatrics ward of a general children's hospital

Exclusion criteria: none stated

Location: Northeast USA

Intervention: compliance enhancement characterised by a single, one-hour session to review expecta-
tions for outpatient treatment, address common treatment misconceptions, a verbal treatment con-
tract, an added compliance enhancement approach consisting of a series of four telephone calls at 1, 2,
4 and 8 weeks' post-discharge (duration not reported), and TAU. Sessions were delivered by three post-
doctoral fellows in psychology (experience not reported).

Comparator: TAU (standard disposition planning) consisting of a brief (duration not reported) inpatient
treatment and/or an outpatient appointment, as appropriate

Concomitant medication(s): "The rates of psychotropic medication use in the compliance enhancement
group (56%) and the standard care group (36%) was...nonsignificant" (Spirito 2002, p. 438).

Length of treatment: eight weeks

Outcomes

Primary outcome(s): i) repetition of SH according to self- and parent-report; however, only data from
self-report were used; ii) suicide (unclear how ascertained); iii) compliance, as measured by the propor-
tion of participants who completed treatment

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Spirito 2002  (Continued)

Notes

Wood 2001a 

Study characteristics

Methods

Source(s) of funding: "This investigation was supported by NIMH grant MH52411 and by a grant from the
van Amerigen Foundation" (Spirito 2002, p. 435).

Conflict(s) of interest: None reported

Single-blind RCT. Participants were individually randomised, using a random numbers table, to either
group-based psychotherapy or TAU.

Follow-up period: 7 months

N lost to follow-up: 1/32 (3.1%) in the intervention arm and 0/32 (0%) in the control arm for repetition of
SH at post-intervention

Participants

Number of total participants: 63 adolescents were randomised; 32 were allocated to group-based psy-
chotherapy and 31 to TAU.

Profile of participants: mean age 14.2 ± 1.7 years (range 12 to 16 years). Just over three-quarters (n = 49;
77.8%) were female. All (n = 63; 100%) had multiple episodes of SH. The majority were diagnosed with
major depression (n = 52; 82.5%).

Source of participants: patients referred to CAMHS following an episode of SH

Inclusion criteria: i) 12 to 16 years of age; ii) referred to CAMHS following an episode of SH; iii) reported
SH on at least one other occasion during the year preceding trial entry

Exclusion criteria: i) too suicidal for outpatient treatment in the clinical judgement of the adolescents'
treating clinician; ii) unable to attend group therapy sessions (e.g. incarcerated); iii) diagnosed with
psychosis; iv) diagnosed with learning problems

Location: Manchester, UK

Intervention: Group-based developmental psychotherapy consisting of a minimum of eight weekly (du-
ration not reported) sessions involving techniques from a variety of therapies, including PST, CBT, DBT,
and psychodynamic group therapy delivered by a senior nurse and a psychiatrist in addition to up to
10 individual sessions (duration not reported) to consolidate CBT work. Sessions were delivered by two
therapists (senior nurse and psychiatrist), one of which had experience in delivering CBT.

Comparator: TAU consisting of a variety of interventions including family sessions and nonspecific
counselling with the adolescent. Could also include psychotropic medication, where clinically indicat-
ed

Length of treatment: six months

Interventions

Outcomes

Notes

Primary outcome(s): i) repetition of SH according to self-report; ii) depression, as measured by the MFQ;
iii) suicidal ideation, as measured by the SIQ; iv) general health, as measured by the HoNOSCA

Source(s) of funding: "This research was supported by a project grant from the Mental Health Foun-
dation and by a Training Fellowship to Miss Trainor from the National Health Service Executive North
West” (Wood 2001a, p. 1246).

Conflict(s) of interest: Not reported

BDI:  Beck  Depression  Inventory;  BHS:  Beck  Hopelessness  Scale;  BPD:  borderline  personality  disorder;  BPFSC:  Borderline  Personality
Features Scale for Children; BSL: Borderline Symptom List; BSSI: Beck Scale for Suicidal Ideation; CAMHS: Child and Adolescent Mental

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Health  Services;  CBT:  Cognitive  behavioural  therapy;  CDRS:  Child  Depression  Rating  Scale;  CES-D:  Center  for  Epidemiologic  Studies
Depression Scale; C-GAS: Children's Global Assessment Scale; CGI(-I)(-S): Clinical Global Impression (-Improvement) (-Severity); CI-BPD:
Childhood Interview for DSM-IV Borderline Personality Disorder; CIS: Columbia Impairment Scale; C-SSRS: Columbia Suicide Severity
Rating  Scale;  DBT(-A):  Dialectical  Behaviour  Therapy  (for  Adolescents);  DERS:  Difficulties  in  Emotion  Regulation  Scale;  DSM-IV(-TR):
Diagnostic and Statistical Manual for mental disorders, version IV (Text Revision); ECRS-RC: Experiences in Close Relationships Scale -
Revised Child version; ED: emergency department; EQ-5D-3L: European Quality of life, 5 Dimension, 3 Level; EUC: enhanced usual care;
GHQ-12  (-9):  General  Health  Questionnaire-12  (or  -9);  HoNOSCA:  Health  of  the  Nation  Outcome  Scale  for  Children  and  Adolescents;
HRSA: Health Resources and Services Administration; HSC: Hopelessness Scale for Children; HUI-3: Health Utilities Index, Mark 3; ISM:
Interpersonal  Sensitivity  Measure;  IQ:  intelligence  quotient;  MADRS:  Montgomery–Åsberg  Depression  Rating  Scale;  MFAD:  McMaster
Family Assessment Device; MBI: Maslach Burnout Inventory; MBT(-A): Mentalisation Based Therapy (for Adolescents); MEPS: Means-Ends
Problem-Solving; MFAD: McMaster Family Assessment Device; MFQ: Mood and Feelings Questionnaire; N/A: not applicable; NGA: newer
generation  antidepressants;  NICE:  National  Institute  for  Health  and  Care  Excellence;  NR:  not  reported;  NSSI:  non-suicidal  self-injury;
PQ-LES-Q:  Paediatric  Quality  of  Life  Enjoyment  and  Satisfaction  Questionnaire;  PST:  problem-solving  therapy;  RCADS:  Revised  Child
Anxiety and Depression Scale; RCT: randomised controlled trial; RFL-A: Reasons for Living Inventory for Adolescents; RFQY: Reflective
Function  Questionnaire  for  Youth;  RTSHI:  Risk-Taking  and  Self-Harm  Inventory;  SA:  suicide  attempt;  SACA:  Service  Assessment  for
Children and Adolescents; SAFETY: Safe Alternatives For Teens and Youth; SASII: Suicide Attempt-Self-Injury Interview; SCID-II: Structured
Clinical Interview for DSM-IV Axis II Personality Disorders; SDQ: Strengths and Difficulties Questionnaire; SH: self-harm; SHIFT: Self-Harm
Intervention: Family Therapy; SIQ(-JR): Suicidal Ideation Questionnaire (Junior); SMFQ: Short Mood and Feeling Questionnaire; SPSI(-
R): Social Problem Solving Inventory (-Revised); SRI: Suicide-Resilience Inventory; STAXI: State-Trait Anxiety Inventory; SUD: substance
use disorder; TAU: treatment-as-usual

Characteristics of excluded studies [ordered by study ID]

Study

Alavi 2013

Czyz 2019

Reason for exclusion

Correspondence with trial authors revealed alternate allocation was used. Non-RCT

At baseline, 30.6% had a lifetime history of SH.

Diamond 2012

Non-RCT

Diamond 2019

At baseline, 57.9% had a lifetime history of NSSI and 39.5% had a lifetime history of suicide at-
tempt.

English 2019

Non-RCT

Esposito-Smythers 2017

At baseline, 30.9% had a lifetime history of SH: 24.7% had a lifetime history of NSSI and 16.0% had
a lifetime history of suicide attempt.

Esposito-Smythers 2019

At baseline, 81.4% had a lifetime history of NSSI and 65.5% had a lifetime history of suicide at-
tempt.

Gillespie 2019

Non-RCT

Kaess 2020a

Kennard 2018

Correspondence with trial authors revealed a significant proportion of participants were recruited
from non-clinical settings.

Data on SH within six months of trial entry not available. However, correspondence with trial au-
thors revealed that 95.5% of participants had engaged in SH within three months of trial entry.

King 2019

At baseline, 73.9% had engaged in SH within six months of trial entry.

Latimer 2014

At baseline, 34.6% had engaged in SH within six months of trial entry.

LoParo 2018

Correspondence with trial authors revealed that the proportion of participants who had engaged
in SH within six months of trial entry could not be determined.

Mubarak 2017

Non-RCT

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

NCT02726035

Trial withdrawn due to death of principal investigator

Perera Ramani 2011

Correspondence with trial authors revealed alternate allocation was used. Non-RCT

Pineda 2013

Rees 2015

Correspondence with trial authors for the 2016 version of this review revealed that participants did
not engage in SH within six months of trial entry.

Study protocol. However, it is likely that a significant proportion of participants will be recruited
from non-clinical settings.

Rengasamy 2019

Correspondence with trial authors revealed the proportion of participants with an episode of SH
within six months of trial entry was not recorded. However, 64.0% had a lifetime history of SH.

Rowe 2018

Participants were recruited from non-clinical settings.

Stallard 2016

Study protocol of a non-RCT

Tracey 2018

Wharff 2019

Non-RCT

Correspondence with trial authors revealed the proportion of participants with an episode of SH
within six months of trial entry was not recorded.

Xavier 2019

Participants did not present to clinical services.

Yen 2019

Yen 2020

At baseline, 16.0% had engaged in SH within six months of trial entry.

Correspondence with trial authors revealed the proportion of participants with an episode of SH
within six months of trial entry was not recorded. However, 51.9% had a lifetime history of SH.

NSSI: non-suicidal self-injury; RCT: randomised controlled trial; SH: self-harm.

Characteristics of ongoing studies [ordered by study ID]

ACTRN12617000668303p 

Study name

A randomised control trial on the effect of emotion regulation group therapy on non-suicidal self-
injury in adolescents

Methods

Double-blind RCT

Assignment: parallel-group, individual-level

Participants

Inclusion criteria: i) between 14-19 years; ii) >= 3 episodes of NSSI within 12 months preceding trial
entry; iii) engaged in treatment with an individual clinician; iv) willing to remain engaged in treat-
ment

Exclusion criteria: i) diagnosed with an autism spectrum disorder, intellectual disability, psychosis;
ii) parents/guardians unwilling to engage with treatment; iii) already engaged in group therapy; iv)
engaged in another research trial; v) undergoing medication changes; vi) active suicidality requir-
ing inpatient treatment

Interventions

Intervention: emotion-regulation group therapy in addition to TAU for a total treatment period of 14
weeks. Weekly sessions (90 minutes) of group therapy with 6-8 participants per group. Sessions will
incorporate elements of DBT and ACT.

Comparator: TAU

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ACTRN12617000668303p  (Continued)

Cochrane Database of Systematic Reviews

Outcomes

Primary outcome(s): i) NSSI, as measured by the DSHI-9; ii) emotion regulation, as measured by the
DERS

Secondary outcome(s): i) NSSI severity, as measured by the need for medical intervention following
an episode; ii) depression, as measured by the DASS; iii) anxiety, as measured by the DASS; iv) alco-
hol and other drug use, as measured by the CRAFFT

Starting date

1 September, 2017

Contact information

Principal investigator:

Prof. Marc Wilson, School of Psychology, Victoria University of Wellington, Wellington, NZ (mar-
c.wilson@vuw.ac.nz)

Notes

We were unable to confirm these details with the principal investigator despite three rounds of cor-
respondence.

ACTRN12618000085279p 

Study name

A pilot randomised trial of standard care versus structured care during an inpatient admission fol-
lowing self-harm and suicidal acts in adolescents

Methods

Open-label RCT

Assignment: parallel-group, individual-level

Participants

Inclusion criteria: i) between 12-18 years; ii) able to provide written informed consent; iii) admitted
to the psychiatric ward of a specialist children's hospital following an episode of SH within 30 days
prior to trial entry; iv) parent/guardian able to provide written informed consent; v) sufficient lan-
guage ability; vi) stable living situation; vii) resides within the catchment area

Exclusion criteria: i) no history of SH within 30 days prior to trial entry; ii) diagnosed with psychosis,
SUD, an autism spectrum disorder, intellectual disability, or any other disorder likely to impact on
the participants' ability to give informed consent; iii) no parent/guardian to participate; iv) trans-
ferred to a medical ward following SH; v) unwilling to engage in community mental health treat-
ment post-discharge; vi) aboriginal or Torres Strait Islander

Interventions

Intervention: therapeutic assessment. Two 60-minute sessions (whilst treated as an inpatient)
of therapeutic assessment consisting of structured safety planning based on the principles of
CBT and CAT. Parents/guardians will also receive two sessions (duration not specified) of attach-
ment-based family therapy based on the principles of Diamond 2014.

Comparator: TAU

Outcomes

Primary outcome(s): i) treatment adherence, as measured by the number of treatment sessions at-
tended

Secondary outcome(s): i) parental protective factors, as measured by a modified version of the
SRI-25; ii) suicide-related resilience, as measured by the Suicide-Resilience Inventory-25; iii) satis-
faction with treatment, as measured by the Experience of Service Questionnaire; iv) therapeutic al-
liance as measured by the Engagement Measure; v) mental health-related readmissions, as mea-
sured by the number of readmissions to the mental health ward; vi) parent satisfaction with treat-
ment, as measured by a modified version of the Experience of Service Questionnaire; vii) emer-
gency department representations, as measured by the number of representations to the emer-
gency department

Starting date

5 March, 2018

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ACTRN12618000085279p  (Continued)

Contact information

Principal investigator:

Cochrane Database of Systematic Reviews

Dr. Chidambaram Prakash, The Royal Children’s Hospital, Melbourne, Australia (Chi-
dambaram.prakash@rch.org.au)

Notes

We are grateful to Dr. Chidambaram Prakash for confirming the above details were correct, 27
September, 2020.

Andreasson 2017 

Study name

MYPLAN – mobile phone application to manage crisis of persons at risk of suicide: study protocol
for a randomized controlled trial

Methods

Single-blind (outcome assessor) RCT

Assignment: parallel-group, individual-level, stratified by: i) sex; ii) history of multiple episodes of
SH

Participants

Inclusion criteria: i) child and adolescents (age range not reported) receiving treatment from partic-
ipating Suicide Prevention Clinics; ii) own a smartphone; iii) sufficient language ability; iv) provides
written and verbal consent to participation

Interventions

Exclusion criteria: no specific exclusion criteria reported. However, those diagnosed with severe
psychiatric disorders (e.g. depression, anxiety, personality disorders, or SUDs) who are not ordinar-
ily treated within Suicide Prevention Clinics in Denmark would not be eligible for participation.

Intervention: collaborative safety planning via mobile telephone application (MyPlan) in addition
to TAU. Participants will complete a collaborative safety plan via an app-based format (MyPlan),
and will be encouraged to use the app for 15 minutes per day to evaluate, review, and develop new
safety strategies.

Comparator: collaborative safety planning via pen and paper in addition to TAU. TAU consists of
eight to 10 sessions consisting of a variety of approaches, including: supportive psychotherapy,
CBT, DBT, and psychodynamic psychotherapy.

Outcomes

Primary outcome(s): i) suicidal ideation as measured by the BSSI

Secondary outcome(s): i) repetition of SH as ascertained from self-report; ii) admissions to psychi-
atric/medical wards as ascertained from register data; iii) hopelessness as measured by the BHS;
iv) depression, as measured by the Major Depression Inventory; v) app user satisfaction as mea-
sured by a modification to the Client Satisfaction Questionnaire; vi) quality of life as measured by
the WHO Five Well-being Index (WHO-5); vii) all-cause mortality as ascertained from mortality regis-
ters

Starting date

November 2016

Contact information

Principal investigator:

Dr. Kate Aamund, Psychiatric Centre North Zealand, University Hospital of Hillerød, Hillerød, Den-
mark (kate.aamund@regionh.dk)

Notes

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

De Silva 2018 

Study name

A pilot randomized controlled trial to evaluate the acceptability and feasibility of a counseling in-
tervention, delivered by nurses, for those who have attempted self-poisoning in Sri Lanka

Methods

Open-label RCT

Assignment: parallel-group, individual-level, blocked randomisation

Participants

Inclusion criteria: i) aged 16 years and older; ii) admitted to hospital following an episode of self-
poisoning; iii) sufficient bilingual language ability (English and Sinhala)

Interventions

Exclusion criteria: i) diagnosed with an intellectual disability, dementia; ii) diagnosed with a physi-
cal illness that would interfere with participation in follow-up interviews; iii) insufficient bilingual
ability (English and Sinhala); iv) unable or unwilling to provide written informed consent

Intervention: a single session (30 minutes) of brief problem-solving intervention based on an adapt-
ed version of Culturally Adapted Manual-Assisted Problem-solving (C-MAP; Husain 2014), delivered
by trained community health nurses. The focus of the intervention will be on assisting participants
to identify and acknowledge problems, explore alternative coping strategies, and relaxation and
self-soothing training. Participants will also receive TAU.

Comparator: TAU. TAU consists of medical management and psychiatric intervention, as necessary.

Outcomes

Primary outcome(s): i) treatment acceptability as determined from qualitative interviews

Secondary outcome(s): i) repetition of SH according to self-report; ii) suicidal ideation according to
self-report; iii) anxiety as measured by the Generalized Anxiety Disorder 7-item scale (GAD-7); iv)
depression as measured by the Patient Health Questionaire-9 (PHQ-9) and the Peradeniya Depres-
sion Scale (PDS); v) distress as measured by the General Health Questionnaire (GHQ-30); vi) psycho-
logical coping as measured by the Brief Coping Inventory

Starting date

27 March 2017

Contact information

Principal investigator:

Dr. Thilini Rajapakse, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka (em-
ba471@gmail.com)

Notes

ISRCTN10541045 

Study name

A comparison of usual care versus usual care plus a smartphone self-harm prevention app (BlueIce)
in young adolescents aged 12-17 who self-harm: Beating Adolescent Self-Harm (BASH) - Version 1

Methods

Open-label RCT

Assignment: computer-generated randomisation in a 1:1 ratio. Participants will be randomised us-
ing REDCap software minimising for gender, age (i.e. over or under 16 years), SH frequency in last
4 weeks (i.e. 0-2 episodes or > 3 episodes), severity of depression (i.e. Mood and Feelings Question-
naire score above or below 27)

Participants

Inclusion criteria: i) between 12-17 years; ii) receiving treatment from specialist Child and Adoles-
cent Mental Health Services (CAMHS); iii) history of two or more episodes of SH over the 12 months
prior to trial entry

Exclusion criteria: i) currently suicidal; ii) diagnosed with psychosis; iii) current safeguarding con-
cerns (i.e. participant has experienced abuse in the six months prior to trial entry or is the subject of

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ISRCTN10541045  (Continued)

Cochrane Database of Systematic Reviews

a safeguarding investigation); iv) diagnosed with a significant developmental disorder (e.g. autism)
which interferes with their ability to engage with the app; v) insufficient language ability

Interventions

Intervention: BlueIce. Participants will receive access to the BlueIce app in addition to TAU. BlueIce
has been co-developed with young people and includes components of CBT, DBT, and mood moni-
toring (Grist 2018)

Comparator: TAU

Outcomes

Primary outcome(s): i) SH, as measured from self-report

Secondary outcome(s): i) anxiety, as measured by the Revised Child Anxiety and Depressions Scale
(RCADS); ii) depression, as measured by the Mood and Feelings Questionnaire (MFQ); iii) hopeless-
ness, as measured by the BHS; iv) strengths and difficulties, as measured by the Strengths and Diffi-
culties Questionnaire (SDQ); v) quality of life, as measured by the Child Health Utility-9D (CHUD-9D)

Starting date

1 June, 2019

Contact information

Principal investigator:

Prof. Paul Stallard, Department for Health, University of Bath, Bath, UK (paul.stallard@oxford-
health.nhs.uk; P.Stallard@bath.ac.uk)

Notes

We are grateful to Prof Stallard for confirming the above details were correct, 1 September, 2020.

Kaess 2019 

Study name

Self-injury - Treatment, Assessment, Recovery (STAR)

Methods

Open-label RCT

Assignment: parallel-group, individual-level, blocked randomisation

Participants

Inclusion criteria: i) 15 to 12 years of age; ii) engaged in NSSI on at least five days in the 12 months
preceding trial entry; iii) willing and able to provide informed consent

Exclusion criteria: i) currently receiving in- or outpatient individual psychotherapy

Interventions

Intervention: 8-12 sessions (duration not reported) of a manualised online intervention (Cutting
Down Program; Taylor 2011) comprising elements of CBT, DBT, and access to a moderated online
group chat program

Comparator: online psychoeducation comprising static content on the causes, consequences, fac-
tors associated with NSSI

Outcomes

Primary outcome(s): i) frequency of NSSI, as measured by the NSSI Severity Questionnaire

Secondary outcome(s): i) health-related quality of life as measured by the KIDSCREEN-10; ii) symp-
tomatology as measured by the Brief Symptom List-23 and the PHQ-A; iii) suicidal behaviour as
measured by the Paykal Suicide Scale

Starting date

1 November 2018

Contact information

Principal investigator:

Dr. Michael Kaess, University of Heidelberg, Heidelberg, Germany (michael.kaess@med.uni-heidel-
berg.de)

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kaess 2019  (Continued)

Notes

Ligier 2016 

Study name

We were unable to confirm these details with the principal investigator despite three rounds of cor-
respondence.

Prevention of recurrence of suicide attempt by adolescent by sending SMS: MEDIACONNEX

Methods

Single-blind RCT

Assignment: parallel-group, individual-level

Participants

Inclusion criteria: i) between 13 and 17 years; ii) treated following a suicide attempt (recency not
stated); iii) living within the catchment area; iv) provides written informed consent (including
parental consent for those below the age of consent)

Exclusion criteria: i) participant and/or parents are unwilling or unable to provide informed con-
sent; ii) currently incarcerated; iii) participant does not own a mobile telephone

Interventions

Intervention: remote contact intervention. Participant will receive a series of text messages over the
course of six months in addition to TAU.

Comparator: TAU

Outcomes

Primary outcome(s): i) time to SH, as measured from hospital records

Secondary outcome(s): i) social support, as measured by the Multidimensional Scale of Perceived
Social Support (MSPSS); ii) quality of life, as measured by the Kidscreen-27 and VSP-A; iii) depres-
sion, as measured by the Center for Epidemiologic Studies Depression Scale (CES-D)

Starting date

13 February, 2017

Contact information

Principal investigator:

Dr. Fabienne Ligier, University of Lorraine, Nancy, France (fabienne.ligier@cpn-laxou.com)

Notes

NCT03353961 

Study name

Internet delivered Emotion Regulation Individual Therapy for Adolescents (ERITA) with nonsuicidal
self-Injury: a randomized controlled study

Methods

Single-blind RCT

Assignment: parallel-group, individual-level

Participants

Inclusion criteria: i) aged between 13 and 17 years; ii) ≥ 5 episodes of NSSI in the year preceding trial
entry, including ≥ 1 within the month preceding trial entry; iii) have at least one parent committed
to participating in the parenting component of the intervention

Exclusion criteria: i) current severe suicidal ideation; ii) diagnosed with psychosis or bipolar I disor-
der; iii) current and/past month substance dependence; iv) diagnosed with any psychiatric disorder
requiring immediate treatment (e.g. severe anorexia nervosa); insufficient language ability

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT03353961  (Continued)

Interventions

Intervention: 11 weeks of a therapist-delivered internet-based emotion regulation therapy pro-
gram, in addition to TAU. Parents/legal guardians also receive six modules of an internet-based
parenting program with online therapist support.

Comparator: TAU

Outcomes

Primary outcome(s): i) frequency of NSSI, as measured by the DSHI-Y

Secondary outcome(s): i) emotion regulation as measured by the DERS and DERS-16 item version;
ii) depression, anxiety, and stress as measured by the DASS; iii) self-destructive behaviours as mea-
sured by the Borderline Symptom List Supplement; iv) acceptance, as measured by the Acceptance
and Action Questionnaire; v) general functioning, as measured by the Children’s Global Assessment
Scale; vi) symptoms, as measured by the CGI

Tertiary outcome(s): i) suicidal ideation, as measured by the SIQ; ii) experiences in close relation-
ships, as measured by the Short version of the Experiences in Close Relationships Scale - Revised
Child version; iii) worry, as measured by the Generalised Anxiety Disorder 7-item scale; iv) costs as-
sociated with psychiatric illness, as measured by the Trimbos/iMTA questionnaire for Costs asso-
ciated with Psychiatric Illness - Child version; v) quality of life, as measured by the Kidscreen-10
(K-10); vi) treatment adherence, as measured by the Patient Internet-delivered cognitive behav-
ioral Adherence Scale; vii) therapeutic alliance, as measured by the Working Alliance Inventory; viii)
parental coping with children’s negative emotions, as measured by the Coping with Children's Neg-
ative Emotions Scale Adolescent Version; ix) satisfaction with treatment, as measured by the Client
Satisfaction Questionnaire; x) adverse events, as measured by self-report; xi) treatment expectan-
cy, as measured by the Credibility/Expectancy Questionnaire

Starting date

20 November, 2017

Contact information

Principal investigator:

Adjunct Prof. Clara Hellner, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm,
Sweden (clara.hellner@ki.se)

Post-doctoral researcher:

Dr. Johan Bjureberg, Karolinska Institutet, Stockholm, Sweden (Johan.Bjureberg@ki.se)

Notes

We are grateful to Prof Hellner for confirming the above details were correct, 1 September, 2020.

NCT03550521 

Study name

A mixed methods investigation of brief mindfulness training and

self-injury attentional bias among self-injuring adolescents

Methods

Single-blind RCT

Assignment: parallel-group, individual-level

Participants

Interventions

Inclusion criteria: i) aged between 12 and 18 years; ii) able to provide written informed consent; iii)
currently engaging in NSSI and/or have a history of NSSI
Exclusion criteria: i) endorse suicidal ideation, planning, and intent as determined by the Mini Inter-
national Neuropsychiatric Interview (MINI); ii) requiring crisis intervention or psychiatric inpatient
hospitalisation

Intervention: single session (duration unclear) of mindfulness. Participants will be instructed to fo-
cus on their breathing and to acknowledge and accept distressing thoughts or emotions by con-
centrating on their breathing.

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT03550521  (Continued)

Cochrane Database of Systematic Reviews

Comparator: participants assigned to the control condition will not receive any specific mindful-
ness training.

Outcomes

Primary outcome(s): i) self-injury attentional bias, as measured by a dot probe paradigm

Secondary outcome(s): none reported

Starting date

1 June, 2018

Contact information

Principal investigator:

Assistant Prof. Michael Riquino, School of Social Welfare, University of Kansas, Lawrence, KS, USA
(mriquino@ku.edu)

Notes

We are grateful to Assistant Prof. Riquino for confirming the above details were correct 31 August,
2020.

NCT03709472 

Study name

Computer assisted family intervention to treat self-harm disparities in Latinas and sexual/gender
minority youth (CA CIFFTA)

Methods

Open-label RCT

Assignment: parallel-group, individual-level

Participants

Inclusion criteria: i) aged between 12 and 18 years; ii) at least one episode of SH in the 6 months
preceding trial entry according to self-report; iii) meets criteria for at least two of the four underly-
ing/maintaining factors associated with SH (i.e. depression, emotion dysregulation, family conflict,
substance use); iv) self-identifies as either a Hispanic female and/or LGBTQ; v) lives with at least
one parental figure who agrees to participate in assessments and treatment

Exclusion criteria: i) diagnosed with any of the following DSM-5 disorders: any developmental disor-
ders, elective mutism, any organic mental disorders, schizophrenia, delusional disorder, any psy-
chosis, or bipolar affective disorder; ii) current suicidal ideation with a plan and means to carry out
that plan

Interventions

Intervention: 16 weekly sessions of 45 minutes of a hybrid intervention that includes individual mo-
tivational interviewing, diary card identification of triggers, computer-assisted psychoeducation,
and intensive family therapy delivered over 16 weeks

Comparator: TAU without technology enhancement delivered over 16 weeks

Outcomes

Primary outcome(s): i) frequency of SH as measured by the DSHI-Y.

Secondary outcome(s): i) LGBTQ-related stressors, as measured by the Sexual Minority Adolescent
Stress Instrument (SMASI); ii) family functioning, as measured by the Family Environment Scale
(FES); iii) emotional regulation, as measured by the DERS; iv) alcohol and drug use, as measured by
the Youth Risk Behavior Survey; v) risky sexual behaviour, as measured by the Risky Sexual Behav-
ior Questionnaire; vi) depression, as measured by the PHQ-9

Starting date

12 November, 2018

Contact information

Principal investigator:

Prof. Victoria Mitrani, University of Miami, Miami, FL, USA (vmitrani@miami.edu)

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT03709472  (Continued)

Notes

NCT04131179 

Study name

We were unable to confirm these details with the principal investigator despite three rounds of cor-
respondence.

Youth Culturally adapted Manual-Assisted Psychological therapy (Y-CMAP) in adolescents Pakistani
patients with a history of self harm.

Methods

Single-blind RCT

Assignment: parallel-group, individual-level

Participants

Inclusion criteria: i) aged between 12 and 18 years; ii) presenting to GPs, EDs, or admitted to a gen-
eral hospital ward following an episode of SH; iii) at least one further episode of SH in the 3 months
preceding trial entry; iv) residing within the study catchment area; v) not requiring inpatient psychi-
atric treatment

Exclusion criteria: i) diagnosed with a severe psychiatric disorder (e.g. psychosis); ii) diagnosed
with any condition that would limit engagement with the intervention (e.g. intellectual disabilities,
autism spectrum disorder); iii) temporary resident unlikely to be available for follow-up

Interventions

Intervention: 8-10 sessions of manualised Youth Culturally adapted Manual Assisted Psychological
(Y-CMAP) therapy delivered over 3 months

Comparator: TAU

Outcomes

Primary outcome(s): i) repetition of SH as measured by the Suicide Attempt Self Injury Interview
SASII

Secondary outcome(s): i) suicidal ideation as measured by the BSSI; ii) hopelessness as measured
by the BHS; iii) distress as measured by the Psychological Distress Scale; iv) quality of life as mea-
sured by the EuroQol-5 Dimensions (EQ5-D); v) satisfaction with treatment as measured by the
Client Satisfaction Questionnaire (CSQ); vi) service use as measured by the Client Services Receipt
Inventory (CSRI)

Starting date

1 November, 2019

Contact information

Principal investigator:

Prof. Nusrat Husain, University of Manchester, Manchester, UK (nusrat.husain@manchester.ac.uk)

Notes

We are grateful to Dr Sehrish Tofique, Trial Manager for YCMAP, for confirming the above details
were correct, 16 October, 2020.

NCT04243603 

Study name

Treatment effects of internet-based Emotion Regulation Individual Therapy for Adolescents (ERI-
TA) added to treatment as usual in young people with non-suicidal self-injury (TEENS) feasibility
trial

Methods

Single-blind RCT

Assignment: parallel-group, individual-level

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT04243603  (Continued)

Participants

Interventions

Outcomes

Inclusion criteria: i) aged between 13 and 17 years; ii) ≥ 5 episodes of NSSI in the year preceding tri-
al entry, including ≥ 1 within the month preceding trial entry; iii) sufficient literacy ability; iv) have
at least one parent committed to participating in the parenting component of the intervention; v)
written informed consent provided by parent/legal guardian

Exclusion criteria: i) judged to be at imminent risk of suicide at screening; ii) requiring inpatient hos-
pitalisation

Intervention: 12 weeks of a therapist-guided, manualised, internet-based emotion regulation ther-
apy program based on principles from CBT, DBT, and ACT, in addition to TAU. Module content (ado-
lescent program) consists of: i) understanding functions of NSSI and identifying valued directions;
ii) impulse control; iii) emotional awareness; iv) identifying primary versus secondary emotions; v)
emotional acceptance; vi) emotional willingness (two modules); vii) developing non-avoidant emo-
tional regulation strategies; viii) validation; ix) repetition; and x) relapse prevention. Module con-
tent for the accompanying parental program consists of: i) psychoeducation; ii) emotional aware-
ness; iii) validation and invalidation; iv) self-validation and invalidation; v) behavioural activation;
vi) summary and evaluation

Comparator: TAU

Primary outcome(s): i) completion of follow-up, as measured by the proportion of participants com-
pleting at least one clinical outcome for NSSI at the end of the intervention; ii) feasibility, as mea-
sured by the proportion of eligible participants who provide consent and are randomised to the in-
tervention or control; iii) treatment adherence, as measured by the proportion of participants who
complete at least 6 of the 12 treatment sessions; iv) NSSI, as measured by the Deliberate Self-Harm
Inventory – Youth (exploratory)

Secondary outcome(s): i) quality of life, as measured by the Kidscreen-10; ii) depression, anxiety,
and stress, as measured by the DASS-21; iii) NSSI, as measured by a binary response; iv) number of
sick days in the past month ascertained from self-report

Tertiary outcomes: i) emotion regulation, as measured by the Difficulties in Emotion Regulation
Scale-16; ii) indirect SH, as measured by the Borderline Symptom List; iii) suicidal ideation, as mea-
sured by the C-SSRS; iv) parental coping skills, as measured by the Coping with Children's Negative
Emotions Scale (CCNES-APP); v) parental coping with negative emotions skills, as measured by the
Coping with Children's Negative Emotions Scale Adolescent (CCNES-A); vi) adverse events, as mea-
sured by the Negative Effects Questionnaire (NEQ); vii) strengths and difficulties, as measured by
the Strengths and difficulties questionnaire (SDQ); viii) therapeutic alliance, as measured by the
Working Alliance Inventory (WAI-SR)

Starting date

11 May, 2020

Contact information

Principal investigator:

Dr. Britt Morthorst, Danish Research Institute for Suicide Prevention, Copenhagen, Denmark (brit-
t.reuter.morthorst@regionh.dk)

Notes

We are grateful to Dr. Morthorst for confirming the above details were correct, 31 August, 2020.

R000011786 

Study name

Randomized controlled trial of eye movement desensitization and reprocessing (EMDR) and inter-
personal psychotherapy (IPT) for non-suicidal self injury in adolescent and young adult females:
JNSSIAP study

Methods

Single blind RCT

Assignment: parallel-group, individual-level

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R000011786  (Continued)

Participants

Inclusion criteria: i) between 12 and 18 years; ii) females; iii) have engaged in NSSI (recency not
specified)

Exclusion criteria: i) males; ii) diagnosed with schizophrenia, bipolar I disorder, schizotypal person-
ality disorder, autism, an intellectual disorder, or epilepsy; iii) prescribed two or more benzodi-
azepines; iv) actively suicidal

Interventions

Intervention: eye movement desensitisation and reprocessing (EMDR). No further information on
dose or duration provided

Comparator: interpersonal therapy. No further information on dose or duration provided

Outcomes

Primary outcome(s): i) post-traumatic symptoms, as measured by the clinician-administered PTSD
scale for DSM-IV

Starting date

26 November, 2012

Contact information

Principal investigator:

Prof. Norio Ozaki, Nagoya University Graduate School of Medicine, Nagoya, Japan (no email provid-
ed)

Notes

We were unable to confirm these details with the principal investigator despite three rounds of cor-
respondence.

ACT: Acceptance and Commitment Therapy; AOD: alcohol and other drug; BASH: Beating Adolescent Self-Harm; BHS: Beck Hopelessness
Scale; BSSI: Beck Scale for Suicidal Ideation; CA CIFFTA: Computer Assisted Culturally Informed and Flexible Family-based Treatment
for  Adolescents;  CAMHS:  Child  and  Adolescent  Mental  Health  Services;  CAT:  Cognitive  Analytic  Therapy;  CBT:  Cognitive  Behavioural
Therapy; CCNES(-A): Coping with Children's Negative Emotions Scale (-Adolescent); CES-D: Center for Epidemiologic Studies Depression
Scale; CGI: Clinical Global Impression; CHUD-9D: Child Health Utility, 9 Dimension; C-MAP: Culturally adapted Manual-Assisted Problem-
solving;  CRAFFT:  Car,  Relax,  Alone,  Forget,  Friends,  Trouble  screening  tool;  CSQ:  Client  Satisfaction  Questionnaire;  CSRI:  Client
Services Receipt Inventory; C-SSRS: Columbia Suicide Severity Rating Scale; DASS(-21): Depression Anxiety Stress Scale (21 item); DBT:
Dialectical Behaviour Therapy; DERS(-16): Difficulties in Emotion Regulation Scale (16 item); DSHI(-Y)(-9): DSM(-IV)(5): Diagnostic and
Statistical  Manual  of  Mental  Disorders  (4th  edition)  (5th  edition);  ED:  emergency  department;  EMDR:  eye  movement  desensitization
and  reprocessing;  EQ-5D:  European  Quality  of  life,  5  Dimension;  ERITA:  Emotion  Regulation  Individual  Therapy  for  Adolescents;
FES: Family Environment Scale; GAD-7: Generalized Anxiety Disorder 7-item; GHQ-30: General Health Questionnaire (30 item); GP: general
practitioner;  IPT:  interpersonal  psychotherapy;  LGBTQ:  lesbian,  gay,  bisexual,  transgender,  and  queer  (or  questioning);  MFQ:  Mood
and  Feelings  Questionnaire;  MINI:  Mini  International  Neuropsychiatric  Interview;  MSPSS:  Multidimensional  Scale  of  Perceived  Social
Support;  NEQ: Negative  Effects  Questionnaire;  NSSI:  non-suicidal  self-injury;  PDS: Peradeniya  Depression  Scale;  PHQ(-9)(-A):  Patient
Health  Questionnaire  (9  item)  (Adolescent);  PTSD:  post-traumatic  stress  disorder;  RCADS:  Revised  Child  Anxiety  and  Depression
Scale; RCT: randomised controlled trial; SASII: Suicide Attempt-Self-Injury Interview; SDQ: Strengths and Difficulties Questionnaire; SH:
self-harm; SIQ(-JR): Suicidal Ideation Questionnaire-Junior; SMASI: Sexual Minority Adolescent Stress Instrument; SMS: Short Messaging
Service;  SRI-25:  Suicide-Resilience  Inventory-25  item;  STAR:  Self-injury:  Treatment,  Assessment,  Recovery;  SUD:  substance  use
disorder;  TAU:  treatment-as-usual;  VSP-A:  Vecu  et  Sante  Percue  de  l'Adolescent;  WAI-SR:  Working  Alliance  Inventory-Short  Revised;
WHO-5: World Health Organisation- Five Well-Being Index; Y-CMAP: Youth Culturally adapted Manual-Assisted Psychological therapy.

R I S K   O F   B I A S

Legend:   

  Low risk of bias    

  High risk of bias    

  Some concerns   

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias for analysis 1.1 Repetition of SH by post-intervention

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Donaldson 2005

Sinyor 2020

Risk of bias for analysis 2.1 Repetition of SH at post-intervention

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Subgroup 2.1.1 Comparator: TAU

Cooney 2010

Subgroup 2.1.2 Comparator: Enhanced usual care

Santamari-
na-Pérez 2020

Mehlum 2014

Subgroup 2.1.3 Comparator: Alternative psychotherapy

McCauley 2018

Risk of bias for analysis 3.1 Repetition of SH by post-intervention

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Griffiths 2019

Rossouw 2012

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias for analysis 3.2 Repetition of SH at post-intervention (Risk-Taking and Self-Harm Inventory)

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Griffiths 2019

Rossouw 2012

Risk of bias for analysis 5.1 Repetition of SH at post-intervention

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Subgroup 5.1.1 Comparator: TAU

Harrington 1998

Subgroup 5.1.2 Comparator: Enhanced usual care

Asarnow 2017

D A T A   A N D   A N A L Y S E S

Comparison 1.   Individual CBT-based psychotherapy versus TAU or other comparator

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1 Repetition of SH by post-interven-
tion

1.2 Treatment adherence: Proportion
completing treatment

1.3 Treatment adherence: Number of
treatment sessions attended

1.4 Depression scores at post-interven-
tion

2

2

2

2

51

63

55

52

Odds Ratio (M-H, Random,
95% CI)

0.93 [0.12, 7.24]

Odds Ratio (M-H, Random,
95% CI)

0.57 [0.20, 1.63]

Mean Difference (IV, Random,
95% CI)

-0.23 [-2.07, 1.60]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.39 [-0.95, 0.16]

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

1.5 Suicidal ideation scores at post-in-
tervention

2

No. of partici-
pants

51

Statistical method

Effect size

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.14 [-0.69, 0.41]

Analysis 1.1.   Comparison 1: Individual CBT-based psychotherapy versus
TAU or other comparator, Outcome 1: Repetition of SH by post-intervention

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

Comparator

Odds Ratio
M-H, Random, 95% CI

Odds Ratio
M-H, Random, 95% CI

Donaldson 2005
Sinyor 2020

4
0

21
5

2
2

18
7

68.6%
31.4%

1.88 [0.30 , 11.73]
0.20 [0.01 , 5.20]

A

?
+

Total (95% CI)
4
Total events:
Heterogeneity: Tau² = 0.73; Chi² = 1.40, df = 1 (P = 0.24); I² = 29%
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable

25

26

4

100.0%

0.93 [0.12 , 7.24]

0.01

0.1
Favours CBT

1

10

100

Favours comparator

Risk of Bias
E
B

D

C

+
+

+
+

+
?

?
-

F

?
-

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions: Repetition of SH by post-intervention
(C) Bias due to missing outcome data: Repetition of SH by post-intervention
(D) Bias in measurement of the outcome: Repetition of SH by post-intervention
(E) Bias in selection of the reported result: Repetition of SH by post-intervention
(F) Overall bias: Repetition of SH by post-intervention

Analysis 1.2.   Comparison 1: Individual CBT-based psychotherapy versus TAU or other
comparator, Outcome 2: Treatment adherence: Proportion completing treatment

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

Comparator

Odds Ratio
M-H, Random, 95% CI

Odds Ratio
M-H, Random, 95% CI

Donaldson 2005
Sinyor 2020

13
5

21
12

13
7

18
12

58.9%
41.1%

0.63 [0.16 , 2.43]
0.51 [0.10 , 2.59]

Total (95% CI)
18
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.85); I² = 0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable

20

33

30

100.0%

0.57 [0.20 , 1.63]

0.01

0.1

1

Favours comparator

10
Favours CBT

100

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.3.   Comparison 1: Individual CBT-based psychotherapy versus TAU or other
comparator, Outcome 3: Treatment adherence: Number of treatment sessions attended

Study or Subgroup

Mean

CBT
SD

Total

Mean

Comparator
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

Donaldson 2005
Sinyor 2020

9.7
5.5

2.4
4.81

15
12

9.5
7.75

1.3
5.41

16
12

82.3%
17.7%

0.20 [-1.17 , 1.57]
-2.25 [-6.35 , 1.85]

Total (95% CI)
Heterogeneity: Tau² = 0.57; Chi² = 1.24, df = 1 (P = 0.27); I² = 19%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable

27

28

100.0%

-0.23 [-2.07 , 1.60]

-10

-5

0

Favours comparator

5
Favours CBT

10

Analysis 1.4.   Comparison 1: Individual CBT-based psychotherapy versus
TAU or other comparator, Outcome 4: Depression scores at post-intervention

Study or Subgroup

Mean

CBT
SD

Total

Mean

Comparator
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Sinyor 2020
Donaldson 2005

20.91
10.9

15.47
15.2

11
15

27.7
16.8

15.73
15.1

10
16

40.2%
59.8%

-0.42 [-1.29 , 0.45]
-0.38 [-1.09 , 0.33]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.95); I² = 0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable

26

26

100.0%

-0.39 [-0.95 , 0.16]

-1

-0.5
Favours CBT

0

0.5

1

Favours comparator

Analysis 1.5.   Comparison 1: Individual CBT-based psychotherapy versus TAU
or other comparator, Outcome 5: Suicidal ideation scores at post-intervention

Study or Subgroup

Mean

CBT
SD

Total

Mean

Comparator
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Donaldson 2005
Sinyor 2020

27.1
8.55

39.8
8.45

15
11

32.2
9.7

30.4
8.74

15
10

58.9%
41.1%

-0.14 [-0.86 , 0.58]
-0.13 [-0.99 , 0.73]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.98); I² = 0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable

26

25

100.0%

-0.14 [-0.69 , 0.41]

-1

-0.5
Favours CBT

0

0.5

1

Favours comparator

Comparison 2.   DBT-A versus TAU or another comparator

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.1 Repetition of SH at post-inter-
vention

2.1.1 Comparator: TAU

2.1.2 Comparator: Enhanced usual
care

4

1

2

270

28

105

Odds Ratio (M-H, Random,
95% CI)

0.46 [0.26, 0.82]

Odds Ratio (M-H, Random,
95% CI)

2.55 [0.20, 31.86]

Odds Ratio (M-H, Random,
95% CI)

0.29 [0.10, 0.85]

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.1.3 Comparator: Alternative psy-
chotherapy

2.2 Frequency of SH repetition at
post-intervention

2.2.1 Comparator: TAU

2.2.2 Comparator: Enhanced usual
care

2.2.3 Comparator: alternative psy-
chotherapy

2.3 Treatment adherence: Number
of individual therapy sessions at-
tended

2.3.1 Comparator: TAU

2.3.2 Comparator: Enhanced usual
care

2.3.3 Comparator: Alternative psy-
chotherapy

2.4 Treatment adherence: Number
of group therapy sessions attended

2.4.1 Comparator: Enhanced usual
care

2.4.2 Comparator: Alternative psy-
chotherapy

2.5 Treatment adherence: Number
of family therapy sessions attended

2.5.1 Comparator: TAU

2.5.2 Comparator: Enhanced usual
care

2.6 Treatment adherence: Number
of telephone therapy sessions

2.6.1 Comparator: Enhanced usual
care

2.7 Depression scores at post-inter-
vention

1

4

1

2

1

4

1

2

1

3

2

1

3

1

2

2

2

2

137

271

27

107

137

267

29

112

126

285

112

173

141

29

112

112

112

103

Odds Ratio (M-H, Random,
95% CI)

0.50 [0.25, 0.98]

Mean Difference (IV, Random,
95% CI)

-0.71 [-1.55, 0.14]

Mean Difference (IV, Random,
95% CI)

0.00 [-0.92, 0.92]

Mean Difference (IV, Random,
95% CI)

-1.02 [-1.84, -0.20]

Mean Difference (IV, Random,
95% CI)

-2.99 [-8.40, 2.42]

Mean Difference (IV, Random,
95% CI)

5.95 [-0.18, 12.07]

Mean Difference (IV, Random,
95% CI)

16.10 [12.16,
20.04]

Mean Difference (IV, Random,
95% CI)

1.82 [-0.63, 4.27]

Mean Difference (IV, Random,
95% CI)

4.70 [1.71, 7.69]

Mean Difference (IV, Random,
95% CI)

5.39 [-0.20, 10.98]

Mean Difference (IV, Random,
95% CI)

6.12 [-3.09, 15.33]

Mean Difference (IV, Random,
95% CI)

3.80 [1.73, 5.87]

Mean Difference (IV, Random,
95% CI)

1.09 [-3.85, 6.02]

Mean Difference (IV, Random,
95% CI)

4.90 [2.57, 7.23]

Mean Difference (IV, Random,
95% CI)

-1.02 [-5.43, 3.39]

Mean Difference (IV, Random,
95% CI)

0.16 [-1.23, 1.55]

Mean Difference (IV, Random,
95% CI)

0.16 [-1.23, 1.55]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.42 [-0.81, -0.03]

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.7.1 Comparator: EUC

2.8 Hopelessness scores at post-in-
tervention

2.8.1 Comparator: TAU

2.8.2 Comparator: Enhanced usual
care

2.9 General functioning scores at
post-intervention

2.9.2 Comparator: Enhanced usual
care

2.10 Suicidal ideation scores at post-
intervention

2.10.1 Comparator: TAU

2.10.2 Comparator: Enhanced usual
care

2.10.3 Comparator: Alternative psy-
chotherapy

2.11 Suicidal ideation scores by 12-
months

2.11.1 Comparator: Enhanced usual
care

2.11.2 Comparator: Alternative psy-
chotherapy

2

2

1

1

2

2

4

1

2

1

2

1

1

103

100

23

77

102

102

256

23

108

125

205

75

130

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.42 [-0.81, -0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.62 [-1.07, -0.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.24 [-1.07, 0.59]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.76 [-1.22, -0.30]

Mean Difference (IV, Random,
95% CI)

5.19 [-5.31, 15.69]

Mean Difference (IV, Random,
95% CI)

5.19 [-5.31, 15.69]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.68, -0.18]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.24 [-1.07, 0.59]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.66 [-1.05, -0.27]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-0.62, 0.08]

Mean Difference (IV, Random,
95% CI)

-0.78 [-6.91, 5.35]

Mean Difference (IV, Random,
95% CI)

-1.60 [-10.91, 7.71]

Mean Difference (IV, Random,
95% CI)

-0.15 [-8.29, 7.99]

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.1.   Comparison 2: DBT-A versus TAU or another
comparator, Outcome 1: Repetition of SH at post-intervention

Study or Subgroup

Events

Total

Events

Total

Weight

DBT-A

Comparator

Odds Ratio
M-H, Random, 95% CI

Odds Ratio
M-H, Random, 95% CI

A

Risk of Bias
E
B

C

D

F

2.1.1 Comparator: TAU
Cooney 2010
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.72 (P = 0.47)

2

2

13
13

1

1

15
15

5.0%
5.0%

2.55 [0.20 , 31.86]
2.55 [0.20 , 31.86]

2.1.2 Comparator: Enhanced usual care
Santamarina-Pérez 2020
Mehlum 2014
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.28, df = 1 (P = 0.60); I² = 0%
Test for overall effect: Z = 2.26 (P = 0.02)

14
39
53

3
3

8
7

15

6

14
38
52

11.6%
15.5%
27.0%

0.20 [0.04 , 1.07]
0.37 [0.09 , 1.55]
0.29 [0.10 , 0.85]

2.1.3 Comparator: Alternative psychotherapy
McCauley 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.01 (P = 0.04)

33

33

72
72

41

41

65
65

68.0%
68.0%

0.50 [0.25 , 0.98]
0.50 [0.25 , 0.98]

+

?

+

?

?

?

+
+

+
+

+
+

+
?

?
?

?
?

+

+

+

?

?

?

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 2.81, df = 3 (P = 0.42); I² = 0%
Test for overall effect: Z = 2.67 (P = 0.008)
Test for subgroup differences: Chi² = 2.53, df = 2 (P = 0.28), I² = 21.1%

138

41

57

132

100.0%

0.46 [0.26 , 0.82]

0.01

0.1

1

10

100

Favours DBT-A

Favours comparator

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions: Repetition of SH at post-intervention
(C) Bias due to missing outcome data: Repetition of SH at post-intervention
(D) Bias in measurement of the outcome: Repetition of SH at post-intervention
(E) Bias in selection of the reported result: Repetition of SH at post-intervention
(F) Overall bias: Repetition of SH at post-intervention

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.2.   Comparison 2: DBT-A versus TAU or another comparator,
Outcome 2: Frequency of SH repetition at post-intervention

Study or Subgroup

Mean

DBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.2.1 Comparator: TAU
Cooney 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)

0.67

0.79

12
12

0.67

1.59

15
15

41.0%
41.0%

0.00 [-0.92 , 0.92]
0.00 [-0.92 , 0.92]

2.2.2 Comparator: Enhanced usual care
Mehlum 2014
Santamarina-Pérez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 1.02, df = 1 (P = 0.31); I² = 2%
Test for overall effect: Z = 2.45 (P = 0.01)

2
0.59

1.2
1.27

39
15
54

3.3
2.13

6.8
1.55

38
15
53

12.0%
44.6%
56.6%

-2.10 [-4.35 , 0.15]
-0.86 [-1.70 , -0.02]
-1.02 [-1.84 , -0.20]

2.2.3 Comparator: alternative psychotherapy
McCauley 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.08 (P = 0.28)

3.56

11.79

6.55

19.22

72
72

65
65

2.4%
2.4%

-2.99 [-8.40 , 2.42]
-2.99 [-8.40 , 2.42]

Total (95% CI)
Heterogeneity: Tau² = 0.23; Chi² = 4.45, df = 3 (P = 0.22); I² = 33%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi² = 3.40, df = 2 (P = 0.18), I² = 41.2%

138

133

100.0%

-0.71 [-1.55 , 0.14]

-10
Favours DBT-A

-5

0

5

10

Favours comparator

Analysis 2.3.   Comparison 2: DBT-A versus TAU or another comparator, Outcome
3: Treatment adherence: Number of individual therapy sessions attended

Study or Subgroup

Mean

DBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.3.1 Comparator: TAU
Cooney 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 8.00 (P < 0.00001)

22.6

6.4

14
14

6.5

4.1

15
15

24.6%
24.6%

16.10 [12.16 , 20.04]
16.10 [12.16 , 20.04]

2.3.2 Comparator: Enhanced usual care
Mehlum 2014
Santamarina-Pérez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.31, df = 1 (P = 0.58); I² = 0%
Test for overall effect: Z = 1.46 (P = 0.15)

13.8
12.4

39
18
57

6.9
8

11.5
11.6

6.4
4.8

38
17
55

25.7%
24.0%
49.7%

2.30 [-0.67 , 5.27]
0.80 [-3.54 , 5.14]
1.82 [-0.63 , 4.27]

2.3.3 Comparator: Alternative psychotherapy
McCauley 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.08 (P = 0.002)

20

7.7

15.3

8.4

39
39

87
87

25.7%
25.7%

4.70 [1.71 , 7.69]
4.70 [1.71 , 7.69]

Total (95% CI)
Heterogeneity: Tau² = 35.67; Chi² = 36.99, df = 3 (P < 0.00001); I² = 92%
Test for overall effect: Z = 1.90 (P = 0.06)
Test for subgroup differences: Chi² = 36.68, df = 2 (P < 0.00001), I² = 94.5%

110

157

100.0%

5.95 [-0.18 , 12.07]

-20

-10

0

Favours comparator

10

20
Favours DBT-A

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.4.   Comparison 2: DBT-A versus TAU or another comparator,
Outcome 4: Treatment adherence: Number of group therapy sessions attended

Study or Subgroup

Mean

DBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.4.1 Comparator: Enhanced usual care
Mehlum 2014
Santamarina-Pérez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 42.04; Chi² = 20.62, df = 1 (P < 0.00001); I² = 95%
Test for overall effect: Z = 1.30 (P = 0.19)

11.2
10.7

39
18
57

0.5
9.4

5.9
5.7

2.1
5

38
17
55

34.4%
31.4%
65.8%

10.70 [8.73 , 12.67]
1.30 [-2.25 , 4.85]
6.12 [-3.09 , 15.33]

2.4.2 Comparator: Alternative psychotherapy
McCauley 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.59 (P = 0.0003)

16.9

6.6

13.1

7.3

86
86

87
87

34.2%
34.2%

3.80 [1.73 , 5.87]
3.80 [1.73 , 5.87]

Total (95% CI)
Heterogeneity: Tau² = 22.67; Chi² = 32.25, df = 2 (P < 0.00001); I² = 94%
Test for overall effect: Z = 1.89 (P = 0.06)
Test for subgroup differences: Chi² = 0.23, df = 1 (P = 0.63), I² = 0%

143

142

100.0%

5.39 [-0.20 , 10.98]

-20

-10

0

Favours comparator

10

20
Favours DBT-A

Analysis 2.5.   Comparison 2: DBT-A versus TAU or another comparator,
Outcome 5: Treatment adherence: Number of family therapy sessions attended

Study or Subgroup

Mean

DBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.5.1 Comparator: TAU
Cooney 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.12 (P < 0.0001)

8

3.1

14
14

3.1

3.3

15
15

35.2%
35.2%

4.90 [2.57 , 7.23]
4.90 [2.57 , 7.23]

2.5.2 Comparator: Enhanced usual care
Mehlum 2014
Santamarina-Pérez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 7.16; Chi² = 3.42, df = 1 (P = 0.06); I² = 71%
Test for overall effect: Z = 0.45 (P = 0.65)

2.6
10.7

39
18
57

2.2
5.7

5.8
9.4

9.8
5

38
17
55

32.9%
31.9%
64.8%

-3.20 [-6.39 , -0.01]
1.30 [-2.25 , 4.85]
-1.02 [-5.43 , 3.39]

Total (95% CI)
Heterogeneity: Tau² = 16.61; Chi² = 16.29, df = 2 (P = 0.0003); I² = 88%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi² = 5.42, df = 1 (P = 0.02), I² = 81.5%

71

70

100.0%

1.09 [-3.85 , 6.02]

-10

-5

0

Favours comparator

5

10
Favours DBT-A

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.6.   Comparison 2: DBT-A versus TAU or another comparator,
Outcome 6: Treatment adherence: Number of telephone therapy sessions

Study or Subgroup

Mean

DBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.6.1 Comparator: Enhanced usual care
Mehlum 2014
Santamarina-Pérez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.24, df = 1 (P = 0.62); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.82)

39
18
57

4.5
3.7

3.3
1.8

3.5
1.3

4.4
1.9

38
17
55

48.6%
51.4%
100.0%

-0.20 [-2.19 , 1.79]
0.50 [-1.43 , 2.43]
0.16 [-1.23 , 1.55]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.24, df = 1 (P = 0.62); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable

57

55

100.0%

0.16 [-1.23 , 1.55]

-10

-5

0

Favours comparator

5

10
Favours DBT-A

Analysis 2.7.   Comparison 2: DBT-A versus TAU or another
comparator, Outcome 7: Depression scores at post-intervention

Study or Subgroup

Mean

DBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

2.7.1 Comparator: EUC
Mehlum 2014
Santamarina-Pérez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 2.11 (P = 0.04)

12.3
24.36

7.5
11.64

39
14
53

15.8
29.25

8.1
15.41

38
12
50

74.7%
25.3%
100.0%

-0.44 [-0.90 , 0.01]
-0.35 [-1.13 , 0.43]
-0.42 [-0.81 , -0.03]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 2.11 (P = 0.04)
Test for subgroup differences: Not applicable

53

50

100.0%

-0.42 [-0.81 , -0.03]

-2
Favours DBT-A

-1

0

1

2

Favours comparator

Analysis 2.8.   Comparison 2: DBT-A versus TAU or another
comparator, Outcome 8: Hopelessness scores at post-intervention

Study or Subgroup

Mean

DBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

2.8.1 Comparator: TAU
Cooney 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.56 (P = 0.57)

5

8.87

2.8.2 Comparator: Enhanced usual care
Mehlum 2014
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.21 (P = 0.001)

18.3

11.11

10
10

39
39

7.23

9.12

13
13

27.3%
27.3%

-0.24 [-1.07 , 0.59]
-0.24 [-1.07 , 0.59]

32.56

23.99

38
38

72.7%
72.7%

-0.76 [-1.22 , -0.30]
-0.76 [-1.22 , -0.30]

Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 1.15, df = 1 (P = 0.28); I² = 13%
Test for overall effect: Z = 2.66 (P = 0.008)
Test for subgroup differences: Chi² = 1.15, df = 1 (P = 0.28), I² = 13.3%

49

51

100.0%

-0.62 [-1.07 , -0.16]

-2
Favours DBT-A

-1

0

1

2

Favours comparator

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.9.   Comparison 2: DBT-A versus TAU or another comparator,
Outcome 9: General functioning scores at post-intervention

Study or Subgroup

Mean

DBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.9.2 Comparator: Enhanced usual care
Mehlum 2014
Santamarina-Pérez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 48.75; Chi² = 6.60, df = 1 (P = 0.01); I² = 85%
Test for overall effect: Z = 0.97 (P = 0.33)

65.88
65

9.52
7.36

38
13
51

65.89
54.29

Total (95% CI)
Heterogeneity: Tau² = 48.75; Chi² = 6.60, df = 1 (P = 0.01); I² = 85%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable

51

13.03
9.37

37
14
51

51.5%
48.5%
100.0%

-0.01 [-5.19 , 5.17]
10.71 [4.38 , 17.04]
5.19 [-5.31 , 15.69]

51

100.0%

5.19 [-5.31 , 15.69]

-20

-10

0

Favours comparator

10

20
Favours DBT-A

Analysis 2.10.   Comparison 2: DBT-A versus TAU or another
comparator, Outcome 10: Suicidal ideation scores at post-intervention

Study or Subgroup

Mean

DBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

2.10.1 Comparator: TAU
Cooney 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.56 (P = 0.57)

5

8.87

10
10

7.23

9.12

13
13

9.1%
9.1%

-0.24 [-1.07 , 0.59]
-0.24 [-1.07 , 0.59]

2.10.2 Comparator: Enhanced usual care
Mehlum 2014
Santamarina-Pérez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.62, df = 1 (P = 0.43); I² = 0%
Test for overall effect: Z = 3.31 (P = 0.0009)

11.11
18.01

18.3
33.06

39
17
56

32.56
41.43

23.99
21.41

38
14
52

29.0%
12.1%
41.1%

-0.76 [-1.22 , -0.30]
-0.42 [-1.13 , 0.30]
-0.66 [-1.05 , -0.27]

2.10.3 Comparator: Alternative psychotherapy
McCauley 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.50 (P = 0.13)

29.96

23.13

36.17

22.43

67
67

58
58

49.8%
49.8%

-0.27 [-0.62 , 0.08]
-0.27 [-0.62 , 0.08]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.92, df = 3 (P = 0.40); I² = 0%
Test for overall effect: Z = 3.35 (P = 0.0008)
Test for subgroup differences: Chi² = 2.30, df = 2 (P = 0.32), I² = 13.0%

133

123

100.0%

-0.43 [-0.68 , -0.18]

-2
Favours DBT-A

-1

0

1

2

Favours comparator

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.11.   Comparison 2: DBT-A versus TAU or another
comparator, Outcome 11: Suicidal ideation scores by 12-months

Study or Subgroup

Mean

DBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

2.11.1 Comparator: Enhanced usual care
Mehlum 2014
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.34 (P = 0.74)

20.45

19.15

2.11.2 Comparator: Alternative psychotherapy
McCauley 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.04 (P = 0.97)

23.78

28.56

38
38

72
72

22.05

21.86

37
37

43.3%
43.3%

-1.60 [-10.91 , 7.71]
-1.60 [-10.91 , 7.71]

28.71

23.36

58
58

56.7%
56.7%

-0.15 [-8.29 , 7.99]
-0.15 [-8.29 , 7.99]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi² = 0.05, df = 1 (P = 0.82), I² = 0%

110

95

100.0%

-0.78 [-6.91 , 5.35]

-20
Favours DBT-A

-10

0

10

20

Favours comparator

Comparison 3.   MBT-A versus TAU or another comparator

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3.1 Repetition of SH by post-intervention

3.2 Repetition of SH at post-intervention
(Risk-Taking and Self-Harm Inventory)

3.3 Depression scores at post-interven-
tion

2

2

2

85

119

128

Odds Ratio (M-H, Random,
95% CI)

0.70 [0.06, 8.46]

Odds Ratio (M-H, Random,
95% CI)

0.48 [0.10, 2.25]

Std. Mean Difference (IV,
Random, 95% CI)

-0.72 [-2.86, 1.42]

Analysis 3.1.   Comparison 3: MBT-A versus TAU or another
comparator, Outcome 1: Repetition of SH by post-intervention

Study or Subgroup

Events

Total

Events

Total

Weight

MBT-A

Comparator

Odds Ratio
M-H, Random, 95% CI

Odds Ratio
M-H, Random, 95% CI

Griffiths 2019
Rossouw 2012

7
20

8
36

4
29

6
35

38.4%
61.6%

3.50 [0.24 , 51.90]
0.26 [0.09 , 0.78]

A

?
+

Total (95% CI)
27
Total events:
Heterogeneity: Tau² = 2.30; Chi² = 3.09, df = 1 (P = 0.08); I² = 68%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable

41

33

44

100.0%

0.70 [0.06 , 8.46]

0.01
Favours MBT-A

0.1

1

10

100

Favours comparator

Risk of Bias
E
B

D

C

+
+

+
+

+
-

?
?

F

?
-

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions: Repetition of SH by post-intervention
(C) Bias due to missing outcome data: Repetition of SH by post-intervention
(D) Bias in measurement of the outcome: Repetition of SH by post-intervention
(E) Bias in selection of the reported result: Repetition of SH by post-intervention
(F) Overall bias: Repetition of SH by post-intervention

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.2.   Comparison 3: MBT-A versus TAU or another comparator, Outcome
2: Repetition of SH at post-intervention (Risk-Taking and Self-Harm Inventory)

Study or Subgroup

Events

Total

Events

Total

Weight

MBT-A

Comparator

Odds Ratio
M-H, Random, 95% CI

Odds Ratio
M-H, Random, 95% CI

Griffiths 2019
Rossouw 2012

20
20

22
36

23
29

26
35

38.3%
61.7%

1.30 [0.20 , 8.61]
0.26 [0.09 , 0.78]

A

?
+

Total (95% CI)
40
Total events:
Heterogeneity: Tau² = 0.69; Chi² = 2.11, df = 1 (P = 0.15); I² = 53%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable

52

58

61

100.0%

0.48 [0.10 , 2.25]

0.01
Favours  MBT-A

0.1

1

10

100

Favours comparator

Risk of Bias
E
B

C

D

+
+

+
+

+
-

?
?

F

?
-

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions: Repetition of SH at post-intervention (Risk-Taking and Self-Harm Inventory)
(C) Bias due to missing outcome data: Repetition of SH at post-intervention (Risk-Taking and Self-Harm Inventory)
(D) Bias in measurement of the outcome: Repetition of SH at post-intervention (Risk-Taking and Self-Harm Inventory)
(E) Bias in selection of the reported result: Repetition of SH at post-intervention (Risk-Taking and Self-Harm Inventory)
(F) Overall bias: Repetition of SH at post-intervention (Risk-Taking and Self-Harm Inventory)

Analysis 3.3.   Comparison 3: MBT-A versus TAU or another
comparator, Outcome 3: Depression scores at post-intervention

Study or Subgroup

Mean

MBT-A
SD

Total

Mean

Comparator
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Griffiths 2019
Rossouw 2012

20.4
9.3

4.7
1.3

22
40

18.2
11.5

6.6
1.1

26
40

49.9%
50.1%

0.37 [-0.20 , 0.95]
-1.81 [-2.33 , -1.29]

Total (95% CI)
Heterogeneity: Tau² = 2.30; Chi² = 30.32, df = 1 (P < 0.00001); I² = 97%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable

62

66

100.0%

-0.72 [-2.86 , 1.42]

-10
Favours MBT-A

-5

0

5

10

Favours comparator

Comparison 4.   Group-based psychotherapy

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.1 Repetition of SH by six months

4.2 Repetition of SH by 12 months

4.3 Depression scores at six
months

4.4 Depression scores at 12
months

4.5 General functioning scores at
six months

2

3

2

3

2

430

490

420

473

402

Odds Ratio (M-H, Random, 95%
CI)

1.72 [0.56, 5.24]

Odds Ratio (M-H, Random, 95%
CI)

0.80 [0.22, 2.97]

Mean Difference (IV, Random,
95% CI)

0.39 [-2.76, 3.54]

Mean Difference (IV, Random,
95% CI)

-0.94 [-4.04, 2.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.05 [-0.25, 0.15]

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.6 General functioning scores at
12 months

4.7 Suicidal ideation scores at six
months

4.8 Suicidal ideation scores at 12
months

2

2

3

396

421

471

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.11 [-0.30, 0.09]

Mean Difference (IV, Random,
95% CI)

1.26 [-7.75, 10.27]

Mean Difference (IV, Random,
95% CI)

-1.51 [-9.62, 6.59]

Analysis 4.1.   Comparison 4: Group-based psychotherapy, Outcome 1: Repetition of SH by six months

Study or Subgroup

Group-based therapy
Events

Total

Comparator

Events

Total

Weight

Odds Ratio
M-H, Random, 95% CI

Odds Ratio
M-H, Random, 95% CI

Green 2011
Hazell 2009

145
30

181
34

142
23

181
34

62.6%
37.4%

1.11 [0.67 , 1.84]
3.59 [1.01 , 12.73]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.45; Chi² = 2.86, df = 1 (P = 0.09); I² = 65%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable

175

165

215

215

100.0%

1.72 [0.56 , 5.24]

0.01

0.1

1

10

100

Favours group therapy

Favours comparator

Analysis 4.2.   Comparison 4: Group-based psychotherapy, Outcome 2: Repetition of SH by 12 months

Study or Subgroup

Group-based therapy
Events

Total

Comparator

Events

Total

Weight

Odds Ratio
M-H, Random, 95% CI

Odds Ratio
M-H, Random, 95% CI

Green 2011
Hazell 2009
Wood 2001a

104
30
2

179
34
32

110
24
10

180
34
31

42.4%
31.2%
26.4%

0.88 [0.58 , 1.35]
3.13 [0.87 , 11.21]
0.14 [0.03 , 0.71]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 1.00; Chi² = 8.75, df = 2 (P = 0.01); I² = 77%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable

245

144

136

245

100.0%

0.80 [0.22 , 2.97]

0.01

0.1

1

10

100

Favours group therapy

Favours comparator

Analysis 4.3.   Comparison 4: Group-based psychotherapy, Outcome 3: Depression scores at six months

Study or Subgroup

Group-based therapy
SD

Total

Mean

Comparator
SD

Mean

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

Green 2011
Hazell 2009

28.5
31.6

16.1
17.5

171
34

27.6
34.1

16.5
17.5

178
37

85.0%
15.0%

0.90 [-2.52 , 4.32]
-2.50 [-10.65 , 5.65]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.57, df = 1 (P = 0.45); I² = 0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable

205

215

100.0%

0.39 [-2.76 , 3.54]

-20

-10

0

10

20

Favours group therapy

Favours comparator

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.4.   Comparison 4: Group-based psychotherapy, Outcome 4: Depression scores at 12 months

Study or Subgroup

Green 2011
Hazell 2009
Wood 2001a

Group-based therapy
SD

Total

Mean

Control
SD

Mean

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

24.4
27.4
21.9

16.6
17.2
15.6

170
34
29

24.6
31.8
23.4

17.6
18.9
18

174
37
29

73.6%
13.6%
12.8%

-0.20 [-3.81 , 3.41]
-4.40 [-12.80 , 4.00]
-1.50 [-10.17 , 7.17]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.83, df = 2 (P = 0.66); I² = 0%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable

233

240

100.0%

-0.94 [-4.04 , 2.16]

-20

-10

0

10

20

Favours group therapy

Favours comparator

Analysis 4.5.   Comparison 4: Group-based psychotherapy, Outcome 5: General functioning scores at six months

Study or Subgroup

Group-based therapy
SD

Total

Mean

Comparator
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Green 2011
Hazell 2009

12.2
60

6.3
8.5

172
25

12.6
59.5

6.1
9.5

180
25

87.6%
12.4%

-0.06 [-0.27 , 0.14]
0.05 [-0.50 , 0.61]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.15, df = 1 (P = 0.69); I² = 0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable

197

205

100.0%

-0.05 [-0.25 , 0.15]

-2

-1

0

1

2

Favours group therapy

Favours comparator

Analysis 4.6.   Comparison 4: Group-based psychotherapy, Outcome 6: General functioning scores at 12 months

Study or Subgroup

Group-based therapy
SD

Total

Mean

Comparator
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Green 2011
Hazell 2009

10.9
60.4

5.9
8.5

168
25

11.7
60.1

6.7
9.5

178
25

87.3%
12.7%

-0.13 [-0.34 , 0.08]
0.03 [-0.52 , 0.59]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.28, df = 1 (P = 0.60); I² = 0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable

193

203

100.0%

-0.11 [-0.30 , 0.09]

-2

-1

0

1

2

Favours group therapy

Favours comparator

Analysis 4.7.   Comparison 4: Group-based psychotherapy, Outcome 7: Suicidal ideation scores at six months

Study or Subgroup

Group-based therapy
SD

Total

Mean

Comparator
SD

Mean

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

Green 2011
Hazell 2009

61.5
68.9

45.5
44.9

171
34

59.9
69.4

48.4
51.4

179
37

83.8%
16.2%

1.60 [-8.24 , 11.44]
-0.50 [-22.91 , 21.91]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Not applicable

205

216

100.0%

1.26 [-7.75 , 10.27]

-20

-10

0

10

20

Favours group therapy

Favours comparator

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.8.   Comparison 4: Group-based psychotherapy, Outcome 8: Suicidal ideation scores at 12 months

Study or Subgroup

Green 2011
Hazell 2009
Wood 2001a

Group-based therapy
SD

Total

Mean

Comparator
SD

Mean

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

48.3
59.8
41.3

42.7
42.1
39.6

169
34
28

49.2
61.7
46

46.8
49.6
48.9

174
37
29

73.2%
14.4%
12.4%

-0.90 [-10.38 , 8.58]
-1.90 [-23.25 , 19.45]
-4.70 [-27.76 , 18.36]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable

231

240

100.0%

-1.51 [-9.62 , 6.59]

-20

-10

0

10

20

Favours group therapy

Favours comparator

Comparison 5.   Family therapy

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

5.1 Repetition of SH at post-inter-
vention

5.1.1 Comparator: TAU

5.1.2 Comparator: Enhanced usual
care

5.2 Treatment adherence by six
months

2

1

1

2

191

149

42

993

Odds Ratio (M-H, Random,
95% CI)

1.00 [0.49, 2.07]

Odds Ratio (M-H, Random,
95% CI)

1.02 [0.41, 2.51]

Odds Ratio (M-H, Random,
95% CI)

0.98 [0.29, 3.31]

Odds Ratio (M-H, Random,
95% CI)

1.99 [1.55, 2.57]

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.1.   Comparison 5: Family therapy, Outcome 1: Repetition of SH at post-intervention

Study or Subgroup

Family therapy
Total
Events

Comparator

Events

Total

Weight

Odds Ratio
M-H, Random, 95% CI

Odds Ratio
M-H, Random, 95% CI

A

Risk of Bias
E
B

C

D

F

5.1.1 Comparator: TAU
Harrington 1998
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.03 (P = 0.97)

11

11

5.1.2 Comparator: Enhanced usual care
Asarnow 2017
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.03 (P = 0.98)

9

9

74
74

20
20

11

11

10

10

75
75

64.4%
64.4%

1.02 [0.41 , 2.51]
1.02 [0.41 , 2.51]

+

+

+

?

?

?

22
22

35.6%
35.6%

0.98 [0.29 , 3.31]
0.98 [0.29 , 3.31]

+

+

+

?

+

?

Total (95% CI)
20
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.96), I² = 0%

97

94

21

100.0%

1.00 [0.49 , 2.07]

0.5
0.1 0.2
Favours family therapy

1

2

5
Favours comparator

10

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions: Repetition of SH at post-intervention
(C) Bias due to missing outcome data: Repetition of SH at post-intervention
(D) Bias in measurement of the outcome: Repetition of SH at post-intervention
(E) Bias in selection of the reported result: Repetition of SH at post-intervention
(F) Overall bias: Repetition of SH at post-intervention

Analysis 5.2.   Comparison 5: Family therapy, Outcome 2: Treatment adherence by six months

Study or Subgroup

Family therapy
Total
Events

Comparator

Events

Total

Weight

Odds Ratio
M-H, Random, 95% CI

Odds Ratio
M-H, Random, 95% CI

Cottrell 2018
Harrington 1998

233
39

415
84

158
28

417
77

83.9%
16.1%

2.10 [1.59 , 2.77]
1.52 [0.81 , 2.85]

499

Total (95% CI)
272
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.85, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 5.32 (P < 0.00001)
Test for subgroup differences: Not applicable

186

494

100.0%

1.99 [1.55 , 2.57]

0.01

0.1

1

10

100

Favours comparator

Favours family therapy 

A D D I T I O N A L   T A B L E S

Table 1.   Methods used at the index episode of self-harm 

Reference

Method

Self-poisoning

Self-injury

n (%)

n (%)

Combined self-poi-
soning
and self-injury

Asarnow 2017

-

-

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

n (%)

-

93

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 1.   Methods used at the index episode of self-harm  (Continued)

Cooney 2010

Cotgrove 1995 1

Cottrell 2018

Donaldson 2005 2

Green 2011

Griffiths 2019

Harrington 1998

Hazell 2009 4

McCauley 2018

Mehlum 2014

Ougrin 2011

Rossouw 2012

Santamarina-Pérez 2020

Sinyor 2020

Spirito 2002 5

Wood 2001a 6

-

101 (96.2)

184 (22.1)

33 (84.6)

5 (2.7)

-

162 (100.0)3

-

-

-

-

2 (1.9)

-

-

594 (71.4)

54 (6.5)

-

-

67 (36.6)

111 (60.7)

-

-

-

-

-

-

-

-

-

-

28 (40.0)

37 (52.8)

5 (7.2)

-

-

-

54 (85.7)

-

-

-

-

-

-

-

-

-

-

-

n: number; %: percentage.
1The method used by the remaining two (1.9%) participants was not reported.
2 The method used by the remaining six (15.4%) participants was not reported.
3Over half (n = 92; 56.8%) used paracetamol/acetaminophen.
4Participants engaged in multiple forms of SH: cutting (97%); head banging (71%); intentional drug overdose (57%); smothering (36%);
strangling (25%); other self-poisoning (19%); attempted drowning (19%); jumping from a height (17%); and other self-harm (35%).
5The method used by the remaining nine (14.3%) participants was not reported.
6Data on the proportion with a lifetime history of self-poisoning or self-injury were reported; however, data on the proportion using these
methods at the index episode were not clearly reported.

A P P E N D I C E S

Appendix 1. Cochrane Common Mental Disorders Group Specialized Register

The  Cochrane  Common  Mental  Disorders  Group  (CCMD)  maintains  an  archived  controlled  trials  register  known  as  the  CCMDCTR.  This
specialized register contains over 40,000 reference records (reports of RCTs) for anxiety disorders, depression, bipolar disorder, eating
disorders, self-harm, and other mental disorders within the scope of this Group. The CCMDCTR is a partially studies-based register with
more than 50% of reference records tagged to around 12,500 individually PICO-coded study records. Reports of studies for inclusion in
the register were collated from (weekly) generic searches of key bibliographic databases to June 2016, which included: MEDLINE (1950
onwards), Embase (1974 onwards), PsycINFO (1967 onwards), quarterly searches of the Cochrane Central Register of Controlled Trials
(CENTRAL), and review-specific searches of additional databases. Reports of studies were also sourced from international trials registries,
drug  companies,  the  handsearching  of  key  journals,  conference  proceedings  and  other  (non-Cochrane)  systematic  reviews  and  meta-

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

analyses. Details of CCMD's core search strategies (used to identify RCTs) are on the Group's website, with an example of the core MEDLINE
search displayed below.

[MeSH Headings]: eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or female athlete triad syndrome/
or pica/ or hyperphagia/ or bulimia/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/
or mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression,
postpartum/  or  depressive  disorder,  major/  or  depressive  disorder,  treatment-resistant/  or  dysthymic  disorder/  or  seasonal  affective
disorder/  or  neurotic  disorders/  or  depression/  or  adjustment  disorders/  or  exp  antidepressive  agents/  or  anxiety  disorders/  or
agoraphobia/  or  neurocirculatory  asthenia/  or  obsessive-compulsive  disorder/  or  obsessive  hoarding/  or  panic  disorder/  or  phobic
disorders/ or stress disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/
or anxiety/ or anxiety, castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body
dysmorphic disorders/ or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ or munchausen syndrome by proxy/ or
munchausen syndrome/ or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse
control disorders/ or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual
dysfunctions,  psychological/  or  vaginismus/  or  Anhedonia/  or  Affective  Symptoms/  or  *Mental  Disorders/  OR  [Title/  Author  Keywords]:
(eating disorder*  or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid*  or
mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or cyclothymic* or
depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or agoraphobia
or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#ation or medical*
unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen or chronic fatigue*
or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder* or mental health).tw,kf. AND [RCT
filter]: (controlled clinical trial.pt. or randomised controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or (random*
adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or place*
or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or study or
studies)).ab,ti. or ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical trial, phase ii/ or clinical trial, phase
iii/ or clinical trial, phase iv/ or randomised controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental or random*)).ti,ab. or
((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)

Records were screened for reports of RCTs within the scope of the Cochrane Common Mental Disorders Group. Secondary reports of RCTs
were tagged to the appropriate study record.

The information specialist with CCMD cross-searched the CCMDCTR-Studies and References register for this review using the following
terms (all fields):

(suicid* or parasuicid* or "auto mutilat*" or automutilat* or "self destruct*" or selfdestruct* or self-harm* or selfharm* or "self immolat*"
or selfimmolat* or "self inflict*" or selfinflict* or "self injur*" or selfinjur* or selfmutilat* or "self mutilat*" or "self poison*" or selfpoison*
or (self adj2 (cut or cuts or cutting or cutter? or burn or burns or burning or bite or bites or biting or hit or hits or hitting)) or "head bang*"
or headbang* or "over dose*" or overdos* or NSSI* or nonsuicid* or non-suicid*)

N.B. This register is only up-to-date as of June 2016.

Appendix 2. MEDLINE, Embase, PsycINFO Ovid search strategy

An information specialist with CCMD searched the main bibliographic, biomedical databases using the terms listed below from January
2015 to 4-July-2020. [N.B. CCMDCTR is current to June 2016 only]

Search summary

Date-of-search: 4-July-2020

• Cochrane Library (CDSR) Systematic Reviews, n=38
• Cochrane Library (CDSR) Protocols, n=12
• Cochrane Library CENTRAL, n=2727
• Cochrane Specialised Register (CCMDCTR), n=291
• Ovid MEDLINE, PsycINFO (cross-search), n=2743
• Ovid Embase (precise), n=1375

Total=7186
Duplicates removed, n=2483
To screen, n=4703
[Cochrane Library CENTRAL-Trial Register Records (removed) n=1969]
Cochrane Library (Issue 7 of 12, 2020) [Date limited, 2015 onwards]
#1 MeSH descriptor: [Self-Injurious Behavior] explode all trees

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

#2 (overdose* and prevent*):kw or (overdos* near/3 prevent*):ti,ab
#3 ((nonfatal or non-fatal) near/2 (overdose* or over dose*)):ti,ab,kw
#4 (NSSI* or ((nonsuicid* or non-suicid*) near/2 (self* or injur*))):ti,ab
#5 (suicid* or parasuicid* or (auto next mutilat*) or automutilat* or (self next destruct*) or selfdestruct* or self-harm* or selfharm* or (self
next harm*) or (self next immolat*) or selfimmolat* or (self next inflict*) or selfinflict* or (self next injur*) or selfinjur* or selfmutilat* or (self
next mutilat*) or (self next poison*) or selfpoison* or (self near/2 (cut or cuts or cutting or cutter* or burn or burns or burning or bite or
bites or biting or hit or hits or hitting)) or (head next bang*) or headbang*):ti,ab,kw
#6 (#1 or #2 or #3 or #4 or #5)
Limited 2015 to date
CDSR-reviews (38); CDSR-protocols (12); CENTRAL (2727); CENTRAL-TR (1969)
***************************
PsycINFO/MEDLINE cross-search

Ovid APA PsycInfo <1806 to June Week 5 2020>, Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and
Daily <1946 to July 02, 2020> [Date limited, 2015 onwards]
Search Strategy:
--------------------------------------------------------------------------------
1 Automutilation/ or Self-injurious Behavior/ or Self-destructive Behavior/ or Self-mutilation/ or Self-inflicted Wounds/ (19601)
2 Suicidal Behavior/ or Suicide/ or Suicidal Ideation/ or Attempted Suicide/ or Suicide, Attempted/ or Self Poisoning/ or Suicide Prevention/
or Suicide Prevention Centers/ or Suicidology/ (97875)
3 (suicid* or parasuicid* or auto mutilat* or automutilat* or self destruct* or selfdestruct* or self-harm* or selfharm* or self immolat* or
selfimmolat* or self inflict* or selfinflict* or self injur* or selfinjur* or selfmutilat* or self mutilat* or self poison* or selfpoison* or (self
adj2  (cut  or  cuts  or  cutting  or  cutter?  or  burn  or  burns  or  burning  or  bite  or  bites  or  biting  or  hit  or  hits  or  hitting))  or  head  bang*  or
headbang*).ti,ab,kf,kw,id. (164244)
4 (NSSI? or ((nonsuicid* or non-suicid*) adj2 (self* or injur*))).ti,ab,kf,kw,id. (3469)
5 (Overdose/ or Drug Overdose/ or Drug Overdoses/) and prevent*.af. (3529)
6 ((nonfatal or non-fatal) adj2 (overdose? or over dose?)).mp. (571)
7 or/1-6 (183505)
8 Randomized Controlled Trial/ (509272)
9 Randomized Controlled Trial.pt. (508805)
10 Randomization/ (103117)
11 Random Allocation/ (103117)
12 Controlled Clinical Trial/ (93744)
13 Controlled Clinical Trial.pt. (93744)
14 Double-blind Method/ or Single-blind Method/ (186347)
15 (randomi#ed or randomi#ation or randomi#ing).ti,ab,kf,kw,id. (726423)
16 (RCT or "at random" or (random* adj3 (administ* or allocat* or assign* or class* or cluster or crossover or cross-over or control* or
determine* or divide* or division or distribut* or expose* or fashion or number* or place* or pragmatic or quasi or recruit* or split or
subsitut* or treat*))).ti,ab,kf,kw,id. (667814)
17 trial.ti. (251482)
18 placebo/ or (placebo and (allocat* or assign* or control* or group*)).ti,ab,kf,kw,id. (204672)
19 (control* adj3 group*).ab. (634930)
20 (control* and (trial or study or group*) and (waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,kf,kw,id. (32182)
21 ((single or double or triple or treble) adj2 (blind* or mask* or dummy)).ti,ab,kf,kw,id. (200109)
22 treatment effectiveness evaluation/ (24511)
23 or/8-22 (1833008)
24 7 and 23 (9906)
25 (2015* or 2016* or 2017* or 2018* or 2019* or 2020*).yr,dc,dp,dt,ep,ez. (7909383)
26 24 and 25 (3732)
27 remove duplicates from 26 (2743)
***************************
Ovid Embase <1974 to 2020 Week 26> [Date limited, 2015 onwards]
Search Strategy:
--------------------------------------------------------------------------------
1 Automutilation/ (17795)
2 suicidal behavior/ or self immolation/ or self poisoning/ or suicidal ideation/ or suicide/ or suicide attempt/ (101066)
3 Drug Overdose/ and prevent*.af. (4897)
4 (suicid* or parasuicid* or auto mutilat* or automutilat* or self destruct* or selfdestruct* or self-harm* or selfharm* or self immolat* or
selfimmolat* or self inflict* or selfinflict* or self injur* or selfinjur* or selfmutilat* or self mutilat* or self poison* or selfpoison* or (self
adj2  (cut  or  cuts  or  cutting  or  cutter?  or  burn  or  burns  or  burning  or  bite  or  bites  or  biting  or  hit  or  hits  or  hitting))  or  head  bang*  or
headbang*).ti,kw. (62383)
5 (NSSI? or ((nonsuicid* or non-suicid*) adj2 (self* or injur*))).ti,ab,kw. (1786)

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

6 ((nonfatal or non-fatal) adj2 (overdose? or over dose?)).mp. (418)
7 or/1-6 (125188)
8 randomized controlled trial/ (608057)
9 randomization.de. (87068)
10 controlled clinical trial/ and (Disease Management or Drug Therapy or Prevention or Rehabilitation or Therapy).fs. (253859)
11 *clinical trial/ (17606)
12 placebo.de. (351476)
13 placebo.ti,ab. (307193)
14 trial.ti. (301646)
15 (randomi#ed or randomi#ation or randomi#ing).ti,ab,kw. (917476)
16 (RCT or "at random" or (random* adj3 (administ* or allocat* or assign* or class* or cluster or control* or crossover or cross-over or
determine* or divide* or division or distribut* or expose* or fashion or number* or place* or pragmatic or quasi or recruit* or split or
subsitut* or treat*))).ti,ab,kw. (769731)
17 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).mp. (309225)
18 (control* and (study or group?) and (waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,kw,hw. (39665)
19 or/8-18 (1732296)
20 ((animal or nonhuman) not (human and (animal or nonhuman))).de. (5683745)
21 19 not 20 (1575127)
22 7 and 21 (8502)
23 (2015* or 2016* or 2017* or 2018* or 2019* or 2020*).yr,dc,dp. (9329153)
24 22 and 23 (3277)
25 limit 24 to exclude medline journals (353)
26 *Automutilation/ (7770)
27 *suicidal behavior/ or *self immolation/ or *self poisoning/ or *suicidal ideation/ or *suicide/ or *suicide attempt/ (49956)
28 *Drug Overdose/ and prevent*.af. (984)
29 4 or 5 or 6 or 26 or 27 or 28 (72349)
30 21 and 29 (2692)
31 23 and 30 (1132)
32 25 or 31 (1375)
***************************

W H A T ' S   N E W

Date

Event

Description

5 March 2021

New search has been performed

This review updates and replaces the Cochrane Review 'Interven-
tions for self-harm in children and adolescents' (Hawton 2015).

5 March 2021

New citation required and conclusions
have changed

A new protocol including updated methodology was applied
(Witt 2020d). Six new studies were included in this review com-
pared to the earlier version (Hawton 2015). 

H I S T O R Y

Protocol first published: Issue 7, 2020
Review first published: Issue 3, 2021

Date

Event

Description

1 July 2020

New citation required and major
changes

We updated the protocol developed for Hawton 2015

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

C O N T R I B U T I O N S   O F   A U T H O R S

Cochrane Database of Systematic Reviews

KH had the idea for the review. All authors screened studies for inclusion. KGW, SEH, GR, and KH extracted data and assessed risk of bias
for included studies. KGW, SEH, and TLTS conducted the statistical analyses. KGW and KH wrote the initial version of the review and all
authors contributed to the writing of drafts. All authors approved the final version of the review for publication.

D E C L A R A T I O N S   O F   I N T E R E S T

KGW: is an editor for the Cochrane Common Mental Disorders Group, and senior editor for the Self-Harm and Suicide Satellite of the group.
SEH: is the joint co-ordinating editor of the Cochrane Common Mental Disorders Group. She is funded by an Auckland Medical Research
Foundation Douglas Goodfellow Repatriation Fellowship to develop and test a digital intervention for young people who engage in self-
harm. She is the Principal Clinical Advisor of the Suicide Prevention Office of the Ministry of Health for the New Zealand Government.
GR: no declarations of interest to report in relation to this review
PH: no declarations of interest to report in relation to this review
TLTS: no declarations of interest to report in relation to this review
ET: no declarations of interest to report in relation to this review
KH: no declarations of interest to report in relation to this review

S O U R C E S   O F   S U P P O R T

Internal sources

• No sources of support supplied

External sources

• National Health and Medical Research Council, Australia

KW is supported by an Emerging Leadership 1 Fellowship awarded by the NHMRC (APP1177787).

• National Institute for Health Research (NIHR), UK

KW received support from the National Institute of Health Research (NIHR131987).

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

None

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Bias;  Cognitive Behavioral Therapy  [methods];  Confidence Intervals;  Depression  [therapy];  Dialectical Behavior Therapy  [methods]; 
Family Therapy;  *Mentalization;  Odds Ratio;  Patient Compliance;  Psychosocial Intervention  [*methods];  Psychotherapy  [*methods];
  Randomized Controlled Trials as Topic;  Recurrence;  Secondary Prevention  [methods];  Self-Injurious Behavior  [prevention & control]
 [psychology]  [*therapy];  Suicidal Ideation;  Treatment Outcome

MeSH check words

Adolescent; Child; Female; Humans; Male

Interventions for self-harm in children and adolescents (Review)
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98
